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Abstract 
The clearance of neurotoxic amyloid beta (A~) from the brain represents a novel 
therapeutic target for Alzheimer's disease (AD). The ability of two blood-brain barrier 
(BBB) drug transporters, P-glycoprotein (P-gp) and the breast cancer resistance protein 
(BCRP), to transport A~ was investigated using a human brain endothelial cell (BEC) line, 
hCMECID3. P-gp expression by hCMECID3 cells was stable over a high passage number, 
polarised on the apical membrane, consistent with the blood side in vivo, and comparable, 
albeit slightly reduced, to primary isolated human BECs. The P-gp inhibitors tariquidar and 
vinblastine prevented the efflux of rhodamine 123 from hCMECID3 cells, indicative of 
functional P-gp expression. hCMECID3 cells therefore constituted a suitable model to 
investigate P-gp substrate interactions in vitro. P-gp, and to a lesser extent BCRP, 
inhibition, increased the net influx and decreased the efflux of 0.1 nM 1251 AP 1-40 in 
hCMECID3 cells. Both P-gp and BCRP inhibition increased the apical-to-basolateral but 
not the basolateral-to-apical permeability ofhCMECID3 cells to 1251 A~ 1-40. This data is 
consistent with P-gp and BCRP, acting in vivo to prevent blood-borne A~ peptides entering 
the brain but not to clear A~ load from the brain. 
Vascular dysfunction is emerging as a key pathological hallmark in AD, including 
increased BBB permeability. The effect of A~ on the permeability ofhCMECID3 cells was 
therefore investigated. A~ 1-40 induced a marked increase in hCMECID3 cell permeability 
to the paracellular tracer 70 kDa FITC- dextran. Increased permeability was associated 
with a specific decrease in the tight junction protein occludin, but not claudin-5 or ZO-l, 
both at the protein and mRNA levels. JNK and p38MAPK inhibition prevented A~ 1-40-
mediated occludin down-regulation and increased paracellular permeability ofhCMECID3 
cells. Our findings suggest that the JNK and p38MAPK pathways might represent 
attractive therapeutic targets for preventing vascular dysfunction in AD. 
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Chapter 1 
General introduction 
1.1 The blood-brain barrier (BBB) 
The blood-brain barrier (BBB) is a tenn used to describe the restricted penneability 
of brain tissue capillaries, compared to capillaries of other organs, especially with regard 
to hydrophilic molecules. The BBB prevents the passage of molecules from the blood into 
the brain, maintaining a homeostatic neuronal extracellular fluid. It is important that the 
interstitial fluid (ISF) of the central nervous system (CNS) is regulated in tenns of ion 
concentrations and signalling molecules, to allow efficient neuronal firing and brain 
function. Neuronal action potentials are dependent on the concentration of ions in both the 
ISF and within the neuron (e.g. Na+, K+ and Ca 2+). The ion concentrations must be 
maintained within a narrow range to allow efficient neuronal firing and neurotransmitter 
release, which in turn are vital for CNS activity. The relative impenneability of the BBB 
to ions means that any acute fluctuations in the circulating blood do not affect the brain 
ISF levels. 
The BBB also protects the neuronal tissue from a range of substances that, although 
relatively non-toxic to peripheral organs, could interfere with neuronal functions and 
damage neurons if allowed to enter the brain. These agents could come from the diet (e.g. 
plant toxins) or drug therapies, and their exclusion is achieved not only by allowing 
limited movement from the blood to the brain, but also by specific transporters e.g. P-
glycoprotein (P-gp) expressed by cerebral brain endothelial cells (BECs), which actively 
efflux a broad range of substances back into the blood. In addition to functioning as a 
barrier to certain molecules, the BBB also supplies nutrients and removes the waste 
products to and from the CNS, processes which are conducted by specific transporters 
[e.g. glucose transporter -1 (Glut-I)]. 
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Increased BBB permeability can give rise to neuronal damage by allowing toxins or 
endogenous molecules to penetrate the BBB and also by the loss of cerebral homeostasis. 
Indeed, BBB malfunction is implicated in many disease states including Alzheimer's 
disease (AD). There are two aims to this thesis, both centred on the neurotoxic 
polypeptide amyloid beta (A~), believed to be at the root cause of AD pathogenesis. The 
first aim is to study the role ofBEC efflux transporter proteins in the transport of A~ 
across an in vitro human BBB model. The second aim is to investigate the effects of A~ 
on the expression of proteins which regulate the permeability ofBECs, and other 
transporter proteins associated with BEC phenotype. This introductory chapter will 
describe the unique properties ofBECs and the potential role of the BBB in AD 
pathogenesis. 
1.1.1 The history of the BBB 
The concept of the BBB was first proposed as an explanation for the exclusion 
from the brain of hydrophilic dyes administered to the peripheral vasculature. Ehrlich in 
1885 [1], whilst comparing the oxygen consumption of different organs using 'intravital 
dyes', observed for the first time, that some aniline derivatives stained many organs but did 
not penetrate the brain. The term BBB is reported to originate from the work of 
Lewandoski [2], who found that intrathecal application of potassium ferrocyanate was 
lethal in dogs and rabbits at 1 % (w/v) of the dose required by the subcutaneous route. 
Allegedly, Lewandoski first used the term bluthirnschranke, or BBB to describe this 
barrier function, although it is debated as to the exact date [3]. Goldman, Ehrlich's student, 
added further evidence for a barrier function protecting the brain, with the observation that 
trypan blue injected directly into the cerebral spinal fluid (CSF) stained all brain tissue cell 
types, whereas intravenous application did not [4]. These findings sparked a search for the 
cellular structure(s) of the BBB, and it was not until the advent of electron microscopy 
- 17 -
(EM) that BECs emerged as a central component of the BBB. During the 1960's, 
horseradish peroxidase (HRP) had been employed as an enzymatic tracer for vascular 
transport studies due to its relatively high sensitivity and low molecular weight (MW 
43,000). HRP had been demonstrated to pass from the circulation to extravascular spaces 
by diffusion through gaps between endothelial cells (ECs) and also via pinocytotic vesicles 
in cardiac and skeletal muscle [5]. In 1967, Reese and Karnovsky [5] demonstrated that 
HRP administered via the tail veins of mice was undetectable in the brain tissue, since 
HRP appeared not to cross the cerebral vascular endothelium. Critically, Reese and 
Kamovski established that neighbouring BECs overlap and are linked together by tight 
junctions (TJs), which prevented the intercellular/paracellular passage ofHRP. The authors 
also found that BECs contained fewer micropinocytotic vesicles than peripheral ECs, 
which reduced (relatively) the intracellular transport of HRP. This type of experiment was 
possible due to high resolution EM, which could distinguish between the fine structures of 
cerebral capillaries. Subsequent experiments have yielded a detailed understanding of the 
BBB. However, these first investigations were vital to the identification of BECs as key 
components of the BBB. 
1.1.2 The BBB as a neurovascular unit 
The lumen of the cerebral vessels that penetrate brain tissue are enclosed by BECs, 
which are interconnected by TJ proteins. Whilst BECs are a key component of the BBB, 
other cell types are also associated with the development and maintenance of BEC 
characteristics. Pericytes are sparingly attached to the abluminal (brain side) surface of 
BECs in capillaries and both cell types are surrounded by a basal lamina. In addition, 
astrocytic end feet are contiguous with the basal lamina and surround BECs (Figure 1.1). 
The term neurovascular unit has recently been introduced to describe the interactions 
between BECs, astrocytes, pericytes and neurons to function as a unit and maintain BBB 
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properties (although fibres of the white matter and oligodendrocytes are sometimes also 
included) [6]. Whilst CNS resident cells including oligodendrocytes, glia and neurones can 
also alter the function of BECs, astrocytes and pericytes lie closest to BECs and form an 
intimate association. Through this close position, both cell types have been demonstrated 
to playa role in the maintenance and induction of the BBB. 
I Pericyte I 1 __________ 1 
Blood lumen 
Figure 1.1 Schematic representation of the cellular components of the BBB. The 
lumen of cerebral capillaries is enclosed by BECs, which are interconnected by TJ 
proteins. Pericytes are attached to the abluminal surface ofBECs and surrounded by a 
basal lamina. Astrocytic end feet are contiguous with the basal lamina and BEes. 
1.1. 2. 1 Astrocyles 
Astrocytes playa variety of active roles in maintaining neuronal physiology and 
homeostasis of the extracellular fluid surrounding neurones. Astrocytes are involved in the 
homeostasis ofK+ ions [7-9], glutamate and ammonia [10-12], to protect and ensure 
optimal neuronal function. K+ ion concentrations must be tightly regulated in order to 
allow neuronal action potentials to occur. Astrocytes act as a spatial buffer and also take up 
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K+ ions through carrier and pore-mediated transport [7, 9]. Astrocytes accumulate excess 
ammonia and convert glutamate to glutamine via glutamine synthase, thereby preventing 
excess neuronal excitation [11]. Recently, an additional astrocyte function has emerged in 
the metabolic coupling of neurons to astrocytes [12-15]. The astrocyte-neuron lactate 
shuttle hypothesis suggests that increased neuronal activity induces lactate production and 
secretion by astrocytes, and neurones then utilise this lactate as an energy source [12-15]. 
The close structural proximity of astrocyte foot processes to BECs provided the 
basis for the view that astrocytes contribute to the development and maintenance of the 
BBB. Indeed, astrocytes can influence the permeability ofBECs (reviewed in [16-18]). In 
vitro, co-cultures of primary isolated BECs or immortalised BEes with astrocytes [19, 20] 
or astrocyte-conditioned media [20-23] improves BBB characteristics, such as increased 
tightness, decreased permeability and the up-regulation of BEC proteins such as Glut-I, p-
gp, amino acid carriers, TJ proteins and 'Y-glutamyl transpeptidase. The exact astrocyte 
derived-factors responsible for the in vitro effects on BECs are unknown, however, 
transforming growth factor ~ (TGF-~) [24], basic fibroblast growth factor ~ (FGF) [25] and 
angiopoietin-l [26], all appear to increase BECs tightness and may be released by 
astrocytes. It is worth noting that BECs can also influence astrocytic properties, for 
example increasing astrocytic anti-oxidant activity [27] and astrocyte differentiation [28]. 
1.1.2.2 Pericytes 
The role ofpericytes in the induction and maintenance of the BBB has not been as 
extensively investigated as astrocytes. However, it appears that pericytes may playa 
critical role in the development of BECs, in the control of capillary diameter and as a 
scavenger housekeeping cell (reviewed in [29-31]). Pericytes are more prevalent during the 
early stages of development and at maturation in rat neural capillaries than any other 
capillary type [32]. In fact, Balabanov and Dore-Duffy [29] have estimated the pericyte to 
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EC ratio to be 1:5 in rat brain capillaries, compared to 1: 1 00 in skeletal muscle capillaries. 
This intimate association between BECs and pericytes appears to correlate with greater 
tightness and TJ protein expression. The recruitment ofpericytes to BECs is considered to 
be a platelet derived growth factor (PDGF)-mediated response [33,34], and PDGF-
deficient mice develop numerous micro-aneurisms [34, 35], possibly due to capillary wall 
instability. A critical mechanism by which pericytes may influence the development of 
BECs is via angiopoietin-l (Angl) secretion, which acts via TIE2 receptors on BECs. 
Consistent with this theory is the finding that Ang 1 and TIE2 knockouts do not develop 
mature brain blood vessels [34, 35]. In addition, Ramsauer et al [36] have demonstrated 
that co-cultured astrocytes, pericytes and BECs form capillary-like structures, which, 
unlike astrocyte-BEC co-cultures, were resistant to apoptosis induction. Furthermore, in 
co-cultures, pericytes can increase the expression of TJ components in rat BECs at the 
mRNA level [37] and reduce the paracellular permeability of immortalised mouse BECs to 
sodium fluorescein [38]. 
An early observation on pericyte ultrastructure by Herman and D' Amore [39], was 
that these cells contain contractile proteins. Oishi et at [40] have demonstrated that mouse 
pericytes cultured in a three-dimensional collagen gel, contract in response to acetylcholine 
(ACh) and noradrenaline, neurotransmitters that can be released in the vicinity of 
capillaries by neuronal fibres. In a novel experiment, Peppiatt et at [31] have shown that 
stimulation of rat retinal pericytes by superfused noradrenaline application caused capillary 
constriction in the cerebellum. Additionally, pericytes express receptors for 
catecholamines, endothelin-l, angiotensin II and vasopressin, which are all potential 
vasoactive mediators [29]. 
1.1.3 Characteristic phenotype of brain endothelial cells 
BECs are characterised by reduced paracellular and transcellular permeability, and 
a high mitochondrial content compared to endothelial cells at other organs. 
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1.1.3.1 Low paracellular permeability 
Although pericytes and astrocytes regulate the development of BECs, it is the 
properties of the BECs themselves that determine BBB function. Blood vessels throughout 
the human body are lined by ECs, which form the main site for nutrient exchange, 
leukocyte diapedesis, signalling molecule transport and all blood-tissue contact. In general, 
ECs fall into three types based on their structure; fenestrated, continuous and 
discontinuous. 
Endocrine and exocrine glands, including the choroid plexus and intestinal villi, 
display discontinuous endothelia with fenestrae between them, and ECs in the liver, spleen 
and bone marrow are discontinuous in nature [41-43]. The increased leakiness offered by 
discontinuous and fenestrated capillaries allows secretory and sensory functions at these 
sites. Continuous ECs lack intracellular gaps and are found in skeletal muscle, lung and 
brain. BECs are of a specialised continuous type, as they are much more restrictive than 
other organs. 
Due to this restrictive nature of the BBB, lipid solubility is the primary factor 
determining the permeability of a substance through the BBB [44]. A substance with a 
high oil/water partition coefficient can, in principle, diffuse freely through BECs and this is 
the primary route of entry and exit for small dissolved gasses to/from the CNS e.g. O2• The 
permeability of BECs to hydrophilic macromolecules (e.g. albumin, HRP) and small ions 
is very low. This property is reflected by a high electrical resistance of pial vessels 
recorded in the frog and rat of 1000-2000 n.cm2 [45,46], which is much higher than that 
in peripheral vessels (2-20 n.cm2) [45,47]. 
The presence of continual complex TJ in BECs is considered to be the primary 
reason for the increased electrical resistance and decreased permeability at the BBB 
compared to discontinuous junctions in peripheral ECs. When BEC membranes containing 
TJs are freeze fractured and viewed via electron microscopy, fracture planes seprate the 
cytoplasmic leaflet of the inner membrane (P-face) from the extracellular leaflet (E-face). 
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TJs in BECs appear as strands on the P-face and grooves on the E-face, [48,49] which 
allows continuous TJ formation [50-52]. The molecular composition and organisation of 
TJs is discussed in detail in section 1.1.4. 
It should be noted that regions exist within the CNS in which the BECs are 
fenestrated and lack TJs. The choroid plexus (in cerebral ventricles) consists of a layer of 
fenestrated ECs surrounded by ependymal epithelium. The function of the choroid plexus 
is to produce cerebral spinal fluid (CSF), which circulates through ventricular cavities and 
the subarachnoid space. However, TJs are found at apical regions of the choroid plexus 
epithelium, which forms a blood-CSF barrier [53]. The other areas of the brain in which 
BECs are fenestrated are collectively called the circumventricular organs (CVOs) [54,55]. 
CVOs are ventricularly located structures which carry out two main functions: 1) 
neuropeptide secretion (e.g. medial eminence, pineal gland, intermediate lobe of pituitary 
gland) and 2) to act as a sensor of circulating levels of hormones and neurotransmitters 
(e.g. subfornical organ, organum vasculosum). 
1.1.3.2 High mitochondrial content 
In addition to a high electrical resistance and the presence ofTJs in most CNS 
regions, BECs also differ from periphery endothelia in terms of mitochondrial content. 
Oldendorf et at [56] calculated the mitochondrial content of rat BECs to be between 8 % 
and 10 % of total cytoplasmic volume, whereas in non-brain EC they represent between 2 
% and 5 %. BECs contain numerous enzymes and transporters that are dependent on 
adenosine triphosphate (ATP). ATP-dependent transporters in BECs function to transport 
blood-borne harmful agents back into the blood (e.g. P-gp; see section 1.1.6.1), whereas a 
number of enzymes (e.g. monamine oxidase (A and B), cytochrome p450 monooxgenase, 
L-amino acid decarboxylase, epoxy hydolases, aminopeptidase A, superoxide dismutase 
[57-61]) are capable of degrading various peptides and reactive oxygen species that could 
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interfere with neuronal function or become neurotoxic. Thus, the high mitochondrial 
content in BECs may reflect the high energy requirements of these cells and their 
protective barrier function. 
1.1.3.3 Low vesicular transport 
In the original EM description of the BBB, Reese and Karnovsky [5] also noted a 
lower frequency of vesicles within ECs in cerebral vessels compared to other capillaries. 
Both the proportion and number of vesicles filled with HRP was much lower in BECs 
compared to cardiac ECs. A decreased vesicular content in BECs is a further indication of 
the barrier function of these cells in which blood-brain vesicular uptake is restricted. 
Thus low transcellular transport, due to decreased vesicular transport, and low 
paracellular transport, as a result ofTJs, together contribute to the barrier function of 
BECs. 
1.1.4 Molecular organisation and regulation of brain endothelial cell tight junctions 
BECs in the cerebral vasculature are linked together by both TJ and adherens 
junctions (AJs). AJs intermingle with TJs [62], and are expressed throughout the 
vasculature and playa role in EC adhesion, paracellular permeability, vascular growth and 
contact inhibition during vascular remodelling (reviewed in [63]). Vascular endothelial cell 
cadherin (VE-cadherin) is the transmembrane component of AJs [64], which is linked to 
the actin cytoskeleleton via ~- and a- catenins, although the exact molecular components 
are under debate [64]. VE-cadherin is expressed by ECs in all tissues and its function is 
modulated by Ca2+ ions [65]. Abbruscato and Davis [66] have demonstrated using cultured 
bovine BECs, that hypoxic conditions cause a Ca2+ -mediated decrease in VE-cadherin 
expression. Although AJs are important for the development and function ofBECs, it is the 
TJs that confer low permeability ofBECs, when compared to other ECs. Multiple proteins 
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comprise TJs including; Junctional adhesion molecules (JAMs), occludin, claudin family 
members (CI), zonula occludens 1,2 and 3 (ZO-1 and 2, 3), cingulin, AF-6 and 7H6, 
associated directly or indirectly to a peri-cellular ring of actin filaments (reviewed in [6, 
63,67-69]) . Generally, occJudin, JAMs and the claudins fonn trans-membrane segments of 
the TJ complex whereas other TJ proteins serve as cytoplasmic anchors to the actin 
cytoskeleton (Figure 1.2). 
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Figure 1.2 The tight junctional complex at the BBB. (a) BECs at the BBB are connected 
by TJ. OccJudin, c1audins and JAM form homodimers (c1audins also fonn heterodimers) 
across the intercellular space and are held anchored to the actin cytoskeleton via scaffold 
proteins (ZO-I, -2, -3, AF6, 7H6 and cingulin). Actin can also be bound directly to 
occludin. (b) Representation of occludin, claudin and JAM structures [70]. 
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1.1.4.1 Occludin 
Occludin was the first TJ protein to be discovered in BECs. Furuse et af [71] 
developed rat antibodies directed against an isolated AJ fraction from chick liver, and 
found staining for a 65 kDa protein at epithelial and BEC TJs. Subsequently, continuous 
occludin expression was confirmed on rat [72], porcine [73] and human isolated brain 
capillaries [74, 75], whilst lower discontinuous expression is detected on non-cerebral ECs. 
Occludin expression is found at sites that display a high degree of tightness and is therefore 
considered to be actively involved in maintaining BBB permeability or function. 
Structurally, occludin comprises four membrane spanning regions, two 
extracellular loops, a short cytoplasmic N-terminus and a long cytoplasmic C- terminus 
[71] (Figure 1.2). Human, murine and canine occludin share,.,. 90 % amino acid similarity 
with each other but a divergence of,.,. 50 % compared to chicken and rat-kangaroo occludin 
[74]. All species however share similarities in the two proposed functional domains: I) the 
first extracellular loop of occ1udin which is rich in tyrosine and glycine content and is 
hypothesised to mediate cell to cell contact [74]; and 2) the C-terminus, which is 
responsible for the association with ZO-I [76, 77]. 
There is conflicting experimental evidence as to the exact importance of occludin in 
TJ structure. Saitou et af [78] demonstrated that occludin-null mice develop a range of 
abnormalities such as chronic inflammation, gastric epithelium hyperplasia, calcification in 
the brain, testicular atrophy, and loss of cytoplasmic granules in striated duct cells of the 
salivary gland. However, the TJs of epithelial intestinal cells were unaffected compared to 
controls. In a follow up study, Schulzke et af [79] found that the barrier properties of 
epithelial cells in the stomach, bladder and throughout the intestine were unaltered as 
assessed by resistance measurements. The authors did find reduced acid secretion and 
morphological alterations in the gastric epithelium, which they attributed to a role for 
occ1udin in epithelial cell differentiation. It is of note that the permeability of the BBB was 
not investigated in either paper. In addition, mouse embryonic stem cells [80] deficient in 
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occludin, when differentiated into epithelial cells, form TJ structures that are impermeable 
to biotin. 
However, there is considerable evidence that occludin confers increased tightness 
in TJ containing cells [81]. Many of these investigations have originated from epithelial 
cells, which also form TJ structures. McCarthy et af [82] have demonstrated that occludin 
over-expression in Madin Darby canine kidney epithelial cells (MDCK) increases the 
number of T J s and also the transepithelial resistance. The transfection of a C-terminal 
truncated mutant form of occludin into MDCK cells [83] or into Xenopus embryo cells 
[84] resulted in increased permeability to different paracellular tracers. Yu et af [85] used 
siRNA techniques to knock-down occludin expression in MDCK cells and found the 
permeability to small ionic cations such as Na+, arginine and ethanolamine was increased. 
Additional evidence for the role of occIudin in the maintenance ofTJs comes from 
observations that occludin down-regulation by different agents is associated with increased 
permeability. Antonetti et af [86,87] have demonstrated using a streptozotocin-induced 
diabetes rat model, a concomitant increase in permeability to BSA and a decrease in 
occludin levels at the blood-retinal barrier. Other factors including histamine [88], CCL2 
[89] and oxidised phospholipids [90] can phosphorylate occludin and induce leaky TJs. 
Occludin regulation therefore appears to play an important part in the TJ regulation of 
endothelial and epithelial permeability. Interestingly, occIudin down-regulation and 
increased permeability of BECs has been reported in experimental animal models of 
neutrophil activation [91] inflammatory-induced pain [92], hypoxia [93] and Alzheimer's 
disease [94], further emphasising the importance of this protein in the regulation ofBBB 
permeability . 
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1.1.4.2 Claudins 
Furuse et al [95] upon re-examination of their isolated AJ fraction from chicken 
liver identified two further TJ proteins, claudin (CI)-I and 2. Subsequently, 24 members of 
the claudin family [96, 97] have been identified through database searches and genomic 
cloning. 
Claudins are 20-27 kDa proteins with four transmembrane domains and one 
extracellular loop (- 53 amino acids) much larger than the second (- 24 amino acids) [95]. 
The C-terminus, as with occludin, has the ability to bind to ZO-I and ZO-2 [98], whilst the 
extracellular loops of claudins can interact with each other via homophilic and heterophilic 
interactions [99]. The ability of claudins to form TJs has extensively been investigated in 
mouse L-fibroblast cultures. CI-I or CI-2 expression in mouse L-fibroblasts results in the 
formation ofTJ strands [100]. Furthermore, transfection ofL-fibroblasts with paired 
combinations ofCI-I, 2 or 3 demonstrated that all transfected cells could form TJs, with 
the exception of those co-transfected with CI-l and -3 [99]. Interestingly, Furuse et al 
[100] also found that L-fibroblasts transfected with occludin do not form in TJs unless CI-I 
is also expressed. 
The expression of claudins varies between cell types, and four particular CIs have 
been identified at the mammalian BBB: CI-I [101],3 [102],5 [103] and 12 [103]. The 
expression of CI-1 by BECs has been brought into question, as the antibody used in many 
studies has been shown to cross-react with CI-3 [102]. Nitta et al [103] have recently 
demonstrated the potential role of CI-5 in the BBB using CI-5-deficient mice. These mice 
die within 24 h of birth, indicating a developmental role for CI-5. The development of the 
blood vessels was normal, and there were no signs of oedema, however paracellular tracer 
experiments revealed increased selective permeability for molecules <800 Da at the BBB. 
Whilst there was no detection of serum albumin leakage into the brain of CI-5 deficient 
mice, the conclusion by these authors that CI-5 exerts a size selective barrier at the BBB 
should be approached with caution. The tracer experiments by Nitta ef al [103] were 
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carried out over a relatively short time period of 5 min, and the larger MW tracers used 
may have required longer to diffuse across the BBB than smaller ones and therefore to be 
detected in the brain parenchyma ofCI-5 deficient mice. The importance ofCI-3 at the 
BBB has recently been highlighted by the work ofWolburg et al [102], who demonstrated 
a selective loss of CI-3 in autoimmune encephalomyelitis (EAE) mouse models and human 
glioblastoma multiforme tissue. 
1.1.4.3 Junctional adhesion molecules 
Members of an additional transmembrane protein family, termed junctional 
adhesion molecules (JAMs) are also present at TJs in BECs [104, 105]. JAMs are part of 
the immunoglobulin-like super-family of adhesion molecules and consist of three main 
members (JAM-I, -2,-3, also referred to as JAM-A, B and C). JAM -1 and -3, but not JAM 
-2, expression has been noted in rat brain blood vessels [106]. JAMs have been 
demonstrated to playa role injunction assembly [104, 107] and leukocyte migration [105] 
at the BBB (reviewed in [104]). Transfection of JAM-l into Chinese hamster ovary cells 
(CHO) enhances endogenous ZO-1 expression and co-transfection of JAM-l and occludin 
into the same cell type results in redistribution of JAM-l to junctional areas [108]. JAM-l 
can also bind to cytoplasmic accessory proteins such as ZO-1 and cingulin [108, 109]. 
However, the exact function of JAMs as BBB TJ proteins has not yet fully been explored. 
1.1.4.4 CytoplasmiC accessory proteins. 
There are several accessory cytoplasmic proteins that associate with the 
transmembrane components ofTJs. However, the function of many of these proteins, e.g. 
cingulin [110, 111], AF-6 [109, 112, 113] and 7H6 [114, 115], has not been extensively 
investigated, especially with regards to the BBB. A notable exception is the ZO family of 
proteins, of which ZO-1 [116] was the first described TJ-associated protein. Stevenson et 
al [116] observed ZO-1 TJ staining in a variety of epithelia, and subsequently, two further 
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ZO family members, termed ZO-2 [117] and ZO-3 [118], were identified via co-
immunoprecipitation of ZO-1 in MDCK cells. 
The ZO proteins are members of the membrane-associated guanylate kinase 
(MAGUK) family, which generally enable multiple protein-protein interactions as 
intracellular scaffolds [119, 120]. ZO proteins share three core regions, a src homology 3 
(SH3) domain, a guanylate kinase-like (GuK) domain and three PSD95-DLG-ZO (PDZ) 
domains which allow binding to different proteins. ZO proteins bind to each other [121], to 
occludin [76, 77, 108, 118, 122, 123] (via the SH3- GuK domains [123]), to claudins [98, 
124] (via the PDZ domains), to JAM [109], to AJ proteins [112, 113, 125, 126] and to actin 
[76, 121] (via the C- terminus). Thus, the ZO proteins anchor transmembrane TJ proteins 
to the actin cytoskeleton, although it should be noted that occ1udin can also bind directly to 
the actin cytoskeleton [121]. 
Many studies have shown that ZO proteins are important for the stability ofTJ 
architecture. Although epithelial cells lacking ZO-1 expression still form well developed 
TJs, loss ofZO-l expression inhibits the Ca+- induced re-formation ofTJs previously 
disassembled by Ca2+ depletion [127, 128]. McNeil et al. [127] demonstrated that in ZO-I-
depleted MDCK cells, formation ofTJs is delayed after Ca2+ removal and this effect could 
be rescued by ectopic expression of the SH3 domain of ZO-I. In addition, Umeda et al 
[128] have demonstrated that suppression of ZO-1 and ZO-2 expression in a mammary 
epithelial cell line, Eph4, results in a lack of organisation of occludin, JAM-l and CI-3. 
One study has shown that ZO proteins may also playa role in development. ZO-l 
knockout mice embryos are not viable and present with defective yolk sac angiogenesis 
and apoptosis of embryonic cells [129]. 
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1.1.4.5 Regulation of paracellular permeability 
There are multiple extracellular mediators that can induce a leaky BBB including 
cytokines, nitric oxide, free radicals, prostaglandins and histamine (reviewed in [46, 130]). 
These extracellular molecules can mediate increased permeability by TJ protein 
translocation at cell-cell contacts and/or a decreased expression ofTJ proteins at the 
messenger level. Intracellular signalling pathways that have been shown to mediate TJ 
reorganisation include protein kinase C (PKC), protein kinase A (PKA), the small G-
protein rho and the mitogen activated protein kinase family (MAPK) (reviewed in [131, 
132]). As an example, when epithelial cells are cultured in low calcium medium, increased 
permeability and decreased transepithelial resistance is observed, which in some cases is 
accompanied by a membrane loss of ZO-I, ZO-2 and occludin at the membrane [133]. 
PKC activation and PKA inhibition have both been demonstrated to preserve the TJs after 
Ca2+ removal from epithelial cell cultures [134-136]. In contrast, the elevation of 
intracellular cAMP in BECs increases the TJ tightness and reduces paracellular 
permeability [46]. Therefore, PKA activation in BECs can enhance the barrier function, 
whilst in epithelial cultures may increase permeability. 
Phosphorylation ofTJ proteins is a further way in which permeability can be 
regulated. Ischemia, oxidative stress, Rho activation, and VEGF can cause phosphorylation 
of occ1udin and increased permeability to paracellular tracers in TJ containing cell lines 
[69, 131]. 
1.1.5 Nutrient transporten at the BBB 
TJ expression and reduced vesicular transport in BECs combine to restrict the 
passage of hydrophilic molecules into the brain. However, the CNS shows a high 
metabolic demand, and essential brain substrates and nutrients require specific carriers and 
receptors to transport them into the brain across BECs. The transporters of glucose, iron, 
essential amino acids and ions are represented in Figure 1.3. 
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Figure 1.3. Transport mechanisms at the BBB. BECs contain a number of transport 
mechanisms to allow homeostatic control of nutrients, ions and signalling molecules. (1) 
Na + dependent transporters (A, ASC, LNAA, EAA T) eliminate non-essential, essential and 
excitatory amino acids from the brain, preventing excess accumulation. (2) Facilitative 
diffusion allows essential amino acids (Ll, y +) and glucose (Glut-I) into the brain and 
elimination of excitatory amino acids (N, Xa) into the blood across the luminal and (3) 
abluminal membranes. (4-5) Ion transporters at the BBB regulate extracellular K+ and Na+ 
ions (Na+ / K+ ATPase) and intracellular pH. (6) ABC transporters (P-gp, BCRP, MRP) 
protect the brain from blood circulating toxins. (7) Receptor-mediated transport allows 
essential proteins and signalling molecules into the brain (e.g. Insulin receptor, transferrin 
receptor). Adapted from [137] [155]. 
1. 1. 5. J Glucose 
Glucose supply to the brain, either as glucose or as its breakdown product, lactate, 
is essential as an energy source for brain resident cells such as neurons. Glucose transport 
at the BBB is primarily mediated by facilitative diffusion via glucose transporters (Glut, 
reviewed in [138]). To date, 13 members of the Glut family have been identified, and 
amongst these Glut-1 is the major isoform present at the BBB. Pardridge et al [139] have 
found that over 90 % of glucose transport in bovine cortex blood vessels is attributable to 
Glut-I. Two different molecular weight forms of Glut-l exist (44 and 55 kDa), which 
differ only in their extent of glycosylation [140]. At the BBB, the 55 kDa form is primarily 
present at both the luminal and abluminal membranes in addition to a large intracellular 
pool, although the exact sub-cellular distribution is not entirely clear [139, 141-147]. 
Farrell et al [144], using EM techniques on rat BECs, found a distribution of Glut-l of 12 
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% luminal, 48 % abluminal and 40 % cytoplasmic and in a study in rabbits, the largest 
proportion of this transporter was similarly observed in the abluminal membrane [141]. 
More recently, Simpson et at [138] have suggested a more symmetrical distribution of 
Glut-l expression. Lee et al [148] isolated bovine luminal and abluminal membrane 
vesicles and demonstrated a similar kinetic profile of glucose transport. Later, Simpson et 
al [147] corroborated this finding in bovine BEes, reporting symmetrical distribution of 
Glut-I. The intracellular pool of Glut-I, might serve to increase luminal Glut-l levels in 
times of increased neuronal demand such as hypoglycaemia [149] and seizures [142]. 
Although Glut-l is the most studied glucose transporter at the BBB, there is also evidence 
for a Na+-dependent glucose transporter [148], which could playa role in glucose 
homeostasis if the glucose content in the neuronal environment is too high. 
1.1.5.2 Iron 
Iron is an essential trace element required for a plethora of functions including 
neurotransmission, myelination, as a component of the electron transport chain and cell 
division [150, 151]. In non-pathological conditions, virtually all iron circulates in the 
plasma bound to hydrophilic transferrin, which in principle would be excluded from the 
brain by the TJs at the BBB. However, BEes contain a receptor for iron-bound transferrin, 
the transferrin receptor [152, 153], which allows iron uptake by the brain. The exact 
mechanism of iron uptake by BEes is still unknown. Moos et al [151], have recently 
suggested a model of iron trafficking at the BBB. In this model, iron-transferrin binding to 
the transferrin receptor results in endosomal intemalisation of the complex and abluminal 
vesicular release. In many cell types, the divalent metal transporter 1 (DMTl) causes the 
transport of iron into the cytoplasm, however DMTI has not been detected in BEes [154]. 
Their theory is therefore, that under the acidic conditions ofthe endosome and an A Tp· 
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citrate-rich abluminal membrane environment secreted by astrocytes, iron becomes 
available for cellular uptake. 
1.1.5.3 Amino acids 
The transport of amino acids at the BBB is complex and carried out by both 
facilitated diffusion and Na+-dependent transport (reviewed in [155]). There are four 
facilitative amino acid carriers expressed by BECs; an essential neutral amino acids system 
(L 1), a cationic amino acids system (Y\ an acidic amino acids system Xo and a glutamine 
system (n). Ll expression was first identified when it was noted that the movement of 
neutral essential amino acids into the brain was greater than that of non-essential amino 
acids [156]. Ll is expressed on the luminal and abluminal membrane ofBECs and 
functions to transport essential amino acids (e.g. Leucine, valine, isoleucine, 
phenylalanine, trypophan) into BECs and the brain [155, 157]. System Y+, located on the 
abluminal and luminal membrane, is primarily a cationic amino acid transporter and acts to 
transport lysine, arginine and ornithine, whilst the presence ofNa + allows association of 
neutral amino acids with this transporter [155, 158-160]. System n, on the luminal 
membrane, allows the facilitative diffusion of glutamine [161], whilst Xo (luminal) has 
affinity for glutamate and arginine [155, 162]. Collectively, Ll and y+ allow access to the 
brain of all essential amino acids. 
Analysis of the CSF composition, a rough indicator of brain extracellular fluid, 
reveals that, with the exception of glutamate, CSF amino acid levels are - 10 % of the 
plasma levels [155]. This led to the identification of five Na+-dependent systems on the 
abluminal membrane ofBECs, which allow the elimination of non-essential and/or toxic 
amino acids as well as maintaining homeostatic control over all amino acids. These five 
Na+-dependent transporters (reviewed in [155]) are A (non-essential amino acid preferring 
e.g. alanine), ASC (alanine, serine, cysteine preferring), N (glutamine, asparagine and 
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histidine preferring), excitatory amino acid transporter family (EAA T, aspartate and 
glutamate preferring) and a Na+-dependent L neutral amino acid transporter system 
(LNAA). 
1.1.5.4 Ions 
The free passage of ions through the BBB is limited by the presence ofTJs. BECs 
contain a number ofNa+ and K+ transporters to regulate their brain concentrations [163-
165]. Na+-K+ ATPase is located on the abluminal EC membrane and serves the dual 
function of maintaining low extracellular K+ levels to enable optimal neuronal action 
potentials, and maintaining a high extracellular Na+ gradient to allow Na+ -dependent 
substrate transport to occur. There is also a Na+/H+ exchanger [165, 166] located on the 
luminal and abluminal membranes at the BBB. Further luminal ion transporters include a 
Na+/Cr co transporter [163], a Na+/K+/Cr co-transporter [167] and also a Na+-CrIHC03" 
[168] dependent influx transporter. 
1.1.6 ATP binding cassette (ABC) transporters 
In addition to transporters involved in nutrient supply and homeostasis, BECs 
express a number of ATP-dependent binding cassette (ABC) transporters which act to 
prevent blood-to-brain transport of a broad range of substances, including xenobiotics and 
endogenously produced molecules. ABC transporters are a large family of membrane 
transporters expressed by a variety of cell types including many mammalian cells and 
bacteria. These transporters require A TP to transport molecules across plasma and 
intracellular membranes. To date, at least 48 ABC transporter genes have been identified 
and are classified into seven subfamilies ABCA to ABCG [169, 170]. At the BBB, ABCBl 
(P-gp), ABCG2 (the breast cancer-related protein, BCRP) and ABCC [multi drug resistance 
proteins, (MRPs)] are the most significant (reviewed in [171]). Whilst the MRP family 
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members expressed at the BBB have a broad substrate range [172], a lack of specific 
inhibitors has hindered insight into their exact function at the BBB. P-gp and BCRP shall 
now be described in more detail, since they are the focus of the work described in this 
study on amyloid beta (A~) transport. 
1.1.6.1 P-glycoprotein (P-gp) 
Juliano and Ling [173] first discovered P-gp, a 170 kDa protein, which 
corresponded to the multi drug resistance activity of Chinese hamster ovary cells (CHO). 
Subsequent work revealed P-gp expression in other mammalian multidrug resistance 
cancer cell lines [174-176] and established a direct link between the MORlABCBI gene 
and P-gp protein expression [175]. In humans, two types ofP-gp exist, which are termed 
class I and class II [172]. Class I P-gp is encoded for by the MDRlIABCBI gene, located 
on the long arm of chromosome 7 [177, 178], whilst class II (M0R2/ABCB4), with a high 
sequence homology, is located adjacently [179]. Class I P-gp is expressed by the epithelia 
of many organs including the gastro-intestinal (GI) tract and kidney, and on ECs of the 
testes and brain (discussed below). Class II P-gp is expressed by canalicular hepatocytes 
and acts as a bile salt transporter [180, 181] and phosphatidyl flippase [182, 183]. In 
rodents, class I P-gp is subdivided into mdrl a (expressed at the BBB) and mdrl b 
(expressed in brain parenchyma) and are the equivalent of human MORt. The rodent 
equivalent of human MDR2 is denoted mdr2. 
Structurally, both P-gp types are around 1200 amino acids in length, and contain 
two nucleotide-binding domains and twelve transmembrane segments. P-gp is arranged in 
two halves, joined by a 75 amino acid linker region [184], with each half consisting of a 
transmembrane domain (TMO) made of six transmembrane segments, and an intracellular 
nucleotide-binding (NBD) domain (reviewed in [172,185-187]). Both the N- and C-
termini are located intracellularly (Figure 1.4). The two halves ofP-gp are believed to form 
- 36-
a barrel-like configuration with the two NBD arranged to form a dimer. The exact 
mechanism of transport of substrates by P-gp is unknown. The most recent model involves 
first the binding of a ligand to the TMD, leading to a conformational change in the NBDs, 
increasing their affi nity for ATP. ATP binding induces the formation of a closed NBD 
dimer, which in turn results in a conformational change in the TMD to induce ligand 
translocation [185] . ATP hydrolysis then causes the dissolution of the closed NBD dimer, 
releasing ADP and allowing P-gp to return to a state of high affinity for the ligand. 
TMDI TMD2 
Extracellular 
Intracellular 
__ eOOH 
NH2 
NBD 1 NBD2 
Figure 1.4. Structure of P-gp. P-gp is a transmembrane efflux transporter consisting of 
two TMD and two NBD. P-gp uses the energy derived from ATP to actively prevent the 
blood-to-brain transport of many substances 
P-gp has a very large structurally diverse substrate list (Table 1.2), which includes 
many endogenous molecules (e.g. steroid hormones, cytokines, lipids), natural products 
and drugs in therapeutic use [172]. Multiple studies attempting to identify characteristics of 
P-gp substrates have been carried out [188-193]. However, a common feature is their 
amphipathic and, in some cases, hydrophobic nature. These properties allow for relatively 
easy diffusion across lipid membranes and have led to the notion that P-gp acts as a 
flippase transporter [186]. The flippase model states that lipophilic molecules associate 
with the inner leaflet of the lipid bilayer, and are flipped out by P-gp. In support of this 
notion, substrate binding sites have been located to the TMD ofP-gp [176, 194], and 
phospholipid flipping is inhibited in vitro by the P-gp inhibitor vinblastine [195]. 
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One of the most widely studied sites ofP-gp expression is the 01 tract. Canapro et 
al [196] have recently demonstrated P-gp expression in human tissue samples throughout 
the ileum, jejunum and stomach, at both the protein and mRNA levels. The majority of 
investigations into intestinal P-gp function have focused on whether P-gp limits the oral 
bioavailability of known P-gp substrates and anti-cancer drugs. In vivo and in vitro studies 
using mdrl all b (-/-) mice, caco-2 cell lines (a human carcinoma cell line) and human 
clinical trials have all been employed to that end. Several groups have suggested that the 
influence of P-gp on intestinal absorption is limited, since P-gp substrates have relatively 
higher absorption rates than expected [197-200]. In contrast, Ogihra et al [201] have 
demonstrated that in mdrlalb-/- mice, the plasma levels of vinblastine after oral 
administration were increased, whereas that of verapamil was not, compared to wild type 
mice. Furthermore, in human volunteers, talinolol significantly increases the availability of 
digoxin [202], and similar findings have been noted with other agents [203]. Overall, P-gp 
in the intestine is located on epithelial cells on the luminal membrane (Le. these cells are 
polarised with regards to P-gp), and, depending on the substrate, P-gp reduces oral 
availability. 
The localisation and function ofP-gp in the kidney, liver, placenta and lung appears 
to follow a similar theme of substrate efflux. In the kidney, P-gp expression is found on the 
luminal surface of epithelial cells of the proximal tubules and functions to excrete 
unwanted molecules into the urine [204]. In the liver, P-gp is found on the canalicular 
membrane ofhepatocytes providing directional transport into the bile [205]. Placental 
expression of P-gp is localised to syncytiotrophoblasts, cytotrophoblasts and ECs in the 
trophoblast layer and, in general, P-gp is thought to playa role in protection of the foetus 
(reviewed in [206]). P-gp is found on ECs in both rat and human testes and Stewart et al 
[207] found P-gp staining in rat on both the luminal and abluminal membrane of testis EC. 
This suggests that the role in rat testis is to efflux substrates from the ECs themselves. 
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P-gp expression at the BBB has been noted in BEes and astrocytes [208, 209]. The 
expression of P-gp is frequently described as luminal, as P-gp expression has been found 
mainly on the luminal membrane of isolated capillaries from rat [210], mouse [211] and 
human [212]. There does exist however, some conflicting evidence with regards to the 
abluminal vs luminal expression ofP-gp. Bendayan et at [213] observed P-gp staining 
along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi complex, and rough 
endoplasmic reticulum (RER), using EM techniques and rat brain tissue. The presence of 
intracellular staining is unsurprising and could represent a basal P-gp production, or a pool 
of P-gp which could translocate to the membrane. However, the authors also demonstrated 
greater abluminal expression than luminal. 
The most convincing indirect evidence for the polarisation of P-gp onto the luminal 
side of the BBB is found in P-gp knockout mouse models. In rodents, there are three P-gp 
genes, two encoding for P-gp type I (mdrla and mdrl b) and one encoding for the 
equivalent of human MDR2 (mdr2). Schinkel et at [214, 215] were the first to describe 
mdrla (-1-) mice. Mdrla(-I-) mice were found to be viable and healthy, but treatment with 
the anti-parasitic drug ivermectin to treat a mite infection revealed a 100-fold increased 
neural tissue accumulation over wild-type mice, and resulted in virtually all the mdrla(-I-) 
mice dying. Follow up studies on mdrla(-I-) and mdrlalb (-1-) mice revealed that after 
peripheral administration there were increased brain levels of many P-gp substrates, 
including cyclosporin A, digoxin, verapamil, vinblastine, steroid hormones, morphine, and 
HIV protease inhibitors, indicative of a brain protective role for P-gp (reviewed in [172, 
216]). Further corroborative findings revealed that brain uptake of colchicine, vinblastine 
and paclitaxel was increased by co-administration of a P-gp inhibitor [217,218] (see 
Tables 1.1 and 1.2 for lists of P-gp substrates and inhibitors, respectively). 
Overall, P-gp is believed to playa protective role by secreting toxic xenobiotics and 
unwanted naturally produced molecules into the intestinal lumen, bile and urine as well as 
protecting specific organs i.e. brain, testes. However, undesirable effects of P-gp include 
- 39-
multi drug resistance of cancerous tissue and the prevention of therapeutic agents reaching 
their intended target organs e.g. BEe P-gp prevents anti-cancer agents and HIV treatments 
reaching brain ti ssue. 
Substrate class Examples 
Anticancer agents Actinomycin D, daunorubicin, docetaxel, doxorubicin, 
etoposide, imatinib, paclitaxel, methotrexate, mitoxantrone, 
vinblastine, vincristine, mitomycin C, teniposide, taxol, 
Antihypertensive Celiprolol , diltiazem, losartan, talinolol, 
agents 
Anti-arrhythmics Digoxin, digitoxin, quinidine, verapamil 
p-adrenoreceptor Bunitrolol , talinol 
antagonists 
Antidepressants Amitriptyline, nortryptiline, doxepin, paroxetine, venlafaxine 
Antimicrobial agents Doxycycline, erythromycin, rifampin, tetracyclines, 
fluoroquinolines 
HIV protease Amprenavir, indinavir, nelfinavir, ritonavir, saqillnavir 
inhibitors 
Anti-emetics Ondansetron, domperidon 
H2 receptor Cimetidine, Ranitidine 
antagonists 
Immunosuppressants Cyclosporin A, valspodar, tacrolimus 
Anti-epileptics Phenytoin, carbamazepine, phenobarbital, topiramate 
Steroid hormones Aldosterone, cortisol, coticosterone, dexamethasone, 
hydrocortisone. 
Opiods Morphine, loperamide 
Lipid lowering agents Lovastatin, cerivastatin 
Fluorescent dyes Rhodamine 123, calcein-AM, hoechst 3342 
Cytokines IL-2, IL-4 IFN- 'Y 
Table 1.1 P-gp substrate list. P-gp acts to prevent the blood-to-brain transport of a broad 
range ofxenobiotics and naturally produced signalling molecules [171 , 172, 176]. 
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Generation 
First generation 
Second generation 
Third generation 
Examples 
Verapamil, cyclosporin A, quinidine, verapamil, vinblastine 
Valspodar (PSC-833), biricodar (VX-7IO) 
ONT-093, zosuquidar (L Y335979), tariquidar (XR9576), 
elacridar (GF120918). 
Table 1.2. A selection ofP-gp inhibitors. First generation P-gp inhibitors are compounds 
that are in clinical use for other indications e.g. cancer therapies although they also display 
P-gp inhibitory action. Second and third generation inhibitors are more specific for P-gp. 
The P-gp inhibitors names given by the drug companies are shown where appropriate, with 
other synonyms shown in brackets. In this study, the name given by the drug company was 
used unless otherwise stated. Adapted from [171, 172, 176] 
1.1. 6. 2 The breast cancer resistance protein (BCRP) 
Similarly to P-gp, BCRP was discovered in a drug-resistant cancer cell line. Chen 
et al [219] identified BCRP in a breast carcinoma cell line (MCF-7/AdrV) that was 
resistant to the cytotoxic effects of antracyclines, even in the presence ofP-gp inhibition. 
Doyle et al [220, 221] subsequently identified and cloned BCRP eDNA from MCF -7 cells 
and found that transfection into MCF-7 cells resulted in the efflux of mitoxantrone, 
doxorubicin and daunorubicin. Two other independent groups also cloned an identical 
sequence from mitoxantrone-resistant human colon carcinoma cells [222] (MXR) and from 
human placenta [223] (PABCB). Currently, this transporter is referred to as BCRP/ABCG2 
(reviewed in [224, 225]). 
BCRP is a 70 kDa protein consisting of one NBD, one TMD containing six 
transembrane segments and N- and C- termini located intracellularly (Figure 1.5). 
Compared to P-gp, BCRP is often referred to as a half transporter, as it is considered to 
form a homodimer through di sulphide bonded cysteine residues in order to function ([224, 
225]). In support of this notion, Mitomo et al [226] have demonstrated that BCRP forms 
homodimers in HEK-293 cells, which can be broken by mercaptoethanol treatment, 
although the exact position of the cysteine(s) residue(s) within the BCRP sequence that 
mediate homodimer formation is still under debate. 
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Figure 1.5. Structure of BeRP. BCRF contains contain one TMD and one NBD, and 
forms cysteine-dependent homodimers in order to function. 
BCRF is found expressed in a large variety of tissues including placenta, liver, 
small intestine, brain, colon and lung, where, similarly to P-gp, it plays a role in organ 
protection. At the BBB, BCRF expression has been observed in BECs of porcine [227], 
mouse [228] and human origin [229]. Using confocal microscopy, Cooray et al [229] 
observed luminal BCRF expression in BECs ofhurnan tissue sections, indicative of barrier 
function . Sequencing of BCRF from normal tissue in comparison to that originally 
described from MCF-l tumour cells, revealed a discrepancy in one amino acid at position 
482 [230] . Wild type BCRP has an arginine (R482) where in many antracycline-resistant 
tumour cell lines there is a glycine or threonine (R482G/T). This difference in the amino 
acid sequence of BCRF has led to some confusion as to the substrate range. It appears as 
though both wild type and mutated BCRF can transport common drugs such as 
methotrexate and mitoxantrone, whilst only the mutated form shows preference for rh123 
and enhanced activity towards daunorubicin and doxorubicin. 
The transport function of BCRF for endogenous substances has not been 
extensively investigated, especially with regards to the BBB. mdrl a (-/-) mice have an 
enhanced BCRF expression of around three-fold in brain microvessels compared to wild 
type mice [228]. Furthermore, Cistemino et al [228] have shown that BCRP inhibition in 
mdrl a (-/-) mice results in enhanced prazosin and mitoxantrone accumulation in the brain. 
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Youdim et al [231] also demonstrated that the brain penetration of the flavanoid quercetin 
was increased by BCRP inhibition in rat models. The substrate range ofBCRP shares an 
overlap with P-gp (e.g. Hoechst 3342 [232,233], mitoxantrone [234], reserpine [235, 
236]), and both P-gp and BCRP are inhibited by elacridar (GF120918) [237, 238]. Future 
investigations wi ll yield a more detailed understanding of the role of BCRP at the BBB 
(see Table 1.3 for substrate list). 
Substrate class 
Anti-cancer drugs 
Anti-HIVagents 
Natural compounds 
Fluorescent dyes 
Inhibitors 
Examples 
Antracyclines, mitoxantrone, methotrexate, prazosin, 
topotecan, 
Lamivudine 
Flavonoids, porphyrins, sulphated oestrogens 
Mitoxantrone, Hoechst 3342 
Fumitremorgin C and analolgues e.g. K0143. Elacridar 
(GFI20918), biricodar (VX-71 0), reserpine, prazosin. 
Table 1.3. BCRP substrates and inhibitors. Substrates of BCRP are less well 
characterised than those of P-gp, however there is a large degree of overlap. The BCRP 
inhibitor names given by the drug companies are shown where appropriate, with other 
synonyms shown in brackets. In this study, the name given by the drug company was used 
un less otherwise stated. Adapted from [221 , 225] 
1.1 .6.3 Regulation of efflux transporter expression 
The regulation of P-gp is an area of extensive research, whilst the regulation of 
BCRP has not been extensively investigated as yet. Many extracellular molecules can alter 
P-gp function and/or expression by BECs. For example, ligands for PXR (ligand-activated 
transcription factors) can increase P-gp expression. Dexamethasone has been demonstrated 
to increase P-gp expression and cyclosporin A transport in isolated rat capillaries via PXR 
signalling [239]. Interestingly, the anti-nociceptive action of intravenous methadone, a P-
gp substrate, was found to be reduced by 70 % in transgenic mice expressing human PXR 
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[240]. PXR ligand xenobiotics could therefore act to induce P-gp expression, self-limiting 
their passage across the BBB. 
Inflammatory mediators can also affect the expression of P-gp. Intracranial 
ventricle injections ofLPS reduce P-gp expression [241]. However, peripheral 
inflammatory pain can increase P-gp expression [242]. Recently, it has been demonstrated 
that TNF-a and endothelin-l rapidly decrease P-gp transport activity after 1 h incubation, 
with no changes in P-gp expression at the protein level in rat brain capillaries [243]. 
However, this effect was transient and by 6 h P-gp expression and function had increased 
to double that of control levels. Overall, many agents can induce a decrease and increase in 
P-gp expression and/or activity (Table 1.4). 
1.1.7 The role of the BBB in CNS pathologies 
There is increasing evidence of a role for the BBB in the pathogenesis of many 
diseases affecting the CNS. Indeed, BBB dysfunction is a hallmark of many pathological 
states including Alzheimer's disease (AD), multiple sclerosis (MS) and cerebral ischemia, 
amongst others. In addition, the presence of an intact BBB may affect the success of 
potentially beneficial therapies for many CNS disorders. For example, P-gp and BCRP 
expressed by BECs hinder access to the brain of many drugs used to treat epilepsy (where 
increased P-gp expression is also found), brain tumours and depression (reviewed in 
[172]). Similarly, many drugs that are effective in peripheral infectious diseases are not 
effective in CNS infections, as is the case of cerebral malaria and HIV -1 encephalopathy. 
In this section, the role of the BBB in mUltiple sclerosis and cerebral ischemia will be 
briefly discussed before we consider in greater detail what is known about BBB 
dysfunction in AD. 
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Model Agent Effect on P-gp expression Reference 
and/or function 
Rat brain Dexamethasone, Increased protein expression and [239] 
capillaries pregnenolone. transport activity. 
Rat BEC cell Dexamethasone, PKC No change in protein expression, [244] 
line, GPNT activation. increased activity. 
Rat brain TNF-a, ET-l Biphasic response. After 1 h [243] 
capillaries incubation decreased activity, 
after 6 h incubation increased 
protein expression and activity. 
Human BEC TNF-a No change in protein expression, [245] 
cell line BB 19 decreased activity. 
Rat BECs cell TNF-a Increased mRNA levels, [246] 
line GPNT decreased activity. 
Primary rat Phenobarbital , Increased protein expression and [247] 
BECs phenytoin, activity. 
carbamazepi ne, 
Rat in vivo Kainate induced Increased protein expression. [248] 
seizures. 
Primary rat Glutamate Increased mRNA levels, protein [249] 
BECs expression and activity. 
Primary rat Hydrogen peroxide, Increased mRNA levels and [250] 
BECs hypoxiaJreperfusion activity. 
Primary rat Repetitive hypoxia. Increased protein expression and [251] 
BECs activity. 
Mice in vivo, HIV-Tat Increased mRNA levels, protein [252] 
and mice expression and activity. 
BECs 
Mouse BECs TGF-p Increased activity. [253] 
cell line, 
MBE4 
Primary rat Glutathione depletion. Increased protein expression and [254] 
BECs activity. 
Mice BECs in Oral rifampin-treated Increased activity. [240] 
vivo mice overexpressing 
human PXR. 
Rat BEes in Intracranial LPS Decreased mRNA levels and [241] 
vivo injections function. 
Rat BECs in Lam bda -carrageenan Increased protein expression and [242] 
vivo hind paw injection. activity. 
Table 1.4. A selection of modulators ofP-pg expression and/or function by BECs 
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1.1.7.1 Multiple sclerosis 
MS is the most common neurological condition affecting young adults, with around 
85,000 people in the UK diagnosed with MS [255]. In many cases, MS follows a course of 
remission and relapse and is characterised by axonal demyelination and microvascular 
inflammation [256, 257]. Active CNS lesions, (manifested by areas of active 
demyelination) are characterised by the activation of microglia and macrophages, possibly 
via a T cell-mediated autoimmune response [256,257]. Axons and astrocytes may also be 
affected in MS. Increased BBB permeability is a characteristic ofMS [258,259] and TJ 
disruption, including alterations in ZO-1 and occludin expression are frequently found in 
active MS lesions [260-262]. In animal models ofMS (allergic encephalomyelitis, EAE), 
and MS patients, the cytokines interleukin-l, TNF-<l and interferon- y (lFN-y) are 
increased (reviewed in [263, 264]). In vitro, all three of these cytokines can alter TJ 
expression, suggesting a potential mechanism by which BBB leakiness is induced in MS 
patients [265-270]. 
1.1.7.2 Cerebral ischemia 
Cerebral ischemia is an event whereby parts of the brain do not receive sufficient 
blood supply to maintain neuronal function. Ischemic events e.g. stroke can lead to 
increased mirovascular permeability and oedema both clinically in vivo and in vitro 
(reviewed in [271]). TJ disorganisation might playa key role in the increased BBB 
permeability observed in ischemia. Witt et al [272] have demonstrated a concomitant 
reduction in occludin expression and increased permeability to sucrose using a low 02 
model of ischemic insult in rats. Fisher et al [273] have demonstrated in vitro using 
porcine BECs, that hypoxia induces increased permeability and ZO-l down-regulation via 
VEGF production. The application ofVEGF to in vitro cultures can reduce the expression 
of occludin and ZO-l in bovine BEes [274]. Van Bruggen et a/ [275] have also found that 
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treatment of mice with a VEGF antagonist can reduce oedema and infarct size in a middle 
cerebral artery occlusion model of stroke. Nitric oxide (NO) is also considered a possible 
modulator ofBBB penneability. Mark et al [276] have demonstrated in vitro that 
increased BECs penneability as a result of oxygen deprivation can be attenuated by 
inhibition of nitric oxide synthase. Thus, the increased BBB penneability that occurs as a 
consequence of ischemia, potentially exacerbates the symptoms found in stroke. 
1.2 Alzheimer's disease (AD) 
Dementia, as defined by the Diagnostic and Statistical Manual of Mental Disorders 
IV [277], is 'the development of multiple cognitive deficits (including memory 
impainnent) that are due to the direct physiological effects of a general medical condition, 
to the persisting effects of a substance, or to multiple aetiologies'. In practise, dementia 
leads to the loss of skills needed to carry out daily functions. Globally, the direct and 
indirect costs of dementia were estimated by Winblad and Wimo [278] to be in the region 
of US $ 248 billion in 2003, which with an ageing population could rise considerably in 
the coming years. The incidence of dementia doubles every 5 yrs after 65 yrs of age, with 
around I in 5 individuals over 80 years of age affected by dementia [279-281]. As global 
demographics shift to an aging population, with more countries developed or developing 
(e.g. China, India), it is more than likely that dementia cases will rise. Indeed, Ferri et al 
[279] have calculated that dementia cases will double every 20 yrs to 81.1 million by 2040. 
AD accounts for 40 - 60 % [280, 282] of all dementia cases, and in 2007, in the UK, there 
were -- 700,000 people who suffered from dementia, at a cost of over £17 billion [283]. 
Approximately 90-95 % of AD cases are idiopathic (no established cause) and occur over 
65 yr of age, tenned late onset/non-familial/sporadic AD (SAD) [284,285]. The remainder 
of cases exhibit inherited patterns and occur frequently in patients under 65 yrs of age, 
tenned early onset/familial AD (FAD). 
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1.2.1 The pathology of AD 
Aloys Alzheimer, a German neurologist, was the first to describe a patient with 
what is currently known as AD. At a conference of psychiatrists in 1906, Alzheimer 
described [286-289] a deceased patient (D. Augustine), who had a five year history of 
progressive memory impairment, hallucinations, delusions and severely impaired social 
functioning, which are hallmarks of AD today. Currently, AD is recognised as a 
progressive neurodegenerative illness (clinical stages are shown in Table 1.5), whereby 
initial minor memory lapses develop into severe motor dysfunction, with death occurring 
10-15 yrs after diagnosis. 
Stage 1: No cognitive decline 
No memory problems evident to a health care professional. 
Stage 2: Very mild decline 
Memory lapses (e.g. forgetting location of keys) not noticeable to friends or 
during medical examination 
Stage 3: Mild cognitive decline 
Friends, family and co-workers notice memory alterations. Memory problems 
can be recognised during medical examination and in some cases diagnosed 
with early stage AD. Problems include; 
Word/name recall problems 
Decreased name retention 
Losing/misplacing an object 
Decreased ability to plan/organise 
Stage 4: Moderate cognitive decline/mild or early stage AD 
Clearly noticeable issues in: 
Decreased current event and personal knowledge 
Impaired mental arithmetic ability 
The individual will appear withdrawn and subdued 
Stage 5: Severe cognitive decline/mid stage AD 
Major cognitive dysfunction emerges and assistance with day-day activities 
may be required. Symptoms include: 
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Unable to recall address, telephone number, education history and can become 
confused with the date and day 
Require help choosing appropriate clothing and with mental arithmetic 
Usually can recall own name and do not require help eating. 
Stage 6: Severe cognitive decline/moderately severe mid stage AD 
In addition to worsening memory, personality changes emerge and individuals 
may; 
Lose awareness of recent experiences and events 
Recollect imperfectly personal history, however can recall own name 
Need help dressing and using the toilet, incontinence 
Hallucinations, delusions, repetitive behaviour 
Stage 7: Very severe cognitive declinellate stage AD 
In the final stage, AD patients often lose the ability to speak and control 
movement: 
Individuals lose the ability to form recognisable speech 
Need constant help eating and using the toilet 
Lose the ability to walk, smile and muscle become rigid 
Death 5-15 years post diagnosis 
Table 1.5. Symptomatic stages of AD. AD is a chronic neurodegenerative illness, with 
memory and normal cognitive function loss becoming progressively worse during disease 
progression. Source [290] 
In the context of AD pathology, Alzheimer, using silver impregnation microscopy 
staining, observed neuronal atrophy, extracellular 'miliary' deposits (which are now known 
as senile plaques) and intraneuronal neurofibrillary tangles (NFT) over the cerebral cortex 
of Augustine [286-289]. Since this initial description, the core of the plaques was found to 
consist of the polypeptide A~ [291-294], whilst the NFT were shown to consist of paired 
helical filaments ofhyperphosphorylated microtubule associated tau protein [295,296]. 
Nowadays, complete diagnosis of AD is only fully confirmed by the identification ofthese 
findings in post mortem tissue and falls into different staging categories. Braaq and Braaq 
have investigated the distribution ofNFT in the AD brain and describe six stages in AD 
pathogenesis (BRAAQ stages) [297]. Initially, NFT appear in the trans-enterorhinal region 
of the basal mediotemporal cortex (stages I and II), then they can be detected in the 
hippocampus (stages III and IV) and the neocortex (stages V and VI). ThaI et af [298-300], 
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have more recently suggested that the expansion of AP deposits correlates with NFT and 
the development of cognitive deficits. These authors have observed five stages of AP 
deposition in the medial temporal lobe; stage 1 occurs in the neocortex, stage 2 in the 
enterorhinal region, stage 3 in the thalamus, basal ganglia and hypothalamus, stage 4 in the 
midbrain and medulla oblongata and stage 5 in the brain stem and cerebellum. It should be 
noted that for both NFT and AP progression in AD, the hippocampus is affected 
throughout the different stages. 
A further characteristic of AD is the loss of cholinergic neurones in the basal 
forebrain of AD patients [301]. ACh is a neurotransmitter involved in the cognitive 
functions including learning and memory. In addition to the loss of cholinergic neurones, 
decreased choline acetyl transferase (the enzyme involved in ACh synthesis), choline 
uptake and ACh release have all been reported in AD patients. 
Overall, AD is characterised by neuronal degeneration, NFT and AP deposits. AP is 
considered at the centre of AD pathogenesis, the evidence of which shall now be discussed 
in more detail. 
1.2.2 Amyloid IJ (AIJ) cascade hypothesis 
There is no clear defining theory for the underlying cause(s) of AD. The most 
widely accepted view is described as the AP cascade hypothesis [302,303] (Figure 1.6), 
although more recently vascular alterations (discussed in section 1.2.4) have come to be 
considered critical events in AD pathogenesis. Under the AP cascade hypothesis, in AD 
patients, an event(s) occurs that causes increased levels of AP in the brain, potentially 
through increased production by brain resident cells or decreased clearance (section 1.2.3). 
AP has a high tendency to self-aggregate and forms soluble oligomers, fibrils and plaques, 
either intra or extra-neuronally. These increased AP species induce an inflammatory 
response, neuronal dysfunction and lead to the symptoms of AD disease. 
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Upstream event (s) such as: 
APP, PS I or PS2 mutations 
Other risk factors e.g. aging, environmental factors 
Increased A~ production or increased A~ 1-42/ 1-
40 ratio 
Decreased A~ clearance/degradation 
Idiopathic? 
y 
Increased A~ 1-42/40 accumulation in extracellular 
space and within neurones 
y 
A~ oligomerisation and deposition as plaques 
y 
Subtle effects on synapses 
and serious neuronal 
injury 
~ 
Microgial and astrocytic 
activation and 
inflammatory response 
Altered neuronal ionic homeostasis and oxidative injury 
Altered kinase/phosphatase activity leading to NFT 
Widespread neuronal/neuritic dysfunction with 
neurotransmitter deficits 
Figure 1.6 AP cascade hypothesis. AP is believed by many in the field to be the cause of 
AD. In the A~ cascade hypothesis, increased AP levels in the brain of AD patients lead to 
widespread neuronal degeneration and inflammation which cause dementia. Adapted from 
[302-304]. 
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1.2.2.1 AfJ processing 
Shortly after the identification of A~ as the main component of senile plaques, its 
precursor protein was identified and named as the amyloid precursor protein (APP) [292] 
(Figure 1.7). APP is part ofa family of type 1 membrane glycoproteins, which in mammals 
includes APP-like protein 1 and 2 (APLP 1 and 2) (reviewed in [305-307]). The human 
AP P gene is located on the long arm of chromosome 21 and codes for three main isoforms 
of695, 751 and 770 amino acids in length. APP 751 and 770 contain a domain that is 
homologous to the kunitz-type serine protease inhibitors (KPI), and are expressed by 
virtually all cell types. APP695 lacks the KPI domain and is primarily expressed by 
neurones. 
APP is processed by three proteinases termed a-, P- and y- secretase. Cleavage of 
APP by a-or p-secretase generates larger soluble APP fragments termed APPsa and APPsP 
and C-terminal fragments (CTFa and P). Subsequent cleavage ofCTFa by y- secretase 
produces a 3 kDa product whilst CTFP cleavage produces AP of various amino acids in 
length, of which AP 1-40 and AP 1-42 are the most prominent, and the APP intracellular 
domain (AI CD). The main neuronal ~-secretase is ~-site APP cleaving enzyme (BACE), 
whilst y-secretase is a protein complex consisting of at least presenilin 1 and 2 (PS 1 and 2), 
nicastrin, anterior pharynx defective-l and presenilin enhancer. BACE, APP and the y-
secretase complex are most likely to degrade APP in endosome compartments and thus 
secrete AP via vesicular release. Thinakaran and Koo [306] have suggested that only 10 % 
of APP is present on the plasma membrane in cultured cells. APP can undergo axonal 
transport and Cirrito et al [308] have recently demonstrated AP vesicular release via 
synaptic exocytosis. 
A~ has a high tendency to self-aggregate, forming soluble dimers and oligomers 
and larger insoluble fibrils and plaques high in p-pleated sheet content. The solubility of an 
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A~ species is generally defined as it ability to remain in the aqueous phase of a solution 
after high speed centrifugation (> 100,000 xg, 1 h). 
(a) Human APP 770 
1 mlpglallll aawtaralev ptdgnaglla epqiamfcgr Inmhmnvqng 
51 kwdsdpsgtk tcidtkegil qycqevypel qitnvveanq pvtiqnwckr 
101 grkqckthph fvipyrclvg efvsdallvp dkckflhqer mdvcethlhw 
151 htvaketcse kstnlhdygm Ilpcgidkfr gvefvccpla eesdnvdsad 
201 aeeddsdvww ggadtdyadg sedkvvevae eeevaeveee eadddedded 
251 gdeveeeaee pyeeatertt siattttttt esveevvrev cseqaetgpc 
301 ramisrwyfd vtegkcapff yggcggnrnn fdteeycmav cgsamsqsll 
351 kttqeplard pvklpttaas tpdavdkyle tpgdenehah fqkakerlea 
401 khrermsqvm reweeaerqa knlpkadkka viqhfqekve sleqeaaner 
451 qqlvethmar veamlndrrr lalenyital qavpprprhv fnmlkkyvra 
501 eqkdrqhtlk hfehvrmvdp kkaaqirsqv mthlrviyer mnqslsllyn 
551 vpavaeeiqd evdellqkeq nysddvlanm iseprisygn dalmpsltet 
601 kttvellpvn gefslddlqp whsfgadsvp antenevepv darpaadrgl 
651 ttrpgsgltn ikteeisevk mdaefrhdsq yevhhqklvf faedvqsnkq 
701 aiiq1mvqqv viatvivitl vmlkkkqyts ihhgvvevda avtpeerhls 
751 kmqqngyenp tykffeqmqn 
(b) 
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Figure 1.7. Production of AP from its precursor APP. (a) The amino acid sequence of 
APP with the A~ 1-42 sequence in bold [309]. (b) APP is cleaved by the action of a-, ~­
and 'Y- secretases to produce A~ 1-40 and A~ 1-42. A selection of FAD mutations are also 
indicated, which increase the net production of A~, the ratio of A~I-42/1-40 or the 
aggregation properties of A~ [309, 310]. 
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1.2.2.2 AfJ levels in AD 
The levels of A~ in the plasma, cerebrospinal fluid (CSF) and total brain continue 
to be an area of intense research with the view to aid the diagnosis and understanding of 
disease progression (reviewed in [311-313]). Some researchers have argued that A~ 
plaques do not to correlate with AD progression, since A~ plaques are found in non-
dementia patients, and in APP transgenic mice, memory impairment and alterations in 
neuronal function occur prior to amyloid deposition [314, 315]. In contrast however, 
increased insoluble, and, importantly, soluble AP oligomers are found in the brain tissue of 
AD patients (reviewed in [311]). For example, Gong et al [316], found an increase of up to 
70-fold in levels of oligomeric species (main constituent 12-mer) in AD patient tissue, 
compared to controls. The increased retention of positron emission tomography (PET) 
agents, which can bind to the fibrillar form of AP, have also been demonstrated in AD 
patients and in a subset of patients with mild cognitive impairment that subsequently 
developed AD (reviewed in [317]). For example, the retention of the Pittsburgh compound-
B (PIB) was higher in AD patients compared to controls and was inversely correlated with 
glucose metabolism [318]. 
Measurements of plasma A~ levels have been inconclusive as to whether A~ levels 
are increased or unaltered in AD (reviewed in [313] ). The contradictory findings can 
originate from the inability of ELISA techniques to sufficiently measure aggregated A~ 
levels, A~ binding to plasma proteins and a high intra- and inter-individual variability. 
More recently, however, increased free [319] and total plasma A~ levels [320] have been 
found in AD patients compared to healthy controls. Furthermore, Van Oijen et al [321] 
have found that high AP 1-40 levels in early life corresponded with an increased risk of 
developing dementia in later life, compared to those who did not develop dementia. 
CSF levels of A~ 1-42 are reduced in AD patients compared to controls, most 
likely as the result of sequestration and deposition in the brain [311, 312, 322]. Indeed, 
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CSF levels are inversely correlated with AP load after autopsy [323] and PIB labelling 
[324]. 
1.2.2.3 Genetic/actors underlying AD pathogenesis 
A key line of evidence for the role of AP in AD has originated from genetic studies. 
Down's syndrome is caused by a trisomy in chromosme 21, where theAPP gene is 
located, and Down's syndrome patients display AD pathologies including increased levels 
of AP 1-40 and AP 1-42 in brain and plasma [325, 326], AP plaques [327,328] and the 
development of dementia at an early age [329]. In a rare case of Down's syndrome, a point 
break mutation left a patient diploid for APP [330]. This patient lived until 78 years of age 
with no evidence of dementia and an autopsy revealed no AP deposition, highlighting a 
central role of AP in AD. 
The genetic mutations found thus far in FAD all reside in the APP, PS 1 or PS2 
sequence (reviewed in [284, 285]). Mutations in the APP sequence are often named after 
the region of origin (e.g. Swedish, Dutch, Arctic, Iowa) and all have the net consequence 
of increasing the production of AP or increasing the ratio of AP 1-42 to AP 1-40 [284, 
285]. In many cases the ability of these mutations to confer AD pathology has been 
confirmed in transgenic mouse models (reviewed in [310, 331, 332]). For example, the Tg 
2756 mouse model expresses the 695 human isoform of the Swedish mutation of APP, and 
develops AP deposits at around 9 months of age. Mutations in PS 1 and PS2 have the net 
result of increasing the production of AP 1-42, which is considered a more toxic species, as 
observed from the plasma and in the media of cultured skin fibroblasts from patients 
harbouring PS 1 and/or PS2 mutations [333]. 
The majority of AD is sporadic, with the only high genetic risk factor being ApoE4 
allele inheritance [334]. The ApoE gene is involved in nerve regeneration, 
immunoregulation and the activation of several lipolytic enzymes [335]. ApoE4 is 
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associated with a higher A~ plaque burden [336, 337] in AD, although the mechanism 
through which this is caused is not clear [338]. Crossing APP transgenic mice with Apo E-
deficient mice results in reduced cerebral A~ deposition [339]. An interesting role of ApoE 
proteins is their ability to block A~ transport from the blood into the brain. ApoE2 and 3 
completely prevent the blood-to-brain transport of A~ in a guinea pig perfusion model, 
whilst 85 % of Apo E4-A~ crossed into the brain, which could increase the brain levels of 
A~ and add to AD pathology [340]. 
1.2.2.4 Effects of soluble AP on neurons 
There is a large body of work that has demonstrated that A~ is toxic to neurones in 
vitro [341-353] and can cause neuronal dysfunction in vivo both in transgenic models and 
after intracerebral injection of A~ [354]. More recently, soluble oligomeric A~ species are 
emerging as the most neurotoxic A~ fonns (reviewed in [355-359]). As noted earlier, 
oligomers have been detected in AD patients at 70 fold higher levels than in control 
patients [316]. The first description of toxic non-plaque A~ species was noted by Oda et at 
[360]. Astrocytic Apo J can prevent the fonnation oflarge aggregates, and was incubated 
with A~ 1-42 and PC12 cells (cell line derived from a pheochromocytoma of the rat 
adrenal medulla) in an attempt to reverse toxicity. Oda et at [360] found enhanced 
neuronal toxicity, which was later attributed to smaller A~ oligomers [361] named A~­
derived diffusible ligands (ADDL) [356, 362]. ADDLs can be anything from dimer to 24 
mer in size and impair synaptic plasticity and hippocampal long tenn potentiation (LTP) 
and induce neuronal cell death. ADDLs can induce hippocampal, but not cerebellar, 
neuronal death in in vitro mice cultures, mirroring AD pathology [356, 357, 362]. In 
addition, de Felice et al [363] have shown that oligomers isolated from human AD tissue 
can induce tau hyperphosphorylation in rat hippocampal neuronal cultures. 
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More recently, synaptic defects are thought to underlie the cognitive dysfunction 
found in AD. A~ administration in vivo and in vitro, similarly to AD transgenic mouse 
models, leads to reduced dendritic spines and synapse number, and inhibition of L TP 
(reviewed in [364-368]). The inhibition ofLTP, which is believed to be critical for 
memory formation, might, in part, be due to A~-induced loss of AMP A receptors and 
PSD-95 ([364-368]). Soluble oligomers can induce many of these changes in vivo [359] . 
For example, Klyubin et at [369] have recently found that A~-dimers, isolated from AD 
patients, impaired L TP, decreased hippocampal spine density and disrupted learned 
memory behaviour in rats, and these effects were inhibited by A~ antibody treatment. 
As described earlier, NFT are considered to be a consequence of A~ in AD. NFT 
are not specific for AD and are found in other eNS disorders with (e.g. fronto-temporal 
dementia with Parkinsonism) and without dementia (e.g. progressive supranuclear palsy). 
NFT are insufficient to induce plaques. By contrast, A~ has been shown to induce tau 
pathology. Gotz et al [370] have demonstrated that intracerebral injection of A~ 1-42 into 
mutant tau over-expressing mice can increase the levels ofNFT by 5-fold. Lewis et al 
[371] observed that transgenic mice expressing mutant tau and APP have increased levels 
ofNFT in the olfactory cortex and limbic system compared to mice that expressed the tau 
mutation alone. Thus, whilst NFT are considered a key component of neuronal toxicity in 
AD, they are more likely to playa secondary role to A~ [372]. 
1.2.2.5 Inflammatory response in AD 
Another component of AD pathology is the presence of brain inflammation. The 
observed inflammatory response includes astrocytic end feet swelling [373], microglia 
activation [374] and either pericytic atrophy [375] or an increase in pericyte capillary 
coverage [376], which may constitute a second line of defence. The activation of astrocytes 
and microglia is often associated with an inflammatory response, and in AD patients the 
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cytokines IL-l a/~, IL-6 and TNF-a are elevated [377]. Increased levels of A~ might in 
part be responsible for the inflammatory response in AD. A~ in vitro has been 
demonstrated to activate astrocytes and microglia to produce the cytokines mentioned 
above ([374, 377]), adding further evidence for the role of A~ in AD. Whilst the relative 
contribution of inflammation to neuronal malfunction and death remains undetermined, it 
is interesting to note that inhibition ofp38MAPK, activation of which is associated with 
increased production of cytokines by microglia, has beneficial demonstrable effects in 
vivo. Munoz et al [378] have recently demonstrated that p38MAPK inhibition suppressed 
hippocampal levels ofTNF-a and IL-l induced by intracerebroventricular A~ 1-42 
injections in mice, which was associated with an improvement in cognitive function. 
1.2.3 Mechanisms of All deposition 
The increased levels of A~ found in AD may be a direct consequence of increased 
production by brain resident cells, or of decreased clearance via the ISF or across the BBB. 
1.2.3.1 Increased production of AP by brain resident cells 
The increased levels of A~ found in the eNS of AD patients are an indication of 
increased production by brain resident cells. Indeed, cultured neurones and astrocytes have 
been shown to produce A~ [379], and neurones in vivo also produce A~ [308]. Neuronal 
APP processing can occur during axonal transport and via the endosomal pathway. Cirrito 
et al [308] have demonstrated that synaptic activity is associated with vesicular A~ release 
in Tg2756 mice. Mutations in PS 1 and/or 2 and APP increase the production of A~ by 
neurones in vitro [380, 381]. It is therefore considered that increased A~ production by 
neurones might be a key pathogenic event in AD. However, there is currently no direct 
evidence of this in non-familial AD, and the mechanisms by which neurones might 
increase A~ production in AD remains unclear. 
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1.2.3.2 Perivascular drainage of Aft 
Reduced perivascular drainage of AP might represent a mechanism by which CNS 
AP levels are increased (reviewed in [382]). The interstitial fluid (ISF) that surrounds the 
brain tissue, is roughly 280 ml in volume, and has a drainage rate of 0.11-0.29 J.lVminute/g 
of brain [382]. ISF drains along the capillary and artery basement membrane to cervical 
lymph nodes. In AD, this pathway for AP elimination might be disrupted. Increased AP 
production by neurones, and stiffening of arteries during aging could reduce the clearance 
of AP via ISF drainage. AP is also found deposited on the blood vessels (arteries and 
capillaries) in many AD patients as a result of a process known as cerebral amyloid 
angiopathy (CAA), and is associated with a loss of smooth muscle cells in arteries [382]. A 
loss in smooth muscle cells might contribute further to reducing the perivasular drainage of 
Ap. 
1.2.3.3 Blood-brain barrier clearance of Aft 
Recently, Zlokovic et al [137, 383] have postulated that faulty clearance of AP at 
the BBB is key to the pathogenesis of AD. BECs express proteins capable of AP transport 
into the brain, most notably the receptor for advanced glycation end products (RAGE) and 
megalin, and from the brain, namely low-density lipoprotein receptor related protein (LRP-
1) and P-gp (Figure 1.8). 
RAGE is a multiligand receptor of the immunoglobulin superfamily, and is found 
expressed on microglia, neurones and BECs. The distribution of RAGE appears to be 
altered in AD. Donahue et al [384] observed an increased microvascular and decreased 
neuronal RAGE expression in the hippocampi of AD patients compared to controls. Miller 
et al [385] have recently confirmed this finding in hippocampal slices and found that 
RAGE levels were increased in cerebral BEes at the onset of AD and also in the 
progression to advanced BRAAQ stages. The interaction of AP with RAGE on neurones 
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can result in direct and indirect (via microglia activation) toxicity [386] and neuronal stress 
[387,388] , whil st in BECs a major consequence of Ap-RAGE interaction is AP 
transcytosis across the BBB from the blood to the brain. 
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Figure 1.8. Proposed BBB transport routes for Ap. Abluminal LRP-l in addition to the 
ABC transporter P-gp, is considered to transport AP from the brain into the blood. RAGE 
mediates blood-to-brain AP transport. LRP-2/Megalin is also a proposed to mediate blood-
to-brain transport of ApoJ-bound Ap. 
Using isolated primary hBECs, Mackie et a/ [389] demonstrated that RAGE 
transcytosed AP 1-40 from the luminal (blood) side to the abluminal side and was blocked 
by an anti-RAGE antibody in vitro. Deane et al [390] used an in vivo model, whereby AP 
1-40 was intravenously infused into mice, and found RAGE-mediated AP transcytosis 
across the BBB. RAGE-Ap interactions in the mouse model also led to the expression of 
inflammatory cytokines including TNF-a. and IL-6, and induced vasoconstriction via 
endothelin-l production. These authors also showed that in RAGE-null mice, the transport 
of AP into the CNS, was undetectable. Soluble RAGE (sRAGE), is a secreted form of 
RAGE, which can act as a signalling decoy receptor, and Emanuele et al [391] have 
recently reported decreased levels of sRAGE in the plasma of AD patients. In AD, 
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increased RAGE expression by BECs, together with decreased plasma sRAGE would 
therefore result in increased susceptibility to AP deposition in the brain. 
A second blood-to-brain AP transporter at the BBB for Apo I-bound AP has also 
been described. Zlokovic et a1 [392] have shown that the infusion of ApoJ-Ap complexes 
in guinea pigs, results in a high affinity brain uptake via LRP-2/megaIinlgp330. However 
the significance of this interaction for AD has not been explored further. 
LRP-l is a multi-ligand scavager receptor expressed on the abluminal membrane of 
BECs and also on neurones. Data from in vitro fibroblast and neuronal cultures have 
demonstrated that LRP-l binds to carrier (<12 macroglobuIin)-bound AP [393], and in vivo 
LRP-l binds to free Ap. At the BBB, interactions between AP and LRP-l result in the 
clearance of AP from the abluminal membrane to the luminal side i.e. clearance of AP 
from the eNS. Shibata et a1 [394] reported that after intracerebral injection of A~ 1-40 in 
young mice, the peptide was rapidly removed from the brain, an effect that could be 
significantly reduced by LRP-l antibodies. Deane et al. [395] further demonstrated in vivo 
the ability of LRP-l to clear AP from the mouse brain and also identified two binding 
regions in LRP-l which AP binds to: cluster II and IV. Subsequently, Sagare et al [319] 
found that treatment with recombinant LRP cluster IV (sLRP-IV) in APPsw +1- mice 
resulted in clearance of A~ 1-40 and A~ 1-42 from the hippocampus, cortex and whole 
brain. The increased clearance of AP appeared to be mediated by sequestration of A~ in the 
plasma by sLRP-IV, and resulted in improvements in cognitive function as assessed by 
operant learning. 
Alterations in LRP-l expression are also found in AD. Kang et a1 [396] have 
described decreased LRP-I expression at the BBB associated with increased plaque 
deposition in AD patients. Donahue et a1 [384] have also demonstrated reduced LRP-l 
expression in cerebral microvessels of AD patients. Intriguingly, Sagare et al [319] have 
also found 30 % reduction in soluble LRP (sLRP) plasma levels in AD patients and an 
increase in free A~ levels. There remains a degree of controversy as to the validity of LRP-
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1 genetic mutations as a risk factor for AD. There are conflicting reports of a 
polymorphism of the LRP-l gene as an increased risk factor for developing AD. A positive 
correlation between with the C766T and C766C genotype but not the T766T genotype of 
LRP-l has been observed in AD patients [397-401], although no correlation was observed 
in other studies [402-405]. In one study, carriers of the T766T genotype were observed to 
have decreased plaque numbers and increased LRP-l expression by BECs, although all 
presented with AD [396]. Therefore in AD, a decreased LRP-l expression at the BBB and 
sLRP-l the plasma, could result in increased A~ deposition in the brain. Currently, the 
application of sLRP to the treatment of AD is under investigation. 
Lam et al [406] were the first to describe the ability of A~ to bind to P-gp. The 
group found that transfection of MDR into a human embryonic kidney cell line (HEK293) 
previously stably transfected with human APP harbouring the Swedish mutation, or co-
transfection with the Swedish mutation APP gene into wild type HEK293 cells, resulted in 
increased A~ levels in the media. However, MDRI transfection resulted in an increased 
APP expression in the cell line, which may account for increased A~ production. A~ was 
confirmed as a P-gp substrate, since A~ 1-40 and A~ 1-42 were shown to decrease the 
transport of colchicine into P-gp-enriched hamster vesicles and also to quench the 
fluorescence of labelled P-gp. Further in vitro [407] evidence for P-gp- mediated A~ 
transport has been derived from a porcine derived kidney epithelial cell line (LLC). LLC 
cells transfected with human P-gp, showed increased A~ 1-40 and A~ 1-42 transport from 
the basolateral-to-apical chamber when grown on filter inserts compared to untransfected 
LLC cells. This increased A~ transport was inhibited by cyclosporin A. In membrane 
vesicles derived from LLC-mdrl cell lines, the transport ofrh123 was increased compared 
to untransfected LLC cells and was also inhibited by AP 1-40 and AP 1-42 to a similar 
extent as that induced by verapamil. 
Cirrito et al [408] have recently investigated P-gp-mediated AP transport in vivo. 
Initially, it was demonstrated that P-gp null mice cleared intracerebrally injected AP 1-40 
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and AP 1-42 at a much slower rate than wild type mice. However, the P-gp null mice also 
showed a marked decrease in expression of LRP-I, which may account for this effect. This 
group therefore went on to investigate the effect of a pharmacological P-gp inhibitor, 
tariquidar (XR9576), in Tg2576 mice. Tariquidar-treated animals showed increased ISF 
levels of AP compared to control animals. In addition, P-gp null mice when crossed with 
Tg2576 mice displayed increased hippocampal AP load, compared to Tg2576 mice. 
However LRP-l down-regulation might have been responsible in part for this effect. 
Whilst an inverse correlation between P-gp expression and AP plaque deposition has been 
noted in non-dementia autopsies [409], the exact role ofP-gp in AD is not fully understood 
and the contribution of P-gp to AP transport at the BBB warrants further investigation. 
1.2.4 Role of vascular dysfunction in AD pathogenesis 
The BBB may play an important role in the transport of AP into and out of the 
brain. In addition, multiple investigators have recently suggested that cerebrovascular 
dysfunction plays an important part in AD pathology (reviewed in [410-420]). This 
includes hypoperfusion and alterations in brain capillary function. 
1.2.4.1 Brain hypoperjusion in AD 
Using epidemological studies, multiple risk factors have been identified for AD 
(Table 1.6), and most, if not all of which are vascular in nature e.g. stroke, cardiac disease 
and atherosclerosis. De La Torre [421] has recently suggested that the risk factors occur 
prior to cognitive decline and result in a 'critically attained threshold of cerebral 
hypoperfusion' (CATCH hypothesis Figure 1.9) which, in combination with vascular 
abnormalities, may cause dementia in the elderly. A variable global decrease in cerebral 
blood flow (CBF) between 70 % and 90 % has been observed in AD patients, when 
compared to controls [413]. Ruitenberg et af [422] have observed that reductions in CBF 
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velocity and brain hypoperfusion precede the onset of dementia and hippocampal atrophy 
as observed via MRI. Hippocampal hypoperfusion as assessed by SPECT analysis, has 
been demonstrated to predict the progression from mild cognitive impairment to AD [423 , 
424]. 
Ischemic events, which are risk factors for AD, could lead to decreased CBF. 
Snowdon el al [425], examining AD patient autopsies, observed that multiple infarcts in 
the ganglia, thalamus, or deep white matter were a positive indicator for dementia severity. 
Results form Vermeer el at [426] corroborate these data with the finding that MRl-
detectable infarcts more than double the risk of dementia development. Medial artery 
occlusion models in rodents can result in hippocampal neuronal damage, capillary 
irregulariti es, glial reactivity and glucose uptake deficiency, and bilateral occlusion ofthe 
carotid artery, can increase the production of A~ [427,428] , adding to the evidence that 
brain hypoperfusion plays a significant role in AD pathogenesis. 
Heart-related risk factors Peripheral risk factors Brain-related risk factors 
Congestive heart failure Smoking Ageing 
Cardiac arrhythmia Alcoholism Ischaemic stroke 
Hypertension High cholesterol Silent stroke 
Hypotension High intake saturated fat Head injury 
Thrombotic episodes Diabetes mellitus Menopause 
Atrial fibrillation Haemorheo\ogical Migraine 
abnormalities 
Atherosclerosis Depression 
Table 1.6. Risk factors for AD. There are multiple identified risk factors for AD, many of 
which can be linked to vascular dysfunction. Adapted from [421] 
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Advancing age/vascular risk factors 
Critically attained threshold of cerebral hypoperfusion 
y 
Progress ive brain capillary degeneration and EC alterations 
Capillary degeneration; Basement membrane thickening, luminal 
distortion, EC shape change, pericyte degeneration 
y 
Haemodynamic disturbances and reduced energy supply to 
neurones 
y 
Neuronal mitochondrial dysfunction, reduced ATP synthesis 
Abnormalities in protein synthesis and 
neuronal function: AP production, 
NFT, ionic homeostasis/disruption 
Free radical formation, 
inflammatory response 
Neuronal death, cognitive decline 
Figure 1.9. Critically attained threshold of cerebral hypoperfusion vascular 
hypothesis in AD. Torre has proposed that a convergence of aging and vascular risk 
factors leads to a critically attained threshold of cerebral hypoperfusion (CATCH). 
CA TCH leads to capillary dysfunction, alterations in the neuronal homeostatic 
environment and a reduction in neuronal energy supply. Reduced neuronal metabolism 
triggers a cascade of events leading to the development of dementia [421]. 
1.2.4.2 Pathological changes of cerebral capillaries in AD 
Multiple alterations throughout the vasculature have been described in AD patients. 
Cerebral capillaries appear fragmented and display atrophy, luminal buckling, decreased 
luminal diameter, basement membrane thickening, deposition of AP on the capillary wall 
and increased leakiness [413]. Morphological changes in small arteries in AD (e.g. pial and 
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intracerebral arteries) include CAA and decreased vascular smooth muscle content and can 
lead to the rupture of vessels. Capillary degeneration in AD may playa significant role in 
AD pathology which in turn may reflect a disturbance in angiogenesis. Wu et a/ [429] 
identified a gene that was under-expressed in AD BECs called mesenchyme homeobox 2 
(MEOX-2), which is a transcription factor involved in vascular differentiation. Restoration 
of MEOX-2 in isolated BECs from AD patients resulted in angiogenesis, suppressed 
apoptosis and increased LRP-l expression. In Meox-2 null mice, a reduction in brain 
capillary density, cerebral blood flow and angiogenic response to hypoxia was observed. 
Decreased cerebral glucose utilisation is also found in AD patients. Hoyer et a/ 
[430] noted a 45 % decline in cerebral glucose utilisation, whilst Fukuyama et a/ [431] 
found a significant decrease in glucose metabolism in the frontal, parietal and temporal 
region as measured by PET in AD patients. Reduced glucose uptake or metabolism in the 
hippocampus [432, 433], enthorinal [434] and posterior cingulate gyrus [435] can also 
predict the conversion of mild cognitive impairment to AD. De Leon et a/ [436] have also 
demonstrated that the development of mild cognitive impairment in the elderly is predicted 
by reduced glucose metabolism. Decreased expression of Glut-l in AD patient capillaries 
has been observed, which could be a major contributing factor to decreased glucose 
utilisation, and might contribute to neurodegeneration [437, 438]. 
The detection of plasma proteins such as albumin, thrombin and IgG in the brain 
parenchyma of AD patients is indicative ofa leaky BBB [439]. An increase in BBB 
permeability is also observed in AD mouse models. Tg2765 mice display increased BBB 
permeability prior to the onset of pathology, which can be reversed by A~ immunisation 
[440]. In an APPIPSI transgenic mouse model, increased BBB permeability was 
associated with occ1udin down-regulation in mice fed on a high fat diet [94]. Intravenous 
infusion of A~ can also lead to a disruption in BBB integrity in rats [441], and A~ 
increases ECs permeability in vitro [442-444]. The pathological significance of increased 
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BBB penneability has not been fully explored, but in principle it could disrupt the neuronal 
homeostatic environment, further contributing to AD pathogenesis. 
1.2.6 Combined neuronal and vascular dysfunction model for AD 
The most commonly accepted view of AD pathology is the A~ cascade hypothesis, 
whereby increased A~ levels induce direct, or indirect via microglia activation, neuronal 
dysfunction and toxicity. The BBB may playa key role in the transport of A~ out of or into 
the brain, and in part detennine the brain amyloid load. However, what is absent in the 
amyloid beta cascade hypothesis is an understanding of how vascular dysfunction 
including increased BBB penneability, brain hypoperfusion and decreased Glut-l 
expression may be linked to AD pathology. These vascular events could be the result of 
increased A~ levels (A~ cascade hypothesis), and might represent a further mechanism by 
which A~ induces AD pathology. A second possibility is that one or more of these vascular 
events precede A~ deposition and act as a causative factor in AD, such as the CATCH 
hypothesis. A third, unifying possibility, is that vascular events and AP production are 
interlinked in a more complex way. Indeed, as proposed by Roy and Rauk [419], an 
event(s) may occur in AD, that causes increased A~ levels, which induce a synergistic 
toxicity of A~ on BECs and neurones (Figure 1.10, Absent). Under their theory, in addition 
to inducing direct neurotoxicity, AP may also induce BEC damage, which in tum may lead 
to decreased glucose uptake into the brain, stroke and other vascular alterations, with the 
net consequence of inducing neuronal cell death. Whilst the initiating event(s) that causes 
AD is/are currently elusive, it remains a possibility that vascular dysfunction, decreased A~ 
clearance across the BBB, and/or in combination with other predisposition(s) may all act to 
induce A~ production. 
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Advancing age/predisposition 
Increased abnormal APP cleavage/decreased clearance 
y 
Increased soluble AplPlaque fo rmation 
EC damage 
r···· .... :;l 
Stroke and other 
pathologies 
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Neuronal death; AD 
. ... 
.......... ~ 
Direct neurotoxicity 
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dysfunction = MCI 
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Figure 1.10 AP synergistic endothelial and neuronal toxicity hypothesis. AP production 
can lead to BEC damage, which in combination with neuronal cell death leads to AD 
[419]. 
1.2.7 Current therapies for AD 
The only two current routine treatments for AD are based on strategies to prolong 
ACh signalling and prevent excitotoxicity. Cholinesterase inhibitors (targeting enzymes 
that degrade ACh, AChE I) were the first FDA-approved treatments for AD. These include 
tacrine, donepezil , rivastigmine and galantamine. Birks [445] has recently evaluated the 
results of 10 randomised double-blind placebo-controlled AD trials with donepezil, 
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rivastigmine and galantamine, and concluded that whilst they improved cognitive function, 
none of the effects were large. This is in agreement with other clinical trials, which 
demonstrate a slight improvement of symptoms [446, 447] or delayed onset in AD [448]. 
Treatment of mild cognitive impairment, a condition where there is cognitive or memory 
impairment that does not interfere with daily function and might represent a pre-clinical 
AD stage, with AChEI does not alter the conversion to AD [449]. The direct application of 
nicotine to AD patients does not improve memory function, but can lead to increased 
attention span [301]. 
The only other FDA-approved drug for the treatment of AD is memantine, a low 
affinity N-Methy-D-aspartate (NMDA) receptor antagonist. Neurodegeneration as a result 
of excess glutamate activity, is considered a possible mechanism in AD pathogenesis, and 
so mementine was approved for AD treatment [450]. Unfortunately, the benefits only 
appear marginal in AD and only to those in late stages of the disease [451]. Therefore there 
is a need to develop new AD treatments. 
More recently, the assumption that Ap is the root cause of AD has led to the design 
of vaccine strategies for the treatment of AD. Vaccination of transgenic mice with AP 1-42 
or peptide fragments has shown great promise in the removal of plaques from the brain 
[452-460]. Schenk et al [456] immunised AD transgenic mice with AP 1-42 both before 
and after the onset on AP plaque formation and found the near-complete reduction in 
plaque deposits and astrocyte activation. Sigurdsson et al [458] have demonstrated that 
immunisation of transgenic mice which express the Swedish APP mutation (Tg2576), with 
an AP homologous peptide which does not form fibrils can reduce cortical and 
hippocampal AP levels by 89 % and 81 % respectively. In a follow up study, this group 
have observed improved cognition in Tg2576 mice possibly through IgM-mediated 
peripheral clearance [457]. Therefore immunisation not only clears AP plaques but also 
improves cognition in transgenic models. Morgan et al [455] used AP 1-42 with Freunds' 
complete adjuvant (inactive nitrobacteria) for immunisation in an APPIPS 1 transgenic 
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mouse model. Using a water maze test, these authors demonstrated superior working 
memory compared to controls. Nasal immunisation using AP peptides can also result in the 
reduction of AP burden [454, 459]. Passive immunisation can also clear AP plaques. Bard 
et al [452] peripherally administered mice antibodies against Ap or commercially available 
AP antibodies to an APP transgenic mouse model and reported reduction in amyloid 
burden in the cortex. The clearance they observed was via a Fc receptor mediated 
microglial phagocytosis, an effect that has been described by other research groups [460]. 
The advantageous effects of vaccination in transgenic models led to the clinical 
trial ofa vaccine containing pre-aggregated AP 1-42 called AN1792 (reviewed in [461]). A 
phase 2 trial was conducted on 372 patients and unfortunately had to be stopped due to 
development of acute meningoencephalitis in 6 % of the patients, possibly due to over-
activation of the Th 1 mediated response. From autopsies of some of the trial participants, 
there was extensive clearance of amyloid plaques and this was associated with microglial 
phagocytotic activity; however amyloid deposition in the cerebral vessel walls and NFT 
remained. There was also very little evidence for any improvement in cognition. The 
relative failure of this trial might be related to the possibility that vaccination needs to start 
before the development of clinical pathology, and future vaccination studies are underway 
which should provide a clearer picture for AD treatment. There may also be a need 
however, to identify areas of treatment which can prevent the signalling of AP to 
immediately protect the vasculature and neurones in AD patients. 
1.3 In vitro models to study AP effects on cellular function 
Much information has been gained on the effect of AP using cell cultures to 
investigate AD pathogenesis. These include primary rodent [343] and human [342] 
neuronal cultures, stable neuroblastoma cell lines [353], microglial cells [462], primary 
human BECs [389] and BECs from other species [463]. Typically, dissolved AP peptides 
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have been added to the cell cultures to observe the effects on cell viability, signalling 
molecules and transport. The most commonly used A~ fragments are A~ 1-40 and A~ 1-42 
although in some cases an A~ 1-40 or AP 1-42 isoform containing FAD mutation(s) is also 
used [464). Smaller fragments of the A~ peptide are also used in vitro. The most common 
is a fragment containing the amino acids 25-35 of full length Ap. It has been proposed that 
AP 25-35 represents a biologically active region of the A~ molecule [465]. Unlike full 
length A~, A~ 25-35 forms ~-sheet fibrils and aggregates immediately on dissolution and 
retains A~ toxicity to neuronal cell cultures [466, 467]. However, fragments of AP may not 
behave as full length A~, in terms of their physical structure and ability to bind to 
receptors. Pre-aggregated AP is also frequently added to cell culture systems, and more 
recently, on the basis of observations in AD patients, soluble oligomers have been used 
[356,357,362]. A drawback of using these species is that it is not currently known what 
particular AP oligomers(s) is/are predominant in AD, or whether the synthetic oligomer(s) 
obtained in vitro correspond to the in vivo species. 
1.3.1 An immortalised human brain endothelial cell for BBB study 
In terms of studying AP effects on BEC function, non-BECs, and primary human 
BECs cultures have been used. A major driving force behind this study was to use BECs of 
human origin. Primary hBECs are phenotypically unstable and after a limited passage 
number undergo cellular senescence. The supply of human tissue is also limited and the 
use of primary human BECs in detailed experimentation is not feasible. A limited number 
of immortalised hBECs [468-472] are described in the literature. However, none are fully 
described with respect to the specific BEC phenotype. A major exception to this is the 
immortalised hBEC line referred to as hCMECID3 [473]. The hCMECID3 cell line was 
produced by lentiviral transduction of isolated human BECs from a female epileptic patient 
with the catalytic subunit of human telomerase (hTERT) and the SV40 large T antigen. 
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hTERT acts to prevent telomere shortening whilst SV40 large T antigen is an oncogene 
capable of transforming cell lines. hCMECID3 cells are utilised by an increasing number 
of laboratories worldwide [263, 474-481] as they retain most of the unique properties of 
the BBB. hCMECID3 cells grow to confluent monolayers and express TJ proteins, 
adhesion molecules, chemokine receptors and ABC transporter proteins. 
P-gp and BCRP functional expression by hCMECID3 cells has been demonstrated 
using substrate uptake experiments. Intracellular rhodamine 123 levels, a fluorescence 
substrate ofP-gp, are increased by co-incubation with a P-gp inhibitor (PSC833). 
Functional BCRP expression has also been demonstrated by assessing intracellular levels 
of 3H daunorubicin (substrate for P-gp, MRP-l and BCRP) in the presence and absence of 
KO-143 (BCRP inhibitor). hCMECID3 cells display restricted permeability to a variety of 
drugs (e.g. vinblastine and colchicine), in good agreement with in vivo perfusion studies in 
rats or mice. hCMECID3 cells are also highly restrictive with regards to FITC-dextran (a 
paracellular marker) of different sizes (4, 40, 70 kDa), inulin and sucrose permeability 
when compared to primary bovine BECs and rat BECs. For example, the permeability of 
the hCMECID3 cells to 14C-sucrose is 1.65 x 10.3 em/min, which although higher, is 
similar in value to a co-culture model of bovine BECs and astrocytes (0.75 x 10.3 em/min) 
[473]. The only major discrepancy ofhCMECID3 cells with regards to the in vivo situation 
is ionic permeability. The trans endothelial electrical resistance (TEER) ofhCMECID3 
cells, when grown on filters is in the range of30-40 n.cm2, much lower than rat and 
porcine cell lines and BECs in vivo. Therefore, hCMECID3 cells do not form a restrictive 
barrier to ions. 
hCMECID3 cells are currently the best characterised and most widely studied 
hBECs cell line. They retain many unique properties of the BBB and are therefore the most 
suitable in vitro tool for human BBB study. 
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1.4 Aims 
The BBB may represent an important aspect of AD pathology. ABC transporters at 
the BBB may act to transport A~ out of the brain, or to protect the brain from blood-borne 
A~ peptides. To date, there are no experiments which have investigated the significance of 
P-gp and BCRP mediated A~ transport by hBECs. In AD, a leaky BBB and decreased 
brain glucose uptake could be the result of a dysfunctional BBB. Increased levels of A~ 
could in principle underlie many of these alterations. The aims of this study were: 
1) To characterise the functional expression ofP-gp and BCRP by hCMECID3 
cells at the protein level and using a functional assay. 
2) To investigate the role ofP-gp and BCRP in A~ transport by hCMECID3 cells 
using inhibitors for each transporter. 
3) To study the effects of A~ on the expression ofTJ and other transporter proteins 
by hCMECID3 cells. 
4) To determine the signalling or molecular pathways responsible for the changes 
found in aim 3. 
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Chapter 2 
Characterisation of functional P-gp and BCRP expression by 
hCMECID3 cells 
Abstract 
The aim of the work described in this study was to investigate the expression of P-
gp and BCRP by hCMECID3 cells. P-gp and BCRP expression by hCMECID3 cells was 
confinued by western blotting, flow cytometry and immunocytochemistry. The expression 
ofP-gp was stable between passages 23 and 38 and whilst primary isolated hBEC P-gp 
expression was - 30 % higher than that ofhCMECID3 cells, the differences in P-gp levels 
were not statistically significant. Using differential detergent fractionation, P-gp was found 
to be associated with a membrane/organelle fraction. Immunogold staining indicated that 
P-gp is expressed at a higher level on the apical as opposed to basolateral membrane. 
Functional P-gp expression was confinued using a rh123 efflux assay. rh123 efflux from 
preloaded hCMECID3 cells was time-dependent and inhibited by the P-gp inhibitors 
vinblastine and tariquidar but not by the BCRP inhibitor FTC. The results demonstrate that 
hCMECID3 cells express functional P-gp, located mainly on the apical membrane and 
therefore represent a suitable model to investigate AP transport across hBECs in vitro. 
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2.1 Introduction 
ABC transporters at the BBB prevent the entry of unwanted endogenous signalling 
molecules and toxic xenobiotics into the brain (reviewed in [171, 172]). P-gp is the most 
extensively studied ABC transporter at the BBB, both in vitro and in vivo, and appears to 
prevent a broad range of lipophilic substances from entering brain tissue including many 
therapeutic drugs in use today (reviewed in [171, 172, 176, 186]). The function of BCRP at 
the BBB is not as extensively investigated as P-gp. However, some BCRP and P-gp 
substrates overlap and both play an important role in the protection of the brain from 
unwanted blood-borne molecules, with the undesirable effect of excluding therapeutic 
drugs (see Figure 1.4 for a comprehensive list). 
P-gp expression has been described on the luminal membrane of rat brain 
capillaries [210, 482], isolated mouse BECs [211] and human brain microvessels [212, 
483], although recently the polarised distribution of this transporter has been called into 
question [213]. Using EM techniques, Bendayan et af [213] have observed enhanced 
abluminal expression of P-gp in rat BECs. Further conflicting evidence on P-gp expression 
was described by Pardridge et af [209], who, using the antibody MRKI6, reported no BEC 
P-gp staining but astrocytic expression in human brain sections. In subsequent studies, this 
group found P-gp co-localised with OF AP in human [208] and rhesus monkey brain tissue 
sections [484]. 
In vivo data supports the notion of a barrier function for P-gp at the BBB. Mice 
lacking either mdr 1 a or combined mdr 1 alb genes display enhanced brain accumulation of 
many P-gp substrates, including verapamil, indinavir, vinblastine and morphine, compared 
to wild type control mice (reviewed in [171, 172,216]). In addition, Drion et al [217] have 
demonstrated that treatment ofrats with PSC-833 (a P-gp inhibitor) increases the brain 
concentrations of colchicine and vinblastine by 8.4 and 9.1, respectively. 
BCRP expression has been observed on the luminal membrane of isolated human 
brain microvessels [229] and, like P-gp, acts to prevent certain substrates from entering the 
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brain. This is evident as BCRP inhibition causes enhanced brain uptake of prazosin and 
mitoxantrone in mdrla(-I-) mice [228]. Youdim et al [231] have also demonstrated 
increased quercetin accumulation in the brain of rats by BCRP inhibition. 
The focus of this study was to investigate the function of P-gp and BCRP in hBECs 
and so to further aid the understanding of substrate transport at the BBB. Whilst in vivo 
studies represent an important data source for evaluation of ABC transporter function at 
the BBB, they are highly costly and may be problematic due to species differences 
between the animal models and humans. For example, the comparison ofP-gp expression 
by Bendayan et al [213] at the abluminal BEC membrane in rats, is in contrast to the data 
from mouse and human studies. It is useful therefore, to investigate the ability of ABC 
transporters to efflux a known/unknown substrate in vitro using BECs of human origin and 
to compare across species. Multiple cell lines are available for the study of P-gp from 
different tissues and species (Table 2.1). In terms ofhBECs, primary and immortalised 
BEC cultures have been investigated. Human primary cell cultures are neither stable over 
passage 5 nor readily available and are therefore not suited for routine high throughput 
studies. There are only two extensively described immortalised hBEC cell lines; 
hCMECID3 [473] and BB19 [470] cells. The BB19 cell line has been shown to express P-
gp, BCRP and MRP family members using mRNA analysis, immunostaining and western 
blotting, whilst the functionality of P-gp in this cell line has been demonstrated by 
increased uptake of daunomycin in cells treated with verapamil [470]. However, the BB19 
cell line has not been used in any subsequent studies and is not fully characterised with 
respect to characteristic BEC protein expression. In contrast, the hCMECID3 cell line has 
been extensively characterised with respect to BEC-specific protein expression and 
permeability to paracellular tracers and has been used in mUltiple follow up studies [188, 
474-476,480,481,485,486]. hCMECID3 cells express TJ proteins and are restrictive to 
molecules over 4 kDa in molecular weight. hCMECID3 cell P-gp expression has been 
demonstrated using western blotting and mRNA analysis, whilst P-gp function was also 
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shown using a fluorescent P-gp substrate, rhodamine 123 (rhI23), and the P-gp inhibitor 
PSC-833 [473]. PSC-833 was demonstrated to increase the net influx ofrhl23, indicating 
active P-gp expression. Functional BCRP expression by hCMECID3 cells has also been 
demonstrated as the BCRP inhibitor K0143 increased the accumulation of 3H 
daunorubicin in these cells. Given the limited availability of primary cells and their poor 
stability over passage number, hCMECID3 cells are the most suitable available option to 
study P-gp function in cells from human origin which retain characteristics of primary 
BECs. 
The aim of this study was to confirm and investigate functional P-gp and BCRP 
expression by hCMECID3 cells, so that the role of these transporters in A~ transport could 
be addressed in further studies. Comparisons were made with primary hBECs and the 
results demonstrate hCMECID3 cell suitability for investigating P-gp substrate interactions 
using the 3rd generation P-gp inhibitor tariquidar [487, 488], and the P-gp competitive 
substrate vinblastine. 
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Source Type Cell line example Reference 
Kidney epithelium Madin-Darby canine kidney MDCK II, MDCK II [489,490] 
cells wild type and -MDRI 
transfected with MDRI gene. 
Porcine cells wild type and LLC-PKI, LLC-PKI- [183] [491] 
transfected with MDRI gene. MDRI 
Intestinal epithelium Human colon carcinoma cell Caco-2, LS 180 [492] [493] 
lines. 
Lung epithelium Primary human bronchiolar [494,495] 
and alveolar cells. 
Primary porcine and rat [495,496] 
pulmonary cells. 
Human lung adenocarcinoma A549 NCI-H460 [497-499] 
cells. 
Hepatocytes Primary rat and human cells. [500,501] 
Liver carcinoma cell lines. HEPG2 [502] 
Embryo Immortalised TR-TBTs [503] 
syncytiotrophoblast cells. 
Brain endothelium Primary rat, human, mouse, Reviewed 
porcine cells. [46, 172, 
504] 
Immortalised rat, bovine, Rat; RBE4, GPNT, Reviewed 
mouse, porcine, human cells. GP8, rBCEC4. [505] 
Mouse; TMBB4 [211,506-
MBEC, bEnd.3, 508] 
bEnd. 5. 
Porcine; PBMEC. [509,510] 
Bovine; SV-BEC, t- [20, 511] 
BBEC-117. 
Human; BB 19, [470,473] 
hCMECID3. 
Table 2.1. Summary of cell lines used for investigation of P-gp function. Multiple cell 
lines have been developed for the study ofP-gp function, including kidney, intestinal and 
lung epithelial cells and ECs from the brain. 
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2.2 Methods 
2.2.1 Culture medium 
hCMECID3 cells were cultured in endothelial growth medium (EGM-2, Lonza, 
Wokingham, UK) supplemented with 2.5 % foetal bovine serum (FBS), ascorbic acid, 
gentamycin sulphate, hydrocortisone and y.. volume of the supplied growth factor 
supplements [vascular endothelium growth factor (VEGF), epidermal growth factor (EGF), 
insulin-like growth factor 1 (lGF-I) and human basic fibroblastic growth factor (bFGF)]. 
Cambrex have optimised the composition ofEGM-2 to induce endothelial cell 
proliferation and do not disclose the concentrations of the supplements. Primary hBECs 
were grown in EGM-2 media to which a full volume of the supplied growth factor 
supplements were added. 
2.2.2 Growth surface preparation 
Both primary hBECs and hCMECID3 cells were grown on tissue culture plastic 
flasks (Greiner, Gluocestershire, UK) coated with collagen type 1 from calf skin (Sigma-
Aldrich, Dorset, UK). The collagen stock solution of 0.1 % w/v was diluted 1 in 20 in 
Hank's balanced salts solution (HBSS) (Sigma-Aldrich, Dorset, UK) and left for 1 hat 
room temperature (RT) on the plastic surface. The flasks were then washed once with 
HBSS and filled with EGM-2 medium in preparation for cell culture. For experiments that 
used transwell polyester membrane inserts (0.4 Jlm pore, 12mm diameter, Coming Costar, 
Buckingham, UK), the filters were coated with collagen and fibronectin which are required 
for optimal for hCMECID3 cell growth. For this, the filters were incubated for 1 h in 
collagen, washed in HBSS and incubated for 1 h with a 5 Jlg/ml solution of fibronectin 
from human plasma (Sigma-Aldrich, Dorset, UK). 
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2.2.3 hCMECID3 and primary human brain endothelial cell (hBEC) culture 
maintenance 
hCMECID3 cells were grown until confluent ( - 1 x lOs cells/cm2) on collagen-
coated flasks at 37°C (5 % C02), with the culture medium changed every 2-3 days. 
Primary hBEC were typically grown to 90 % confluence, due the difficulty in trypsinising 
these cells at full confluence. To split cell cultures, both hCMECID3 cells and primary 
hBECs were washed in HBSS without Ca2+ and Mg2+ [HBSS w/o Ca2+ Mg2+ (Sigma-
Aldrich, Dorset, UK)] at 37°C for 1-5 min and then incubated with 0.25% w/v porcine 
trypsin and 0.02 % w/v ethylene diamine tetraacetic acid (EDT A) (Sigma-Aldrich, Dorset, 
UK) at 37°C until detached. EGM-2 was then added to neutralise trypsin activity and cells 
were split at a ratio of 1:5 onto collagen-coated tissue culture flasks. For all experiments, 
hCMECID3 cells between passage (P) 23 and 33 were used, unless stated otherwise, whilst 
primary hBEC were used up to p4. 
2.2.4 Isolation of primary hBECs 
Solution A: HBSS w/o Ca2+ Mg2+ containing 10 mM HEPES (Sigma-Aldrich, Dorset, 
UK), 50 Ulml penicillin, 50 ug/ml streptomycin (Invitrogen. Paisley. UK). 2.5 Ilg/ml 
amphotericin B (Invitrogen, Paisley, UK) and 0.4 % w/v BSA (Sigma-Aldrich. Dorset, 
UK). Adjusted to pH 7.4 by eye and sterile filtered through 0.22 Ilm filter. 
25 % w/v BSA: BSA dissolved in solution A, sterile filtered through 0.8 Ilm and 0.22 Ilm 
filters. 
Collagenase/dispase: 1 mg/ml collagenase/dispase solution (Roche, West Sussex, UK) 
supplemented with 10 Ilg/ml DNase (Sigma-Aldrich. Dorset. UK) and 0.147 Jlg/ml N-p-
tosyl-L-Iysine chloromethyl ketone hydrochloride (Sigma-Aldrich. Dorset. UK). 
Percoll gradient: Prepared immediately prior to use in an ethanol-sterilised (20 min. 70% 
ethanol) and blocked (solution A. 10 min) dupont tube. A 50% percoll solution (Sigma-
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Aldrich, Dorset, UK) in HBSS was added to the dupont tube and centrifuged for 1 h at 
25,000 xg, 4°C. 
In procedures approved by ethical committiees at both Kings College London and 
The Open University, human brain tissue was obtained with written consent from patients 
undergoing cerebral cortical lobectomies, conducted at Kings College Hospital to relieve 
medically intractable seizures. The isolation of hBECs was carried out within 24 h post 
operation based on the protocol by Hughes and Lantos [512], and unless stated otherwise, 
all steps were carried out on ice or at 4°C. 
The brain tissue was placed in a sterile petri dish and the meniges removed using 
autoclaved forceps. The tissue was then placed in 1 ml of solution A and cut into small 
pieces using a scalpel blade. Tissue fragments were then centrifuged at 300 xg for 10 min 
in 10 ml of solution A, the pellet resuspended in 15 ml of collagenase/dispase solution and 
incubated for 1 h at 37°C. The digest was then centrifuged (300 xg, 5 min, 4°C) and the 
resulting pellet re-suspended in 5 ml of solution A, using initially a glass pasteur pipette 
and subsequently a heated end glass pasteur pipette. The digest was then centrifuged (300 
xg, 5 min, 4°C). 
The capillaries were then isolated using density dependent centrifugation in 25% 
BSA. Brain tissue fragments were re-suspended in 20 ml of 25 % BSA solution and 
centrifuged for 15 min at 1000 xg at 4°C. The myelin plug was removed by gently turning 
the tube and poured swiftly into a separate tube leaving the initial tube upturned to prevent 
any BSA re-suspending the capillaries, since prolonged BSA can become toxic. The 
myelin was then resuspended and centrifuged a further couple of times (15 min, 1000 xg, 
4°C) to increase the yield of pelle ted capillaries. Capillary pellets were then pooled in 
solution A and centrifuged (300 xg, 5 min, 4°C). The capillaries then underwent a further 1 
h digestion in 5 ml of collagenase/dispase for 1 h at 37°C. 
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A Percoll gradient was used to separate the capillary fragments from the red blood 
cells and surrounding cell contaminants. Pelleted capillary fragments (300 xg, 5 min, 4°C) 
were resuspended in 1.5ml of solution A and pipetted carefully on top of 7 ml of a 
prepared Percoll gradient and centrifuged at 1000 xg for 10 min. Three layers formed (the 
middle containing BECs), and each layer was carefully pipetted out into separate tubes 
containing 10 ml of solution A and centrifuged (300 xg, 5 min, 4°C). The resulting pellets 
were re-suspended in 10 ml of 1:1 solution A and EBM-2 medium, centrifuged (300 xg, 5 
min, 4°C) and resuspended in 5 ml medium containing amphotericin B (2.5 Ilg/ml) and 
placed in collagen-coated 25 cm2 tissue culture flasks. Each layer of the Percoll gradient 
was collected to increase the EC yield, as EC can sometimes reside in the top and bottom 
fractions. After 48 h the culture medium was replaced with fresh culture medium 
containing 0.5 Ilg/ml puromycin (Sigma-Aldrich, Dorset, UK), which was left in the 
culture medium for 5 days in order to selectively inhibit the growth of contaminating cells 
that lack P-gp expression and are therefore vulnerable to intracellular puromycin 
accumulation. The medium was changed every 48 h. 
2.2.5 SDS-P AGE and western blotting 
Lysis buffer: RIPA buffer (Sigma-Aldrich, Dorset, UK) containing ImM 
phenylmethanesulfonyl fluoride [PMSF (Sigma-Aldrich, Dorset, UK)], lOng/ill of 
leupeptin (Sigma-Aldrich, Dorset, UK), pepstatin A (Sigma-Aldrich, Dorset, UK) and 
aprotinin (Sigma-Aldrich, Dorset, UK). 
Laemmli's buffer reducing 4 X: 0.01 % w/v bromophenol blue (Sigma-Aldrich, Dorset, 
UK), 15 mg/ml D,L- dithiothreitol [DTT (Sigma-Aldrich, Dorset, UK)], 40 % v/v glycerol 
(Sigma-Aldrich, Dorset, UK), 8 % w/v sodium dodecyl sulphate [SDS (Sigma-Aldrich, 
Dorset, UK)] in 250 mM trislHCI pH 6.8. 
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Running gel: 10 % v/v Proto gel [30 % acrylamide, 0.8 % methylene bis-acrylamide, 
(National diagnostics, North Yorkshire, UK)], 0.1 % w/v SDS, 0.37 M trislHCI pH 8.8, 
0.05 % v/v tetramethyl-ethlenediamine [TEMED (Sigma-Aldrich, Dorset, UK)] and 0.1 % 
w/v ammonium persulphate [APS (Sigma-Aldrich, Dorset, UK)]. 
Stacking gel: 5 % v/v Protogel, 0.1 % w/v SDS, 0.12 M trislHCI pH 6.8, 0.05 % v/v 
TEMED, and 0.1 % w/v APS. 
Running Buffer: 25 mM Tris, 192 mM glycine, 0.01% SDS in deionised water [prepared 
from lOx stock (National diagnostics, North Yorkshire, UK)]. 
Transfer buffer: 25 mM Tris and 192 mM glycine, [prepared from lOx stock (National 
diagnostics, North Yorkshire, UK)] with 20 % v/v ethanol in deionised water. 
Blocking buffer: 0.2 % v/v tween 20 (Sigma-Aldrich, Dorset, UK). 5 % w/v fat-free dried 
milk dissolved in PBS. 
Washing solution: 0.2 % v/v tween 20 dissolved in PBS. 
Full range molecular weight marker: Rainbow marker (Amersham, Buckinghamshire, 
UK). 
Stripping solution: 2 % w/v SDS, 0.0625 M Tris pH 6.8, 0.008 % v/v p-mecaptoethanol. 
hCMECID3 cells (P23) were grown to confluence (total- 1 x 107 cells) in a 75 cm2 
collagen-coated flask and left for 2 days. hCMECID3 cells were then detached and passed 
1 in 5 into another 75 cm2 flask. The remaining cells were washed twice in PBS and 
resuspended in 500 III of lysis buffer. The suspension was left on ice for 5 min and then 
sonicated on ice 3 times for 5 seconds (Soniprep 150, MSE, London, UK). The cell lysate 
was then centrifuged at 8000 xg for 5 min at 4°C and the supernatant collected. This 
procedure was repeated for the cells every 3rd passage up to p44. 
The protein concentration of the samples was calculated using the detergent 
compatible (DC) protein assay (Biorad, Hertfordshire UK), using BSA as a standard. For 
each lane of the western blotting gel, 20 Ilg of total protein in 1 x Laemmli' s buffer was 
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loaded on 10 % polyacrylamide resolving gels with a 5 % stacking gel. Prior to loading, 
the samples were denatured by heating at 95°C for 5 min. The proteins were resolved on 
the gel by applying a 100-150 V potential until the dye front reached the end of the gel. 
Following electrophoresis, proteins were transferred onto nitrocellulose membranes 
(Amersham, Buckinghamshire, UK) using a wet blotting system run at a constant current 
of 0.15 A overnight at 4°C, with transfer buffer. Post-transfer, the nitrocellulose 
membranes were incubated with blocking buffer for 1 hat RT and incubated over-night at 
4°C with 500 nglml ofC219, an anti-P-gp antibody [mouse monoclonal IgG2a, (Abeam, 
Cambridgeshire, UK)]. Membranes were then subjected to six 10 min washes in washing 
solution and a horse-radish peroxidise (HRP)-conjugated anti-mouse IgG secondary 
antibody [diluted 1120000 (Pierce Biotechnology, Cheshire, UK)] was added for 1 hat RT. 
The membranes were then washed five times for 10 min with washing solution, followed 
by a 10 min wash in PBS. The membrane were then developed using an enhanced 
chemiluminescence (ECL) western blotting detection reagents system (Amersham, 
Buckinghamshire, UK), exposed to films (Amersham, Buckinghamshire, UK) and films 
were developed with an X-Omat 1000 automatic processor (Kodak, New York, USA). 
Film exposure times were adjusted to ensure adequate signal development. 
In order to check for equal loading, the nitrocellulose membrane was subjected to a 
harsh stripping procedure. Membranes were placed in stripping buffer for 40 min at 50°C 
and washed for 30 min with frequent changes of washing solution. The membrane was 
then blocked as described above and re-probed using an anti-actin antibody [1 Jlg/ml, 
mouse monoclonal IgG., (Sigma-Aldrich, Dorset, UK)]. The signal intensities of the bands 
on the films were analysed using image J software and P-gp expression was normalised to 
actin expression. 
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2.2.6 Flow cytometry analysis 
Permeabilisationlblocking buffer: 3 % v/v normal goat serum [NGS, (Sigma-Aldrich, 
Dorset, UK)], 0.1 % v/v triton X-IOO (Sigma-Aldrich, Dorset, UK) in PBS. 
hCMECID3 cells or primary hBECs were grown to confluence in 6 well tissue 
culture plates (total - 1 x 106 cells per well), detached, centrifuged (300 xg, 5 min, 4°C) 
and fixed in 4 % w/v p-formaldehyde (PAF, BDH, Dorset, UK) in PBS for 10 min at RT. 
After one wash in PBS, cells were incubated for 30 min in permeabilisation buffer, which 
contained 3 % NOS to prevent non-specific binding of antibodies. The cells were 
subsequently counted and 0.5 x 106 cells per treatment were incubated overnight at 4°C 
with 50-100 JlI of permeabilisation buffer containing a primary antibody or isotype-specific 
control at a concentration of 5 Jlg/ml. The antibodies used were anti-BCRP BXP-21 
[mouse monoclonal IgG2a, (Merck, Nottinghamshire, UK)] or anti-P-gp JSB-I [mouse 
monoclonal IgGJ, (Abeam, Cambridgeshire, UK)]. The isotype-specific controls were 
mouse Ig02a (Sigma-Aldrich, Dorset, UK) or mouse IgG) (Sigma-Aldrich, Dorset, UK) as 
appropriate. JSB-l rather than C219 was used for flow cytometry staining of P-gp as it 
proved more suitable for this staining technique. 
After incubation with the primary antibody, the cells were washed three times in 
PBS and resuspended in permeabilisation buffer containing 1 ° Jlg/ml of a 
fluoresceinisothiocyanate (FITC) - conjugated goat anti-mouse IgG antibody (Chemicon, 
Hampshire, UK). After two final washes with PBS, the cells were suspended in 500 JlI PBS 
and analysed using a FACSCalibur flow cytometer with Cellquest software [488 nm 
Aexcitation, 530 nm Aemission, (Becton Dickinson, Oxfordshire, UK)]. For each sample the 
median fluorescence of 10,000 cells was determined. 
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2.2.7 Differential detergent fractionation 
In order to investigate the localisation ofP-gp, hCMECID3 whole celllysates were 
separated into cytosolic, membrane/organelle, nuclear and cytoskeletal fractions using 
differential detergent fractionation as described by Ramsby et al. [513]. 
Extraction buffer 1 (EBl): 10 mM piperazine- 1, 4'-bis (2-ethanesulphonic acid) [PIPES, 
(Sigma-Aldrich, Dorset, UK)] pH 6.8, containing 300 nM sucrose (Sigma-Aldrich, Dorset, 
UK), 100 mM sodium chloride [NaCI (Sigma-Aldrich, Dorset, UK)], 3 mM magnesium 
dichloride [MgCh (Sigma-Aldrich, Dorset, UK)], 5 mM [EDTA (Sigma-Aldrich, Dorset, 
UK)], 1.2 mM phenylmethylsulphonyl fluoride [PMSF (Sigma-Aldrich, Dorset, UK)] and 
0.01 % w/v digitonin (Sigma-Aldrich, Dorset, UK). 
Extraction buffer 2 CEB2): 10 mM PIPES pH 7.4, containing 300 mM sucrose, 100 mM 
NaCI, 3 mM MgCh , 3 mM EDTA, 1.2 mM PMSF and 0.5 % v/v triton X-I 00. 
Extraction buffer 3 (EB3): 10 mM PIPES pH 7.4, containing 10 mM NaCI, 1 mM MgCh, 
1.2 mM PMSF, 0.5 % v/v triton X-100, 1 % v/v tween-40, 0.5 % w/v sodium deoxycholate 
(Sigma-Aldrich, Dorset, UK). 
hCMECID3 cells were grown until confluence in a 75 cm2 flask (1 x 107 cells), 
detached by trypsinisation, washed once in HBSS and lysed in 250 JlI of EB 1 buffer. The 
whole cell lysate was incubated on ice for 10 min with occasional inversion to ensure 
solubilisation. After centrifugation (500 xg, 10 min, 4°C), the supernatant was collected 
(cytosolic protein fraction) and the pellet resuspended in 250 JlI ofEB2 buffer. The whole 
cell lysate was then incubated on ice for 20 min (with occasional inversion), centrifuged 
(5000 xg, 10 min, 4°C), and the supernatant collected (membrane/organelle fraction). The 
remaining pellet was resuspended in 125 JlI ofEB3, incubated on ice for 10 min and 
centrifuged (7000 xg, 10 min, 4°C). The supernatant contains the nuclear proteins, whilst 
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the pellet contains cytoskeletal proteins. The pellet was dissolved in 250 I.d of 1 x 
Laemmli's buffer. 
Laemmli's buffer was added to each fraction collected and the samples denatured at 
95°C for 5 min. Samples were then resolved using SDS-PAGE and western blotting as 
described in section 2.2.5.20 JlI of the cytosolic, membrane-organnelle and cytoskeletal 
fractions and 10 JlI of the nuclear fraction were loaded per lane. Antibodies against the 
transcription factor Sp3 [200 ng/ml, mouse monoclonal IgG2a, (Santa Cruz, California 
USA)], P-gp (500 ng/ml, C219), BCRP (200 ng/ml, BXP-2I,) and actin (1 Jlg/ml), were 
used for western blotting detection as described in section 2.2.5. The intensity of the 
signals were analysed using image J software. For each protein, the intensity of the signal 
corresponding to each fraction (cytosolic, membrane/organelle, nuclear or cytoskeleton) 
was expressed as a percentage sum of the signals for all the fractions. 
2.2.8 Immunocytochemistry 
Perrneabilisationlblocking buffer: 3 % v/v NGS, 0.1 % v/v triton X-IOO (Sigma-Aldrich, 
Dorset, UK) in PBS. 
hCMECID3 cells were grown to confluence on collagen-coated Labtek chamber 
slides (Nunc Scientific laboratory supplies, Nottinghamshire, UK), washed in PBS and 
fixed in 4 % P AF for 10 min. After three washes (PBS, 5 min each) 
perrneabilisationlblocking buffer was added to each chamber for 30 min. Anti P-gp (JSB-
1), BCRP (BXP-21) or isotype controls (IgG1 or IgG2a respectively) were added to the 
fixed cells at 5 Jlg/ml overnight at 4°C. After three 10 min washes in PBS, a FITC-
conjugated goat anti-mouse IgG secondary antibody (as described in section 2.2.6) was 
added for 1 hat RT. After three further washes in PBS, a drop of 4',6-diamidino-2-
phenylindole (DAPI) mounting media (Dako, Cambridgeshire, UK) was added for 5 min 
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and then, after a final wash in water, the slides were mounted with a glass coverslip and 
viewed with a fluorescent microscope (Olympus BX61 ,Olympus, Hertfordshire, UK). 
For imaging via confocal microscopy, hCMECID3 cells were grown to confluence 
on collagen- and fibronectin- coated transwell polyester membrane inserts (0.4 Jlm pore, 
12mm diameter, Coming Costar, Buckingham, UK) and stained as above with the 
exception that instead of DAPI, 5 JlM DRAQ5 (Biostatus, Cambridegshire, UK) was added 
with the secondary antibody to stain nuclear DNA. hCMECID3 cells were then viewed 
with a confocal microsope, (Leica DMIRBE, Leica, Buckingham UK), taking XY and Z 
cross sections over a selected field to reconstruct a three dimensional image using Volocity 
software (Improvision, Coventry, UK). 
2.2.9 Transmission electron microscopy combined with immunogold labelling 
Phosphate buffer (PB): 0.018 M NaH2P04.H20 (VWR, Leicestershire, UK), 0.082 M 
Na2HP04 (VWR, Leicestershire, UK). 
Paraformaldehyde-Iysine-periodate fixative (PLP): 2 % w/v PAF, 0.01 M sodium 
metaperiodate (Sigma-Aldrich, Dorset, UK), 0.075 M lysine monohydrochloride (Sigma-
Aldrich, Dorset, UK). 
For the detection ofP-gp at the ultrastructural level, the method of Bendayan et al 
[213] was followed with technical and experimental help from the EM suite at The Open 
University. hCMECID3 cells were grown to full confluence on collagen- fibronectin-
coated transwell polyester membrane inserts (0.4 Jlm diameter pore, 12 mm diameter 
width) and left for 2 days. hCMECID3 cells were then fixed for 21 h (6 h RT, 15 h 4°C) 
with PLP. Post fixation, hCMECID3 cells were washed twice with PB (1-5 min) cut into 2 
mm strips and processed using 'progressive lowering of temperature' with a Leica AFS2 
automatic freeze substitution system (Leica, Buckingham UK). This method was used to 
dehydrate and prevent translocation of the antigen and involves the progressive lowering of 
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temperature from 0° to -30°C whilst increasing the methanol content of the solution (Table 
2.2). hCMECID3 cells were infiltrated in the acrylic resin Lowicryl K4M (Agar Scientific, 
Essex, UK) and polymerised at -30°C under ultra violet (UV) light. 
Ultrathin sections of the membrane insert were then cut (80 nm) using a Diatome 
diamond knife on a Leica ultra-microtome (Leica UCT, Leica, Buckinghamshire UK). The 
sections were mounted on formvar (Agar Scientific, Essex, UK) coated nickel slot grids, 
and all reactions were performed using 20 J.lI droplets on a parafilm lined box lid which 
was covered during incubation. Non-specific binding was blocked using 1 % w/v 
ovalbumin (Sigma-Aldrich, Dorset, UK) in 0.01 M PBS for 30 min at RT. Grids were 
incubated with droplets of anti-P-gp (5 J.lglml, C219, dissolved in PBS) or an isotype 
matched control (5 J.lglml, IgGza,) antibody overnight at RT in a humidified box. The grids 
were then washed by transferring from drop to drop (3 x 5 min in PBS), blocked (1 % 
ovalbumin, 10 min, RT) and incubated with a goat anti-mouse IgG conjugated to 10 nm 
gold secondary antibody for 2 h at RT (British Biocell International, Cardiff, Wales). The 
samples were then washed (3 x 5 min, PBS), fixed in 2.5 % w/v glutaraldehyde in PBS 
(Agar Scientific, Essex, UK), washed (2 x 5 min in PBS, 1 min with deionised water), 
allowed to air dry and counterstained with 4 % w/v aqueous uranyl acetate (Agar 
Scientific, Essex, UK) for 15 min. After a final three washes in distilled water the sections 
ofimmunolabelled hCMECID3 cells were examined using a JEOL JEM 1400 transmission 
electron microscope (JEOL, Hertfordshire, UK) operating at 80 kv. The images were 
acquired using an AMT XR60 11 mega pixel digital camera calibrated for magnification 
such that each image displayed a scale marker. Images of7.5 J.lm lengths of membrane 
were taken every 2-3 frames for a total of 500 J.lm membrane. For both the apical and 
basolateral membranes, the number of gold particles within 100 nm was counted in each 
7.5 J.lm length of membrane and expressed as gold particles per 1 J.lm of membrane. 
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Reagent Temperature Temperature Time 
Start ee) End (h) 
30 % MeOH 0 0 0.5 
50 % MeOH 0 -10 0.5 
75 % MeOH -10 -20 0.5 
100 % MeOH -20 -30 0.5 
100 % MeOH -30 -30 0.5 
25 %K4M:75 % MeOH -30 -30 1 
50 % K4M: MeOH -30 -30 1 
80 % K4M: MeOH -30 -30 1 
K4M 
-30 -30 1 
K4M -30 -30 15 
K4M 
-30 -30 1 
K4M -30 -30 48 
Table 2.2. Protocol for progressive lowing of temperature for electron microscopy 
and immunogold staining. Fixed hCMECID3 cells were subjected to this protocol in 
order to prevent antigen translocation during dehydration and embedding for TEM 
immunolabelling (K4M: lowicryl K4M). 
2.2.10 Methylthiazolyldiphenyl-tetrazolium (MTT) bromide cytotoxicity assay 
The cytotoxicity of the P-gp inhibitors tariquidar (a kind gift from Xenova, 
Berkshire, UK), vinblastine (Sigma-Aldrich, Dorset, UK) and the BCRP inhibitor 
fumitremorgin C [FTC, (Axxora, Nottingham, UK)] were investigated using a 
Methylthiazolyldiphenyl-tetrazolium bromide [MIT, (Sigma-Aldrich, Dorset, UK)] 
toxicity assay. 
hCMECID3 cells were seeded in 96 well tissue culture plates (3 x 104 per well), left 
for 2 days and the cell culture medium replaced with 100 J.11 of fresh culture media 
containing tariquidar (20-600 nM), FTC (0.3-22 J.1M), vinblastine (0.100 - 40 J.1M) in 
vehicle (DMSO or ethanol for vinblastinelFTC and tariquidar, respectively) or medium 
containing vehicle alone « 1 % v/v), for either 24 h or 48 hat 37°C. After the indicated 
time, 10 J.11 ofMTT (stock 5 mg/ml) was added to each well to give a final concentration of 
0.5 mg/ml and the plates left for 4 h at 37°C. The media was then aspirated and the cells 
washed twice in PBS. Finally, 200 J.11 of isopropanol (Sigma-Aldrich, Dorset, UK) was 
added to lyse the cells and to solubilise precipitated formazan salts, produced by the action 
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of mitochondrial dehydrogenase in living cells on MIT. After complete solubilisation, the 
plates were read on a colourimeter (BMG, Offenberg, Germany) at a wavelength of 550 
nm. 
2.2.11 Rhodamine 123 (rhI23) efflux assay 
The principles underlying the rhodamine 123 (rhI23) efflux assay are depicted in 
Figure 2.1. hCMECID3 cells were grown to confluence in collagen-coated 75 cm2 flasks, 
detached, and the cells counted using a haemocytometer. For each test condition, 2.5 x lOs 
cells were used in duplicate. The test conditions for time-dependent efflux were: 
hCMECID3 cells preloaded with rh123 and kept at 4°C, rhl23-preloaded hCMECID3 cells 
incubated at 15,30,60, 120, 180 and 360 min in the absence or presence of vinblastine, 
hCMECID3 cells that were not preloaded with rh123 in order to later subtract background 
fluorescence. For each experiment, two aliquots of 3.5 x 106 cells were centrifuged at 300 
xg for 5 min at 4°C and re-suspended in efflux buffer [RPMI-1640, (Cambrex, Berkshire, 
UK) containing I % w/v BSA] at 4°C. From each aliquot of cell suspension, 2.5 x lOs cells 
were taken and placed on ice for the duration of the experiment (negative control). The 
remaining cells were then centrifuged (300 xg, 5 min, 4°C), re-suspended at 1 x 106/ml in 
efflux buffer containing 10 Jlglml (22 JlM) rh 123 (Sigma-Aldrich, Dorset, UK) and 
incubated on ice for 1 h. Rh123 preloaded cells were washed twice in efflux buffer and 
redistributed into different tubes according to each treatment. From each repetition, 2.5 x 
lOS cells rh123 preloaded cells were placed at 4°C in efflux buffer, whilst the remaining 
cells were incubated at 37°C with vinblastine (22 JlM) in vehicle, or vehicle only, in efflux 
buffer. At 15,30,60, 120, 180 and 360 min intervals, 2.5 x lOS cells were removed and 
placed on ice/4°C for the duration of the experiment. After all samples had been collected, 
cells were washed twice in PBS and resuspended in 500 JlI PBS. The samples were then 
read using a F ACSCalibur with Cell quest software (488 nm Aexcitation, 530 nm Aemission) and 
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the median fluorescence of 10,000 cells per sample recorded. The median fluorescence 
intensity of the negative control was subtracted from all the other treatments and the data 
expressed as a percentage ofrh123 preloaded cells kept at 4°C. For each experiment the 
time taken for the fluorescence intensity to decline by 50 % was calculated, by plotting 
cellular rh123 levels against time, and using cells incubated at 4°C as time = 0 min. 
For some experiments, the effects of inhibitors were tested on hCMECID3 cells 
both preloaded with rh 123 alone or with an inhibitor and incubated at 37°C for 1 h. The 
following inhibitors in vehicle or vehicle only were used; FTC (22 J!M), vinblastine (22 
J!M) or tariquidar (300 nM). 
2.2.12 rh123 permeability 
The permeability of hCMECID3 cells grown on Transwell polyester membrane 
inserts (0.4 J!m pore, 12mm diameter) to rh123 was investigated (Figure 2.2). hCMECID3 
cells were cultured on collagen- and fibronectin-coated 12 well membrane inserts until 
confluent and left for 2 days. The cells were then washed with permeability buffer 
(DMEM, 2 % v/v FCS Sigma-Aldrich, Dorset, UK) and rh123 (22 J!M), alone or in the 
presence oftariquidar (300 nM), vinblastine (22 J.lM) or FTC (22 J.lM), was added to the 
apical chamber (upper). The inserts were then transferred sequentially at 5 min intervals 
from well to well containing 1.5 ml of transport buffer (+1- appropriate inhibitors) for 30 
min. The fluorescence diffusing to the basolateral (bottom) chamber was measured at an 
excitation wavelength of 485 nm and emission wavelength of 520 nm with a fluorescence 
plate reader (BMO, Offenberg, Germany). A vehicle control received DMSO (0.1 %) since 
ethanol had no appreciable difference in the efflux experiment. 
Permeability coefficients of the hCMECID3 cell mono layers were calculated using 
the following calculations [473]; 
Cleared volume = (AUa- AUb )lFi 
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The cleared volume (in J.lllml) represents the cumulative volume ofrhl23 solution 
passing through the cell monolayer at a particular time. AUa is the total fluorescence 
(arbitrary units) in the basal compartment, AUb is the background fluorescence, Fi is the 
fluorescence of the initial solution (AU/ml). The cleared volume is plotted against time and 
the permeability coefficients (Pc in cm/min) for the EC monolayer calculated as ; 
lIPS = IIPSef- llPSf and Pc= PSIS 
PScf and PSf correspond to the gradients of the curves for EC grown on filters or 
filters alone (mllmin). PS is the permeability surface area of the EC monolayer (mllmin) 
and S is the surface area of the filter. The higher the Pe value the more permeable the EC 
are to the fluorescent dye. 
To investigate the basolateral-to-apical permeability, 1.5 ml rhl23 (22 J.lM) was 
added to the basolateral chamber of a 12 well plate [+1- tariquidar (300 nM), vinblastine 
(22 J.lM) or FTC (22 J.lM)] and filters containing the appropriate inhibitors placed into the 
well. The filter was left in place for 30 min and the fluorescence of the apical and 
basolateral chambers measured. The P e values were calculated using the assumption that 
the curve was linear: 
PSef= [(AUa- AUb)/Fi] 130 
2.2.13 Statistical analysis 
All data are represented as means +1- SEM and the number of experiments, n, 
indicated each time. For each data the statistical significance was calculated using 
ANOV A followed by Student's t test, comparing each treatment to the control (* p < 0.05). 
For the permeability experiments, a paired t-test was used, as there was an internal control 
specific for each experiment. 
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Figure 2.1. Principles underlying rh123 emux experiment. rh123, a fluorescent P-gp 
substrate, is effluxed from preloaded hCMECID3 cells in a time-dependent manner. 
Inhibition of P-gp raises the intracellular levels, indicative of functional P-gp. 
Basolateral 
Key 
P-gp 
............ => Paracellular permeability 
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Figure 2.2. In vitro BBB model used to investigate hCMECID3 cell permeability to 
rh123. hCMEC/D3 cells were grown to confluence on transwell filters . A rh123 solution 
(22 )lM) was added to either the basolateral or apical chamber with or without the 
inhibitors tariquidar, vinblastine and FTC. Ultrastructural localisation ofP-gp (i.e. whether 
located on the apical or basolateral plasma membrane) is thought to influence the passage 
of rh 123 from the compartment to which it was added to the other compartment. 
- 94-
2.3 Results 
2.3.1 Morphology of hCMECID3 and primary hBECs 
A main advantage of hCMECID3 cells is that they can be used for high throughput 
studies. For that reason, a morphological examination was carried out, comparing 
hCMECID3 cells to primary hBECs. Primary hBECs grew outwards from isolated 
capillary fragments to form colonies of spindle-like shaped cells (Figure 2.3a). These 
colonies were noticeable 1-2 days post isolation, formed confluent mono layers after 1-2 
weeks and appeared free of contaminating cells. After pS, primary hBECs neither appeared 
completely spindle-shaped nor continued to grow at a sufficient rate to reach confluence. 
hCMECID3 cells, grew in a similar elongated spindle-shaped manner (Figure 2.3b) and 
reached confluence 2-3 days after a 1 in 5 passage. In contrast to primary hBECs, there 
were no alterations in shape or growth rates over the passage ranges used in this study (p 
23 - 44). From a strictly morphological view, hCMECID3 cells and primary hBECs 
appeared very similar. 
2.3.2 Expression of P-gp by hCMECID3 cells over passage as assessed by western 
blotting 
One of the aims of this study was to investigate the role of P-gp-mediated AP 
transport by hCMECID3 cells. The expression of P-gp by hCMECID3 cells was therefore 
characterised, and compared to that of another ABC efflux transporter with an overlapping 
substrate range, BCRP. Firstly, the expression ofP-gp over passage was investigated in 
order to determine the maximum passage in which this cell line could be used for further 
experimentation and also to ensure that results obtained between passages were 
comparable (Figure 2.4). Using western blotting techniques, P-gp expression was detected 
as a diffuse band of - 160 kDa, which probably reflects different glycosylation patterns of 
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the MDRI product in hCMECID3 cells. P-gp expression was similar between p23 and 38 
(n = 1), but at higher passages (> p4l) appeared decreased (Figure 2.4a). In contrast, actin 
levels were maintained with the exception of the highest passage investigated (P44) 
expression declined. P-gp expression was quantified by measuring the signal intensity and 
nonnalised to actin as a control to account for loading differences (figure 2.4b). From this 
experiment, a maximum passage of38 was selected for further experiments, as by 
comparison p 41 had a 30 % decrease in P-gp levels. 
2.3.3 The expression of P-gp and BCRP by hCMECID3 and primary hBECs as 
measured by flow cytometry 
To provide a more accurate quantitative method for protein expression, the 
expression of P-gp and BCRP by hCMECID3 cells was measured using flow cytometry 
(Figure 2.S). Flow cytometry showed a higher median fluorescence intensity when 
antibodies against P-gp (20.1 ± I.S) and BCRP (30.96 ± I.S3) were used when compared 
to their controls [IgG) (4.6 ± 1.0,) and IgG2a (3.9 ± 0.3), respectively] (n = 3, P < 0.01), 
indicating that both ABC efflux transporters are expressed by hCMECID3 cells. 
The levels ofP-gp expression were then compared between hCMECID3 cells and 
primary hBECs using flow cytometry to detennine the suitability of the fonner cell line as 
a hBEC model. Both primary hBECs and hCMECID3 cells demonstrated a higher median 
fluorescence staining intensity compared to their controls (n = 3 experiments with 
duplicate samples, P < 0.01, Figure 2.6). Whilst primary hBECs expressed 37.6 % ± 8.0 
more P-gp than hCMECID3 cells, these levels were not significant (for primary hBECs, n 
= 3 from 2 donors, P > O.OS). The results indicate that the expression of P-gp by 
hCMECID3 cells is close to that of primary hBECs cells and so they represent a suitable 
model for the study ofP-gp expression. 
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2.3.4 The expression of P-gp by hCMECID3 cells as assessed by 
immunocytochemistry 
The ability of P-gp to act as an efflux transporter is dependent on its localisation to 
the plasma membrane. Furthermore, the polarisation of P-gp to either the basolateral or 
apical membrane will determine the direction of efflux, which in vivo corresponds to the 
brain or blood side of the BBB respectively. Therefore, the sub-cellular localisation ofP-
gp was investigated by ICC. Using fluorescence microscopy, both P-gp and BCRP 
displayed a diffuse staining at the cytoplasm and membrane, but not in the nucleus (Figure 
2.7, n = 3). As for fluorescence microscopy, the sub-cellular localisation ofP-gp could not 
be discerned by confocal microscopy (Figure 2.8, n = 1). P-gp expression was not detected 
in the nucleus but appeared to be distributed throughout the cytoplasm and plasma 
membrane. The results indicate that either both techniques are not sufficiently sensitive to 
detect the sub-cellular localisation of P-gp, or that P-gp is distributed throughout 
hCMECID3 cells. 
2.3.5 Sub-cellular localisation of P-gp as assessed by differential detergent 
fractionation 
Since P-gp appeared distributed diffusely throughout hCMECID3 cells, a 
biochemical assay was employed to investigate the relative sub-cellular distribution of P-
gpo hCMECID3 cells were separated into cytosolic, membrane/organelle, nuclear and 
cytoskeletal fractions using differential detergent fractionation. The expression ofP-gp and 
BCRP in each fraction was determined by western blotting and compared to a nuclear 
marker, the transcription factor Sp3, and a cytoskeletal marker, actin (Figure 2.9). 
Sp3 was found almost entirely in the nuclear fraction (89.3 % ± 5.4, n = 3), whereas 
actin was expressed highest in the cytoskeletal followed by nuclear and membrane 
fractions (75.2 % ± 9.5, 15.5 % ± 4.8 and 8.3 % ± 5.4, respectively, n = 3). P-gp and BCRP 
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were both predominantly expressed in the membrane/organelle fraction (78.5 % ± 2.6, 88.8 
% ± 5.09, respectively, n = 3). Therefore, both efflux pumps under investigation were 
located on cellular membranes, which includes both plasma membrane and membranes of 
intracellular organelles. 
2.3.6 Localisation of P-gp at the ultrastructural level 
It is essential to determine whether P-gp expression is polarised on the plasma 
membrane as this would determine whether substrates would be effiuxed on the apical or 
basolateral side of hCMECID3 cells, corresponding to the blood and brain sides 
respectively, in vivo. As ICC techniques were unable to demonstrate the polarised nature of 
P-gp, TEM and imrnunogold staining techniques were employed. Gold particles were 
observed in the apical, basolateral and intracellular compartments (Figures 2.10 a, b and c, 
respectively) in agreement with ICC staining. When quantified, the number of gold 
particles associated with the apical plasma membrane was 2.9 times greater than on the 
basolateral membrane (Figure 2.10 b, 66 images analysed over a 500 Jlm section of plasma 
membrane). Therefore, whilst P-gp molecules are distributed on both membranes, the 
majority are on the apical membrane, which corresponds to the blood side in vivo. Located 
on this membrane, P-gp would be situated to prevent the movement of unwanted substrates 
from the blood into the brain. 
2.3.7 Cytotoxicity of P-gp and BCRP inhibiton 
An aim of this chapter was to investigate the functional expression ofP-gp by 
hCMECID3 cells using the P-gp inhibitors tariquidar, vinblastine and the BCRP inhibitor 
FTC. To determine non-cytotoxic doses of these inhibitors, an MTT assay was carried out 
encompassing a concentration range previously reported to inhibit drug efflux by the ABC 
transporters. Figure 2.11 shows that tariquidar (0 - 600 nM) and FTC (0 - 22 JlM) did not 
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affect cell viability following a 48 h incubation period, indicating non-cyotoxicity to 
hCMECID3 cells over the range of concentrations tested. In contrast, vinblastine caused a 
concentration-dependent decrease in cell viability at 48 h with an IC 50 of 26.3 J.l.M ± 6.1 
(n = 3). The cytotoxicity was significant at concentrations of 0.5 J.l.M and above when 
compared to the control (n = 3, P < 0.05). However, a 24 h incubation with the same doses 
of vinblastine (0 - 40 J.l.M), did not decrease cell viability (n = 3, P > 0.05) over the entire 
concentration range investigated. In subsequent experiments, 22 J.l.M vinblastine was used 
at incubation periods of 12 h or shorter, whilst 300 nM tariquidar and 22 J.l.M FTC were 
used for periods shorter than 48 h. 
2.3.8 P-gp-mediated effiux of rh123 by hCMECID3 cells 
In the original characterisation of the hCMECID3 cell line, P-gp functional 
expression was demonstrated by an increase in the net influx ofrh123 in the presence of 
PSC-833 [473]. The aim here was to expand on this evidence by investigating whether p. 
gp acts to efflux rh123 from preloaded hCMECID3 cells. Efflux is potentially a more 
sensitive assay than influx as a measure of activity, since it is dependent on the efflux 
activity ofP-gp rather than a measure of the relative contribution of efflux versus influx 
mechanisms. Localisation of P-gp to the plasma membrane is also a prerequisite for the 
efflux function ofP-gp, which has been demonstrated in Figure 2.10. hCMECID3 cells 
were preloaded with 22 J.l.M rh123 (1 h, 4°C) and incubated at 37°C over 6 h (Figure 2.12). 
Compared to cells preloaded with rh 123 and incubated at 4°C, cellular rh 123 levels 
decreased sharply in the first hour and then continued to decline. The tll2 was estimated to 
be 13.3 min ± 1.1 (n = 3). The addition of22 J.l.M vinblastine to the efflux buffer during 
incubation at 37°C resulted in a less steep decline and a tll2 of 112.2 min ± 3.7. At every 
time point measured (15, 30, 60, 120, 180 and 360 min), the median fluorescence intensity 
of cells treated with vinblastine was higher and statistically significant compared to those 
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treated with DMSO control (n = 3, P < 0.05). These results indicate that rh123 is effluxed 
from hCMECID3 cells via functional P-gp. 
A mutation at arginine position 428 to glycine or threonine of BCRP can result in 
enhanced substrate specificity to rh123 [221], and so it remained a possibility that BCRP 
could act as a rh123 transporter in hCMECID3 cells. To further determine the relative 
contribution ofP-gp or BCRP to rh123 efflux, the effects oftariquidar (300 nM), FTC (22 
J..lM) and vinblastine (22 J..lM) were investigated. hCMECID3 cells were pre loaded with 22 
J..lM rh123 at 4°C for 60 min, followed by incubation at 37°C for 60 min with the different 
treatments (Figure 2.13).300 nM tariquidar increased cellular rh123 levels compared to an 
ethanol control (n = 3, P < 0.01).22 J..lM vinblastine, but not 22 J..lM FTC, also increased 
cellular rh123 levels compared the DMSO control (n = 3, P < 0.01). rhl23-mediated efflux 
by hCMECID3 cells was therefore mainly mediated by P-gp and not BCRP. 
Tariquidar has been demonstrated to have a long lasting, possibly irreversible 
inhibition on P-gp activity, whilst vinblastine acts as a competitive inhibitor. To investigate 
the mechanism of P-gp inhibition by tariquidar and vinblastine, hCMECID3 cells were pre-
loaded at 4°C with 22 J..lM rh123 in combination with either tariquidar (300 nM) or 
vinblastine (22 J..lM), followed by incubation at 37°C for 60 min with either tariquidar, 
vinblastine or a control. After preloading hCMECID3 cells with rh123 and tariquidar, 
cellular rh 123 levels were of similar high magnitude following incubation with tariquidar 
or a vehicle control (control 53.7 % ± 5.3, tariquidar 55.7 ± 4.3, n = 3). In contrast, after 
preloading hCMECID3 cells with rh123 and vinblastine, the presence of vinblastine during 
the incubation at 37°C was required to inhibit efflux ofrh123 (control 5.8 % ± 1.4, 
vinblastine 50 % ± 12.2, n = 3). The results imply that tariquidar is a long lasting P-gp 
inhibitor that unlike vinblastine, can exert its effect after preincubation, even if absent 
during the efflux stage of an assay. The long lasting inhibition of P-gp by tariquidar might 
be caused by high affininty binding of tariquidar with P-gp, which persists even after 
washing steps. 
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2.3.9 The permeability of hCMECID3 cells to rh123 
P-gp efflux activity may limit the permeability of its substrates across BEC 
monolayers since P-gp was located mainly on the apical membrane. Therefore the 
permeability ofhCMECID3 cells grown on transwell filters to rh123 was investigated 
(Figure 2.14). Apical-to-basolateral permeability ofhCMECID3 cells to 22 11M rh123 was 
unaffected by both 300 nM tariquidar and 22 11M vinblastine (n = 3, P> 0.05). The 
basolateral-to-apical permeability ofhCMECID3 to rh123 was also unaffected by 300 nM 
tariquidar or 22 11M vinblastine compared to the control (n = 3, P> 0.05). The results show 
that hCMECID3 cells might not be suitable to measure the polarised transport of lipophilic 
molecules with a molecular weight of - 400 Da. Indeed, Weksler et at [473] have 
demonstrated that hCMECID3 cells are useful for investigating the permeability of 
paracellular tracers larger than or equal to 4 kDa in size. 
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(a) Primary brain endothelial cells 
Freshly isolated Growing towards confluence 
(b) hCMEC/D3 cells 
115 passage Fully confluent 
Figure 2.3. Morphology of hCMECID3 cells and primary hBECs viewed by phase 
contrast microscopy. (a) Freshly isolated primary hBECs grew outwards from isolated 
capillary fragments. One week after isolation, colonies of spindle shaped cells formed 
confluent monolayers. (b) hCMECID3 cells were split at a ratio of 1 in 5 onto collagen-
coated tissue culture flasks. When confluent, - 2-3 days, hCMEC/D3 cells formed a 
monolayer of spindle shaped, tightly packed cells. Images taken on Nikon eclispse IS 1 00. 
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Figure 2.4.The expression ofP-gp by hCMECID3 cells over passage. (a) Fully 
confluent hCMEC/D3 cells were lysed in RIP A buffer and the expression ofP-gp (C219, 
mouse monoclonal IgG2a) and actin (mouse monoclonal IgGt) was determined over 
passage number from 23 to 44 using western blotting techniques.(b) The signal intensity of 
the bands corresponding to P-gp and actin were determined by image J and P-gp 
expression normalised. n = 1, with single samples. 
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Figure 2.5. The expression of P-gp and BCRP by hCMECID3 cells as assessed by flow 
cytometry. Fully confluent hCMECID3 cells were fixed in 4% PAF, permeabilised using 
0.1 % triton X-I 00 and stained with antibodies for (a) P-gp (JSB-1 , mouse monoclonal 
IgG J) (b) BCRP (BXP21 , mouse monoclonal IgG2a) or their negative controls (mouse IgG J 
and IgG2a respectively) and analysed via flow cytometry (488 nm '-excitation 520 nm '-emission) 
(C) Data represents mean ± SEM, n = 3 with duplicate samples. ** P < 0.01 using 
Student's t test. 
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Figure 2.6. The expression of P-gp by hCMECID3 cells and primary hBECs as 
assessed by flow cytometry. Fully confluent (a) hCMECID3 cells (P23-28) and (b) 
primary hBEC (P2-4) were fixed in 4% PAF, permeabilised using 0.1 % triton X-IOO and 
stained with antibodies for P-gp (JSB-1 , mouse monoclonal IgGt) or a negative control 
(mouse IgG 1) and analysed via flow cytometry (488 nm Aexcitation 520 nm Aemission) (c) Data 
represents mean ± SEM, n = 3 with duplicate samples. ** P < 0.01 using Student's t test. 
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Figure 2.7. Expression of P-gp and BCRP by hCMECID3 cells as viewed by 
fluorescence microscopy. hCMECID3 cells were grown on collagen-coated Labtek slides 
until confluent, fixed (4 % PAP), perrneabilised (0.1 % triton X-IOO) and stained for (a,b) 
P-gp [JSB-l (mouse monoclonal IgG1)] or isotype-matched control or (c,d) BCRP 
[BXP21 ,(mouse monoclonal IgG2a)] , counterstained for the nucleus with DAP! and viewed 
via fluorescence microscopy. Images are a representation of hCMECID3 cells at p 26. (n = 
3 with single samples) 
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(c) 
Figure 2.8. Expression of P-gp by hCMECID3 cells a viewed by confocal micro copy 
hCMECID3 cell (p 28) were grown to confluence on collagen- and fibron ctin- coated 
transwell polyester membrane in ert (0.4 ~m pore, 12mm diam ter) fixed (4 ~ PAF) 
permeabilised (0.1 % triton X-lOO) and stained for P-gp (JSB- ) mou monoclonal IgG 1) 
or an isotype control (mou e IgG 1), counterstain d with the nuclear ta in DAPI and 
viewed on a confocal micro cope. (a) An XY Z cro - ection wa taken ov r a el cted 
field, enabling top down (b) and (c) three dimen ional recon truction with Volocity 
software. Images are from one experiment carried out in duplicate. 
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Figure 2.9. The sub-cellular localisation ofP-gp, BCRP, Sp3 and actin in hCMECID3 
cells as determined by western blotting after differential detergent fractionation. (a) 
Fully confluent hCMECID3 cells were separated into cytosol, membrane/organelle, 
nuclear and cytoskeletal components using differential detergent fractionation and the 
expression ofSp3 (rabbit polyclonal IgG), actin (mouse monoclonal IgG 1) , BCRP [BXP21, 
(mouse monoclonal IgG2a anti-human)] and P-gp [C219,(mouse monoclonal IgG2a) was 
assessed by western blotting, (b) Relative expression of each protein in cytosol, 
membrane/organelle, nuclear and cytoskeletal fractions as a percentage of total expression, 
Data represents mean ± SEM, n = 3 with single samples. 
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Figure 2.10. Expression ofP-gp by hCMECID3 cells as assessed by TEM and 
immunogold staining. hCMECID3 cells (p 28) were grown to confluence on transwell 
polyester membrane inserts (0.4 11m pore, 12mm diameter), fixed (PLP), mounted on 
nickel slots, stained for P-gp [C219, (mouse monoclonal IgG2a) or an isotype control 
(IgG2a) and viewed in TEM. One frame length of7.5 11m was taken every 2-3 frames (a-c) 
for a total of 500 11m, and the number of gold gold particles counted within 100 nrn of the 
apical or basolateral membrane per image. (d) The average number of gold particles per 
11m was then calculated. --. Indicates gold particles. Scale bar = 100 nrn 
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Figure 2.11. Cytotoxicity of vinblastine, tariquidar and FTC to hCMECID3 cells as 
assessed by an MTT assay. Cytotoxicity of (a) tariquidar, (b) FTC and (c) vinblastine in 
fully confluent hCMECID3 cells was assessed using an MTT assay. Data represents mean 
± SEM, n = 3 with quintuplet samples. * P < 0.05 using Student's t test for raw data. 
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Figure 2.12. Time-dependent efflux of rh123 by hCMECID3 cells. (a) Fully confluent 
hCMECID3 cells were preloaded with rh123 (22 ~M) for 1 h at 4°C and then incubated at 
37°C in the presence of 22 11M vinblastine or DMSO for 15, 30, 60, 120, 180 or 360 min 
and analysed via flow cytometry (488 nm A.ell:ci lation 520 nm Aemission). (b) The median 
fluorescence intensity was measured and expressed as a percentage of preloaded cells 
incubated at 4°C. Data represents mean ± SEM, n = 3 with duplicate samples. * P < 0.05, 
** p < 0.01 using Student's t test comparing vinblastine to DMSO at each time point. 
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Figure 2.13. Rh123 effiux inhibition by tariquidar and vinblastine from hCMECID3 
cells. (a) hCMECID3 cells were preloaded with rh123 (22 J,lM) at 4°C for 60 min followed 
by 60 min incubation at 37°C in the presence oftariquidar (300 nM), vinblastine (22 J,lM), 
FTC (22 J,lM) or an appropriate control and the median fluorescence intensity measured by 
flow cytometry. Data represents mean ± SEM, n = 3 with duplicate samples. * P < 0.05, ** 
p < 0.01 using Student's t test comparing treatment to appropriate control. (b) hCMECID3 
cells were preloaded with rh123 and either tariquidar (300 nM) or vinblastine (22 J,lM) for 
60 min at 4°C followed by 60 min incubation at 37°C in the presence or absence of the 
appropriate inhibitor. n = 3 with duplicate samples. 
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Figure 2.14. The permeability of hCMECID3 cells to rh123 in the presence or 
absence of tariquidar and vinblastine. hCMECID3 cell were grown to confluence on 
collagen- and fibronectin- coated filter inserts. rhI23 (22 ~M) was then added to the apical 
or basolateral side of the filter in the presence oftariquidar, vinblastine or DMSO and the 
amount ofrhI23 that crossed the filter was measured using a fluorescence plate reader. (a) 
Shows a typical curve of the volume of rh 123 cleared versus time for apical to basolateral 
permeability. (b) The apical-to-basolateral permeability coefficient (Pe) ofhCMECID3 
cells was calculated using the slope of the curve. Data represents mean ± SEM, n = 3 with 
duplicate samples. P > 0.05. (c) RhI23 (22 ~M) in the presence oftariquidar (300 nM), 
vinblastine (22 ~M) or appropriate control was added to the basolateral chamber of fully-
confluent hCMECID3 cells grown on filters . After 30 min the fluorescence was measured 
in the apical and basolateral chambers and the P e calculated. Data represents mean ± SEM, 
n = 3 with duplicate samples. P > 0.05. 
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2.4 Discussion 
2.4.1 P-gp expression by hCMECID3 cells 
hBECs express P-gp which acts as a barrier for many therapeutic drugs and 
endogenous molecules, preventing their entry into the brain (reviewed in [172, 186]). The 
study of P-gp in vitro is a useful tool for identifying potential substrates and inhibitors. The 
overall aim of this chapter was to fully characterise P-gp expression by an immortalised 
hBEC cell line, hCMECID3 cells, previously suggested as a suitable in vitro human BBB 
model [473]. The data presented here shows that hCMECID3 cells express P-gp as 
assessed by flow cytometry, western blotting, ICC and TEM staining. This data is 
agreement with multiple studies that have demonstrated BEC P-gp expression at both the 
protein and mRNA level from in vitro cultures of both primary and immortalised cells of 
rat, mouse and human origin [172, 186,210-212,473,482,504,506,514,515]. 
In terms of P-gp expression, the BEC phenotype appears to be preserved in 
hCMECID3 cells over a wide range of passages (up to p38) and P-gp expression was 
comparable, albeit slightly reduced, to primary BECs. It is likely that the primary BECs 
used here however would have a marked decrease in P-gp expression compared to isolated 
capillaries, which more closely mimic the in vivo situation as has been demonstrated in a 
number of animal and human studies. Regina et al [244, 516] demonstrated that compared 
to isolated rat brain capillaries, an immortalised rat BEC cell line, RBE4, and primary rat 
BECs express less P-gp when assessed by western blotting and by RT-PCR for mdrla. The 
authors also found that P-gp expression was higher in primary rat BECs than in RBE4 
cells, which is similar to the observations made in this study with hCMECID3 cells and 
primary hBECs. Barrand et al [517] have also demonstrated that isolated BECs express 
less P-gp than cerebral microvessels from rats. Seetharamam et al [212] have corroborated 
this finding in humans, reporting that isolated BECs express less P-gp, assessed by ICC 
when compared to brain capillaries. P-gp expression can be elevated in cell culture using a 
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variety of different agents including puromycin, dexamethasone, cAMP elevation and PKC 
activation [518] [244,519]. hCMECID3 cells, however, have not been demonstrated to 
induce P-gp in response to a number of different agents (D.K.Male, The Open University 
personal communication) including TNF-a and puromycin. 
2.4.2 P-gp cellular distribution in the eNS 
There has been some controversy surrounding the expression of P-gp by BECs. In 
1997, Pardridge et al. [209] found that MRK16, an antibody directed against an external 
epitope of P-gp, co-localised with GF AP but not with Glut-l in isolated human brain 
microvessels and rhesus monkey tissue samples. GFAP is a typical astrocyte marker, 
whereas Glut-l is an EC marker. In a follow up study, there was a similar finding in 
unfixed isolated human brain capillaries, whereby GF AP and MRK16 staining were co-
localised in a discrete continuous pattern. This led the authors to conclude that P-gp was 
located on astrocytic foot processes on the abluminal side on ECs [208], although the 
activation state of the astrocytes in the post mortem tissue might have induced P-gp up-
regulation. This finding has been challenged by several groups on the basis that only one 
P-gp antibody was used in the experiment and it has been suggested that in certain cell 
types, the glycosylation state ofP-gp can mask the antibody binding site ofMRK16 [172, 
186,515]. It is of interest to note that using a rabbit polyclonal anti-P-gp antibody, a group 
of researchers including Pardridge demonstrated P-gp expression on both astrocytes and 
ECs from normal primate brain [484]. Bendayan et al [213] have also noted astrocytic P-
gp expression from human brain tissue sections using TEM. Whilst the numerous data 
describing BEC P-gp expression far outweighs the relatively few studies, described above, 
which do not show P-gp expression by BECs, this does not exclude the possibility that 
astrocytes do express P-gp. A recent study by Yolk [248] indicated that in acetone-fixed rat 
brain tissue, P-gp is predominately expressed by capillary ECs and weakly by perivascular 
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astrocytes. After kainate induced seizures, P-gp was found unregulated in hippocampal 
neurones but not in astrocytes. Interestingly, however, in PAF- fixed sections, P-gp 
localisation was absent in BEes, whilst astrocytic P-gp expression was found up-regulated 
post-seizures [248]. This demonstrates that the fixation method can alter the pattern ofP-
gp expression, which could explain the results obtained by Pardridge. Astrocyte P-gp up-
regulation has been observed in animal studies in response to seizure inducing agents [520] 
and increased astrocytic P-gp staining has been observed in epileptic brain tissue 
specimens [521]. Such observations may indicate a role for astrocytes as a second line of 
defence, to protect the brain after insult [522] 
In this study P-gp expression was observed on both primary BECs and hCMECID3 
cells, which is consistent with the P-gp staining found in isolated human brain capillaries 
[212] and tissue sections [483]. 
2.4.3 Sub-cellular P-gp localisation by hBEC 
In this study, P-gp expression was localised to the membrane/organelle fraction, 
when isolated using differential detergent fractionation. Using TEM and immunogold 
staining, P-gp was found to be localised mainly in or at the apical membrane, although 
labelling in the cytoplasm and basolateral membrane was also observed. These results are 
in partial agreement with Bendayan et al [213] who found abluminal, luminal and 
cytoplasmic (cytoplasmic vesicles, Golgi complex, and rough endoplasmic reticulum) 
staining ofP-gp in rat and human brain tissue. However, Bendayan demonstrated 
abluminal polarisation ofP-gp in rat brain tissue and overall the number of gold particles 
per Jlm of membrane was much higher than that observed in our study (1.17 ± 0.04 
abluminal, 0.85 ± 0.03 luminal compared to 0.038 ± 0.009 and 0.11 ± 0.017, respectively, 
in this study). These contrasting results might reflect species differences between rats and 
humans. Indeed, numerous lines of evidence point to the polarisation of P-gp on the 
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luminal membrane of BECs. Luminal P-gp expression has been observed in isolated 
human brain capillaries [212] and human tissue [483]. Virgintino et al [483] have 
demonstrated, using confocal microscopy, luminal microvessel P-gp expression in the 
human cerebral cortex. In vivo, Mdrla or mdrlalb knock out mice display enhanced 
accumulation of many intravenously injected P-gp substrates, including cyc1osporin A, 
vinblastine, digoxin, morphine and digoxin, colchicine and morphine (reviewed [172, 
186]). The polarised nature of BEC function has been demonstrated in vitro on isolated 
BECs grown on filter inserts, which show directional transport of cyclosporin A and 
vincristine in mouse BECs [211,523]. 
In summary, the expression ofP-gp by BECs is more likely to be luminal in nature 
as a protection mechanism from blood substrates. However, further research is required to 
clarify differences in the polarisation ofP-gp expression by BECs across species. 
2.4.2 Cytotoxicity of P-gp and BCRP substrates and inhibiton 
FTC is a selective inhibitor of BCRP. The ability of FTC to block BCRP was first 
described by Rabindran et aI, [524] who demonstrated that FTC was able to reverse the 
drug resistance of a human carcinoma cell line. Since that discovery, FTC has been used in 
a variety of cellular models at doses in the 5-10 J-lM range, to inhibit BCRP function [525-
528] and its toxicity has been evaluated in vivo [529]. It has been suggested that FTC acts 
as a competitive inhibitor ofBCRP [524]. The finding that FTC was non-toxic up to 22 
J-lM for 48 h to hCMECID3 cells meant that subsequent experiments could be carried out in 
the J-lM range. 
As mentioned in section 1.1.5.1, P-gp expression has been detected in many 
tumours, conferring tumour cell resistance to many anti-cancer drugs. To combat this 
multi drug resistance, many P-gp inhibitors have been developed (reviewed [530]). 
Tariquidar (XR9576) is a 3rd generation P-gp inhibitor that has been demonstrated to block 
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P-gp activity in cell cultures at concentrations in the nM range and is also effective in vivo 
[487,531-537]. Tariquidar has been confirmed to have a superior potency than cyclosporin 
A and verapamil in vitro, and also to have a long duration of action, since it is not itself a 
P-gp substrate. In human and murine cell lines, Tariquidar was found to block the efflux of 
rh 123 mediated by P-gp, and also to increase the cellular of 3H daunorubicin levels, a P-
gplMRP-1 substrate [531]. In the current study, Tariquidar was found to be non-toxic to 
hCMECID3 cells at concentrations up to 600 nM for 48 h and so it was used at 300 nM in 
subsequently studies, a dose at which it effectively inhibited P-gp activity. 
Vinblastine was found to be non-cytotoxic to hCMECID3 cells after 24 h 
incubation, but cytotoxic after 48 h incubation at concentrations over 0.5 ~M. The 
maximum incubation time for that vinblastine was used at later studies was 12 h at 22 ~M, 
i.e. non-cytotoxic concentrations. It is likely, however, that even at a non-cytotoxic dose, 
vinblastine was altering the protein expression and/or microtubule architecture of 
hCMECID3 cells. Vinblastine is a vinca alkaloid, which is used in cancer chemotherapy as 
it induces mitotic arrest. Vinca alkaloids bind to tubulin and prevent the assembly of 
microtubules, halting tumour cells in metaphase [538-540]. Vinblastine has demonstrable 
toxic effects on ECs [541-543]. In a co-culture model of porcine BECs and astrocytes, Van 
der Sandt et al [543] demonstrated that vinblastine caused a dose-dependent reduction in 
the TEER of porcine BECs between 0 and 1 ~M, after 6 h incubation. This reduction in 
TEER was increased by the addition of cycloporin A, verapamil and PSC-833. Vinblastine 
has also been demonstrated to inhibit EC proliferation, motility and organisation at low 
concentrations [541,542,544] and also to up-regulate the expression of genes associated 
with cell cycle and apoptosis [545]. Pierre et al [546] have also demonstrated that 
treatment of primary isolated rat BEes with 5.51 ~M vinblastine results in complete 
apoptosis of all cells. Tariquidar, FTC and vinblastine have no cytotoxic effects on 
hCMECID3 cells at the doses and incubations times selected for later experiments in this 
study. 
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2.4.3 P-gp activity in hCMECID3 cells 
A rh123 efflux assay was used to determine functional P-gp expression in 
hCMECID3 cells. Rh123 is a low molecular weight (MW 380.82) fluorescent substrate of 
P-gp, which has been used to investigate P-gp activity in a range of different cell lines. 
Specifically for BECs, many groups have investigated the net influx ofrh123 in the 
presence or absence ofP-gp modulators (Table 2.3). Using this method and the P-gp 
inhibitor PSC-833, Weksler et al [473] have demonstrated that P-gp inhibition increases 
the intracellular accumulation of rh 123 in hCMECID3 cells by 50 % after 1 h incubation. 
In this study, tariquidar and vinblastine inhibited the efflux ofrhl23 by - 55 % and 42 % 
compared to cells incubated at 4°C. Therefore, the sensitivity ofP-gp-mediated inhibition 
appears similar for rh123 influx and efflux experiments. However, if the raw median 
fluorescence intensity data for tariquidar and vinblastine is divided by the control data, as 
carried out for influx data [473], the cellular levels are 779 % and 691 % higher than 
controls, respectively, revealing an increased sensitivity and improved P-gp functional 
assay than influx. 
The efflux of pre loaded rh123 (22 J..lM) was time-dependent with a tl/2 of 13.3 min 
± 1.1, whilst in the presence of vinblastine the t\/2 was 112.2 ± 3.7 min. The tll2 obtained 
here is in agreement with Ji et al.[547], who obtained a t\12 of similar magnitude in rat 
primary BECs (- 20 min). However, in contrast to the relatively modest increase in the t\12 
caused by verapamil in that study, in the present study vinblastine caused a much more 
potent inhibition. These contrasting results could be explained by differences in 
methodology, since the rat BECs were loaded at 37°C and the data is expressed as a 
percentage of time zero, rather than cells left at 4°C. The levels ofP-gp expression might 
also differ between the cell lines. Since vinblastine and tariquidar both inhibited rh 123 
efflux, there is strong evidence that rh123 efflux from hCMECID3 cells is mediated by P-
gpo In agreement with other research groups, FTC in this study did not inhibit rh123 efflux 
[473,548]. BCRP has been demonstrated to recognise rh123 as a substrate only when there 
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is a mutation at position 482 [221,230,549,550]. Therefore it is likely that hCMECID3 
express wild type, non-mutated BCRP, since BCRP activity has been demonstrated in 
hCMECID3 cells [473] 
The inhibition of P-gp function by tariquidar was longer lasting than that of 
vinblastine. This observation is in agreement with Misty et aI, [531] who reported an 
irreversible long- lasting inhibition ofrh123 and 3H daunorubicin efflux by tariquidar in a 
human ovarian carcinoma cell line, only if the inhibitor was present in the preloading 
stage. This evidence suggests that tariquidar might be a more suitable inhibitor than 
vinblastine for the study of the role of P-gp in the CNS penetration of drugs. 
2.4.4 Permeability of hCMECID3 cells to rh123 
The permeability ofhCMECID3 cells grown on filters to rh123 was unaffected by 
P-gp inhibition in both the apical-to-basolateral and basolateral-to-apical directions. This 
result is consistent with Gaillard et al [551] who found no significant polarised transport of 
rh123 and doxorubicin in either direction across porcine BEC monolayers, unless co-
cultured with astrocytes (Table 2.3). The lack of polarised P-gp transport may not reflect 
an unpolarised distribution of P-gp expression by hCMECID3 cells as strong luminal 
expression was observed in this study. Rather, it may reflect a reduced tightness of the EC 
layer. Rh123 is a small molecular weight molecule (MW 380.80) and the Pe values 
obtained for rh123 are similar to those obtained for sucrose (1.65 x 10-3 cm/min) in the 
original description of the hCMECID3 cells [473]. This permeability coefficient is high 
when compared to larger molecular weight molecules (4 kDa FITC· dextran 0.235 x 10-3 
cm/min) and it has been suggested that the hCMECID3 cells are a good model for 
measuring the paracellular permeability of molecules over 4 kDa in MW, due to the 
relatively low TEER values. Thus the tightness of the hCMECID3 cells may not be 
sufficient to allow a barrier function for rh123, masking the contribution ofP-gp to 
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polarised transport [473]. Rh123 is lipophilic whereas sucrose is hydrophilic, and so the 
main route of entry of sucrose is paracellular, whilst rh 123 can cross hCMECID3 
mono layers by paracellular and transcellular pathways. Therefore, if the hCMECID3 cell 
layers are not very tight, as indicated by the low TEER values obtained by Weksler et al 
[473], then the paracellular diffusion ofrh123 will mask the influence ofP-gp over its 
transcellular transport. Astrocytes in the co-culture system described by Gaillard [551] 
might have increased the TEER values of BECs to an extent that permeability might be 
solely transcellular in nature. Indeed, Kunhe et al [407] have demonstrated that in porcine 
kidney epithelial cells (LLC cells) transfected with the MDRI gene, the basolateral-to-
apical transport ofrh123 was increased compared to untransfected cells. LLC cells form 
much tighter monolayers than BECs, which may allow rh123 to be used as a polarisation 
transport marker. 
2.5 Conclusions 
In this study, functional P-gp expression by hCMECID3 cells has been 
demonstrated. hCMECID3 cells were found to express P-gp polarised on the apical 
membrane as previously reported in isolated human brain capillaries and are therefore a 
good in vitro model for investigating the transport of P-gp substrates. P-gp expression was 
also found lower than primary BECs in agreement with the literature. The supply of human 
tissue is fairly limited for this study and so the hCMECID3 cell line represents the most 
suitable human in vitro BEC model for investigation P-gp function. Tariquidar and 
vinblastine were demonstrated to inhibit the effiux of rh 123 and so can be used to inhibit 
P-gp function by hCMECID3 cells. Whilst P-gp was functional and polarised, rh 123 
cannot be used as a as a permeability tracer due to the hCMECID3 cells high permeability 
to low molecular weight molecules. 
- 121 -
Type of rh123 Cell line 
experiment 
Influx 
Rat BECs 
Bovine BECs 
RatBECs 
hCMECID3 cells 
Immortalised rat 
BECs 
MiceBECs 
BovineBECs 
RatBECs 
RatBECs 
Result Reference 
Net influx ofrhl23 (5 JlM 90 min) increased after the addition ofverapamil (10 JlM) [547] 
and amplodipine derivates (CJXI and CJX2 1-10 JlM). Verapamil increased influx by 
297.3% 
Net influx ofrh123 (4 JlM, 20 min) increased after ultrasound induced hypothermia (74 [552] 
% increase) and PSC-833 (I Jlm,60%). 
Net influx ofrhl23 (2.6 JlM, 60 min) increased by 2.5 fold by addition of cyclosporin [251] 
A (50 JlM) in hypoxic BECs. 
Net influx of rh123 (10 JlM, 30 min) increased by 70% of control by PSC-833 (10 JlM) [473] 
Net influx ofrhl23 (10 JlM 1 h) increased by PSC-833 (10 Jlm, 30 min preloading) by [504] 
~70%. 
Net influx (10 JlM, 60 min) decreased by TAT 1-72 partially overcome by verapamil. [252] 
Cyclosporin A and verapamil increase the net intracellular accumulation of 3.2 JlM [553] 
rh 123 afer 60 min. 
Cyclosporin A (50 JlM) and verapamil (200 JlM) increase the cellular uptake ofrh123 [247] 
(200 JlM). 
Glutamate (100 JlM, 30min) decreases rh123 accumulation (5 JlM, 90 min) to 43 % of [249] 
control. 
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Effiux 
Permeability 
Rat BECs 
HumanBECs 
Human Ovarian 
cancer cell line 
RatBECs 
LLC-MDRI 
BovineBECs 
BEC loaded with 5 11M rhl23 for 90 min at 37°C, followed by incubation at 37°C +/-
verapamil (10 11M). Control tlfl ~ lO min and ~ 20 min with verapamil. Amlodipine 
derivates also increased cellular retention. 
BEC loaded with rh123 (10 11M rh123 15 min, followed by 1 h incubation +/-
verapamil (30 11M). Cellular retention increased by 1.2-1.4 relative to control. 
2780AD cells loaded for 1 h with 2 J.lM rh123 +/ tariquidar (200,300nM) and then 
incubated minus inhibitors for 2 h. Cyclosporin A did no inhibit (t1l2 ~ 20 min. 
Tariquidar caused complete inhibition 
[547] 
[554] 
[529] 
Apical-to-basolateral permeability ofBECs to rh123 (4 11M) unaffected by PSC-833 (1 [555] 
11M) after 30 min. 
LLC-MDRI cells have increased basolateral to apical transport ofrh123 (lO J.lM), but [407] 
not apical to basolateral, when compared to LLC. 
No polarised transport ofrh123 by bovine endothelial cells alone, only when co- [551] 
cultured with astrocytes 
Table 2.3. rh123 assays used to investigate P-gp function in brain endothelial cells and epithelial cells. 
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Chapter 3 
Role ofP-gp and BCRP in AP transport across hCMECID3 cells 
Abstract 
The aim of this study was to investigate whether A~ was a substrate for the brain 
efflux transporters P-gp and BCRP. The net influx of fluorescein-tagged A~ 1-40 and A~ 
1-42 (fA~ 1-42 and fA~ 1-40 at 0.1 /lM and 1 Mm, respectively) into hCMECID3 cells was 
unaltered by inhibitors for P-gp (tariquidar, vinblastine) or BCRP (FTC). In addition, the 
efflux offA~ 1-40 and fA~ 1-42 from preloaded cells (1 /lM, 24 h) was not affected by P-
gp and BCRP inhibition. In contrast, at physiological concentrations of A~ e25I A~ 1-40, 
0.1 nM), influx was increased and efflux was decreased by the addition ofP-gp inhibitors 
(vinblastine, tariquidar) in hCMECID3 cells. Importantly, the permeability of the 
hCMECID3 cells to 1251 A~ 1-40 in the apical-to-basolateral direction, but not in the 
basolateral-to-apical direction, was increased by P-gp and BCRP inhibition. This finding 
was consistent with P-gp and BCRP acting to prevent blood-borne A~ peptides entering 
the brain in vivo. 
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3.1 Introduction 
Increased levels of neurotoxic A~ in the brain are thought to be central in the 
pathogenesis of AD [302]. A potential therapy for AD is to increase the clearance of A~ 
peptides from the brain, thus reducing the amyloid burden (reviewed in [137, 390, 556]). A 
number of transporters for A~ have been demonstrated at the BBB which lead to A~ 
transport into (RAGE, LRP-2/megalin) or out of (LRP-l, P-gp) the CNS. 
LRP-l, a member of the low density lipoprotein receptor family, is the most 
extensively described brain-to-blood A~ transporter at the BBB [319, 384, 394-396, 400, 
401,557-563], binding to both free A~ [395] and A~ bound to a carrier (A poE, a2 
macroglobulin) [396, 563, 564]. In vitro, both A~ 1-40 and A~ 1-42 bind with high affinity 
to two LRP-l extracellular binding domains, called cluster II and IV [395], which results in 
intemalisation [396] [563] and transcytosis [395] of the peptide in cultured BECs. In vivo, 
A~ binds at the abluminal membrane ofBECs via LRP-l [395] and results in the 
transcytosis and clearance from the brain [319, 394, 395], whilst LRP-l in the liver clears 
AP from the circulation [565] in rats. Recently, Sagare et ai, [319] demonstrated that 
soluble recombinant LRP-l cluster IV can reduce A~-related dysfunction in mice 
heterogeneous for the Swedish mutation of human APP, evidence that suggests treatment 
may be effective in AD. 
RAGE acts to transport A~ from the blood into the brain [389, 390], and increased 
microvascular RAGE expression has been observed in AD hippocampi sections compared 
to controls, whilst decreased BEC LRP-l expression is found in AD patients [384]. 
Importantly, Deane et al [383] have calculated that if AP blood-to-brain transport was shut 
down, LRP-l could remove all soluble AP from the ISF in the CNS in AD patients in - 40 
min. 
P-gp, similarly to LRP-l, appears to transport A~ from the brain into the blood, 
although the interaction is much less well investigated. Lam et al [406] were the first to 
describe in vitro that both A~ 1-40 and A~ 1-42 bind to P-gp, using a human embryonic 
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kidney cell line (K269sw) enriched with the human MDRI gene product and vesicles 
derived from the membrane of CHO cells. Further in vitro [407] evidence has shown that 
porcine kidney epithelial cells transfected with human MDRI (LLC-MDR1), transcytose 
AP 1-40 and AP 1-42 from the basolateral-to-apical compartments when grown on filter 
inserts, and this transport is inhibited by cyclosporin A. In vivo data is consistent with in 
vitro observations. Cirrito et al [408] have found that Mdrla/b(-I-) mice clear 
intracerebrally injected 1251 AP 1-40 and 1-42 from the CNS at half the rate of wild type 
mice. However, LRP- 1 was found to be down-regulated at the BBB of these mice. To 
clarify the contribution of P-gp to AP clearance, the same research group went on to show 
that Tg2576 transgenic mice (harbouring the human APP Swedish mutation gene), treated 
with a P-gp inhibitor (XR9576), have increased ISF levels of AP in the brain. Whilst there 
is no direct evidence of P-gp dysfunction in AD patients, it is of note that Vogelgesang et 
al. [409] found an inverse correlation between senile AP plaque deposition and P-gp 
expression in the median temporal lobe of non-demented subjects. There is also a reported 
P-gp down-regulation in Creutzfeldt-Jacob disease, a disease in which, at later stages, 
amyloid plaques and prion proteins are sometimes found aggregated [566]. 
There do, however, remain a few questions over the interactions between P-gp and 
AP at the BBB. The in vitro data collected thus far has originated from cell types that are 
not BEC in origin and so may express different levels of P-gp in addition to other AP 
transporters. Whilst the few in vitro studies too support the notion of P-gp functioning as a 
transporter for AP, a recent study using MDCK epithelial cells transfected with the human 
MORI gene (MDCK-MDRI cells), found that the basolateral-to-apical transport of AP 
was the same for MOCK and MOCK-MDRI cells [561]. Furthermore, using the P-gp 
inhibitors verapamil and quinidine, the brain-to-blood transport of human AP at the rat 
BBB in vivo has been demonstrated to be partially due to LRP-l, but not to P-gp [560]. 
In chapter 2, it was demonstrated that hCMECID3 cells express functional P-gp 
polarised to the apical membrane. The aim of this chapter was to investigate whether P-gp 
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and BCRP could act as transporters of A~ at high concentrations (0.1-1 JlM), using 
fluorescein tagged A~, and at physiological concentrations of A~, (0.1 nM) using 125IA~. 
To do this, the effects ofP-gp and BCRP inhibition on the net influx of A~, and efflux of 
A~ preloaded from hCMECID3 cells, were investigated. If A~ is a substrate for P-gp or 
BCRP, then their inhibition would be expected to increase A~ net influx and decrease 
efflux from hCMECID3 cells, as is noted with other P-gp substrates such as rh123. It 
should be noted however, that influx and efflux, as indicated by cellular levels, represents 
all process by which A~ could associate and dissociate with the hCMECID3 cells. These 
include receptor mediated transport, diffusion, endocytosis, vesicular release and any 
'sticking' to the cell membrane. In addition, the contribution of each transporter to the 
permeability of hCMECID3 cells to A~ was investigated. 
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3.2 Methods 
3.2.1 MTT cytotoxicity assay 
AP 1-40, AP 1-42 (Bachem, Weil am Rhein, Gennany), scrambled AP 1-40 and 
scrambled AP 1-42 (sAP) (Covalence, California, USA) peptides were dissolved in DMSO 
(stock of 5 mM), and stored in Sigmacote (Sigma-Aldrich, Dorset, UK)-coated eppendorf 
tubes at -80°C. The toxicity of AP and sAP peptides was investigated after 48 h incubation 
with a concentration range of 0.05 to 5 J..1M, in the presence oftariquidar (300 nM) or FTC 
(22 J..1M) in vehicle, or medium containing vehicle alone, using the MTT method described 
in section 2.2.10. The data is presented as a percentage of the vehicle control, however 
statistical analysis was perfonned on the raw data. 
3.2.2 Influx of fluorescein-conjugated AP (fAP) peptide! 
Fluorescein tagged AP (fAP) peptides (Anaspec, California, USA) were dissolved 
and stored as for AP peptides (section 3.2.1). 1 x lOs hCMECID3 cells were seeded on 
collagen-coated 12 well plates, grown to confluence, and left for 1-2 days. 500 J..1I of fresh 
culture media was then added, containing 1 J..1M fAPI-40 or fAPI-42, and the hCMECID3 
cells were incubated for 1, 6, 24 or 48 h at 37°C. At each time point, hCMECID3 cells 
were detached, washed twice in PBS and resuspended in 500 J..1I of PBS. The samples were 
then analysed using a FACSCalibur flow cytometer with Cell quest software (488 nm 
!..excitation, 530 nm !..emission) and the median fluorescence of 10,000 cells per sample was read. 
The median fluorescence intensity of a negative control, not incubated with fAP, was used 
for statistical analysis. 
To characterise the concentration-dependent influx offAP with BECs, hCMECID3 
cells were grown to confluence and incubated with 0.001, 0.01,0.1 and I J..1M fAP 1-40 or 
fAP 1-42 for 24 h and analysed via flow cytometry as described above. 
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In order to investigate the role of different transporters/receptors in the influx of 
fA~ with BECs, hCMECID3 cells were grown to confluence and either 1 JlM fA~ 1-40 or 
0.1 J.lM fA~ 1-42 was added for 24 h with 300 nM tariquidar, 22 J.lM vinblastine, 22 J.lM 
FTC, 200 nM receptor associated protein (RAP, an inhibitor ofLRP, EMD Biosciences, 
California, USA), 2 IlM A~ 1-40,2 IlM sA~ 1-40,2 IlM A~ 1-42,2 IlM sA~ 1-42 or a 
DMSO vehicle control. hCMECID3 cells were then detached and read via flow cytometry 
as previously described, with the exception that background fluorescence was subtracted 
from all treatments prior to statistical analysis. 
3.2.3 Emux of lAP 1-40 and lAP 1-42 
hCMECID3 cells were grown to confluence as described in section 3.2.2 and 
preloaded with 1 IlM fA~ 1-40 or fA~ 1-42 for 24 h. hCMECID3 cells were then detached, 
washed and incubated at 37°C in culture media for 1,3,6 and 12 h or incubated at 4°C for 
12 h. The samples were kept at 4°C until all incubation time points had been collected and 
the samples were washed twice in PBS and resuspended in 500 JlI of PBS. The 
fluorescence intensity of cells was then measured via flow cytometry as described in 3.2.2. 
The median fluorescence intensity of each sample after background subtraction was 
expressed as a percentage of that for fA~ preloaded cells that had been kept at 4°C. 
In some experiments, hCMECID3 cells were preloaded with 1 IlM fA~ 1-40 or fA~ 
1-42 for 24 h, washed and incubated at 37°C in cell culture media for 6 h with 300 nM 
tariquidar, 22 JlM vinblastine, 22 JlM FTC or a DMSO vehicle control and the 
fluorescence measured by flow cytometry as described above. 
3.2.4 Intracellular detection of lAP by confocal microscopy 
hCMECID3 cells were grown to confluence on collagen-coated 12 well tissue 
culture plates and incubated with 1 IlM fA~ 1-40 or fA~ 1-42 for 24 h. hCMECID3 cells 
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were then detached, washed twice in PBS, fixed in 4 % P AF and incubated with 5 J..lM 
DRAQS in PBS for 1 h. After two washes, the cells were resuspended in PBS and - 5 x 
104 cells were placed on a glass slide and mounted with a glass coverslip. hCMECID3 cells 
were then viewed with a confocal microscope (Leica DMIRBE, Leica, Buckingham UK), 
taking XY and Z cross sections over a selected field to reconstruct a three dimensional 
image using Volocity software (Improvision, Coventry, UK). 
3.2.5 Influx of l2SI AP 1-40 
hCMECID3 cells were seeded on collagen-coated 24 well plates (S x 104 per well), 
grown to confluence and left for 2 days. Fresh culture media containing 0.1 nM 1251 A~ 1-
40 (1110 Cilmmole, Weil am Rhein, Germany) was then added and the hCMECID3 cells 
were incubated for O.S, 1, 3, 6 and 24 h. From all samples, the 1251 A~ remaining in the 
media and in trypsinised hCMECID3 cells was measured using a y-counter (Wallac 
Wizard, Perkin Elmer, Cambridgeshire, UK). 
To further characterise 125 I A~ 1-40 influx, hCMECID3 cells were grown to 
confluence as described above and incubated for 30 min with 0.1 nM 125 I A~ 1-40 and 
vinblastine (2 JlM), tariquidar (300 nM), FTC (2 J,lM), A~ 1-40 (100 nM), sA~ 1-40 (100 
nM), or a DMSO vehicle control. The 125 I A~ 1-40 counts were then measured in the 
supernatant and trypsinised cells. For both experiments the amount of protein in each 
sample was determined using a DC protein assay. For data analysis, the hCMECID3 
cellular levels of 1251 A~ 1-40, in fentomoles, was related to the total protein in the cell 
suspension (fmoles/mg). 
3.2.6 Emux of llsI AP 1-40 
To measure 1251 A~ 1-40 efflux from hCMECID3 cells, cells were grown as 
described in 3.2.S, preloaded with 0.1 nM 1251 A~ 1-40 for 3 h, the culture media removed, 
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the amount of 125 I AP 1-40 counted, and fresh culture media added. hCMECID3 cells 
were then incubated for 7.5,15,30,60 and 180 min at 37°C and the 125 I radioactivity 
measured in the trypsinised cells. A further treatment was also collected whereby 
preloaded cells were incubated at 4°C for 180 min. Cellular 125 I AP 1-40 levels were 
calculated as before. The t1/2 was calculated with the assumption that the sample incubated 
at 4°C for 180 min represented the maximal cellular levels of 1251 AP 1-40 and also 
represented T = 0 min. 
The effect of P-gp and BCRP inhibitors was then investigated on 1251 AP 1-40 
efflux form hCMECID3 cells. Fully confluent hCMECID3 cells were loaded with 0.1 nM 
1251 AP 1-40 for 3 h and then incubated for 10 min at 37°C in fresh culture media 
containing vinblastine (2 ~M), tariquidar (300 nM), FTC (2 ~M) or DMSO and the 1251 
radioactivity measured in trypsinised cells as above. 
3.2.7 The permeability ofhCMECID3 cells to 115 I AP 1-40 
hCMECID3 cells were grown on filter inserts (0.4 J.lm pore diameter, 12 mm 
diameter), until confluent and rested for 1-2 days. The permeability ofhCMECID3 cells to 
1251 AP 1-40 and the paracellular tracer 14C Inulin was then determined. Fresh media 
containing 0.1 nM l2.51 AP and 0.1 mM 14C Inulin (1-3 J.lCi/mg; MP biomedicals, Ohio, 
USA) in the presence of vinblastine (2 ~M), tariquidar (300 nM), FTC (2 J.lM) or DMSO 
vehicle contol was added to the apical or basolateral chamber and left for 30 min. The 
amount of l2.51 AP 1-40 in the apical medium, basolateral medium, trypsinised cells and 
filter was then counted. For 14C inulin, the amount in the apical and basal compartments 
was measured (Wallac trilux, Perkin Elmer, Cambridgeshire, UK). 
The data was analysed using an AP clearance quotient (AP CQ) as described by 
Nazer et. al. [561] with modifications: 
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14C 114C AP total 
A~ CQAP = 1251.!ll, 11251 !Q!ru 
14C 114C BL total 
12Sltotal represents the total counts for the apical and basal compartments plus trypsinised 
cells plus the filter. 14Ctotal is the total inulin counts for apical and the basolateral 
compartment. 12SIAP are the apical counts whilst I2SIBL represents basolateral counts. The 
amount of 1251 in the trypsinised cells only accounted for - 0.2% of total 1251 counts and so 
whilst not accounted for with the 14C counts, the contribution was considered to be 
negligible. 
3.2.8 Statistical analysis 
All data are represented as means +/- SEM and the number of experiments, n, 
indicated each time. For all experiments, the statistical significance was calculated using 
ANOV A followed by Student's t test, comparing each treatment to the control (* P < 0.05, 
.. P < 0.01). For the permeability, influx and efflux experiments, a paired t-test was 
employed, since each experiment was carried out with paired control and treated samples. 
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3.3 Results 
3.3.1 Cytotoxicity of AP 1-40 and AP 1-42 peptides to hCMECID3 cells 
An aim of this chapter was to investigate the interactions of A~ peptides with P-gp 
and BCRP at high and low concentrations. An MTT cytotoxicity assay was initially carried 
out to ensure that non-toxic concentrations of A~ were used (Figures 3.1 and 3.2). 
Incubation ofhCMECID3 cells with A~ 1-40, sA~ 1-40, A~ 1-42 or sA~ 1·42 for 48 h did 
not affect cell viability over the concentration range 0 - 5 JlM as assessed by fonnazan 
production from MTT (n = 3, P> 0.05). Following co-incubation of A~ and sA~ peptides 
with tariquidar (300 nM) or FTC (22 JlM), there was no increase in A~-induced 
cytotoxicity to hCMECID3 cells (n = 3, P> 0.05). This suggests that ifP-gp or BCRP 
inhibition increase A~ levels in hCMECID3 cells, this was not sufficient to induce cell 
death at the concentrations used here. The highest concentration of A~ used in subsequent 
experiments was 1 JlM for 24 h incubation. 
3.3.2 Sub-cellular localisation of lAP peptides as assessed by confocal microscopy 
In order to investigate the interaction of A~ with hCMECID3 cells, fA~ was 
employed for ease of detection. fA~ differs from A~, by the addition of a fluorescein 
molecule on the N-tenninus of the peptide and it should be noted that the fluorescence tag 
increases the molecular weight of AP 1-40 from 4329.86 to 4688.2 and A~ 1-42 from 
4514.1 to 4873.4. For A~ to be effluxed from hCMECID3 cells by BCRP and/or P-gp, it 
should first access the intracellular compartment. Therefore, confocal imaging was carried 
out to investigate fA~ peptide sub-cellular localisation (Figure 3.3 and 3.4). Confocal 
imaging shows that both fA~ peptides appeared intracellularly but not in nuclear 
compartments. There is particularly strong staining in the area around the nucleus, where 
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the golgi apparatus, which is involved in the trafficking of vesicles, is located. These data 
indicate that a high proportion of fAP peptides are located intracellularly. 
3.3.3 Influx of fAP peptides into hCMECID3 cells 
Next, the effect ofP-gp, BCRP and LRP-I inhibition on fAP influx was 
investigated. Initially, a time-course and dose-response curve of fAP 1-40 and fAP 1-42 
influx into hCMECID3 cells was determined, in order to pick optimal conditions for 
subsequent influx experiments with inhibitors (Figure 3.5). 0.1 J.lM fAP 1-42 influx into 
hCMECID3 cells increased with time, with a maximum at 24 h, and then a slight decrease 
after 48 h incubation to 70.4 % ± 1.8 of maximum levels (n = 3, P > 0.05). The pattern of 
fAP 1-40 influx was similar, reaching a maximum at 24 h and then decreasing to 75.9 % ± 
1.53 of maximum levels after 48 h incubation (n = 3, P> 0.05). However, from 6 h, the 
median fluorescence intensity values for fAP 1-40 were much lower than those for fAP 1-
42 (e.g. 56 ± 16 and 20 ± 1.5 for fAP 1-42 and 1-40, respectively, after 24 h incubation). 
For fAP 1-40, the median fluorescence intensity was higher than background for all time 
points investigated (n = 3, P < 0.01) whilst for fAP 1-42 the levels were only significant at 
24 h and 48 h (n = 3, P < 0.05) due to the high variability at lower time points. The results 
indicate that the maximal influx of both fAP species into hCMECID3 cells occurs at 24 h. 
The concentration-dependent influx of fAP peptides into hCMECID3 cell was next 
investigated. A concentration-dependent increase in fAP 1-42 influx into hCMECID3 cells 
was observed after 24 h incubation, which was significant compared to background median 
fluorescence intensity at concentrations of 0.1 J.lM and 1 J.lM (n = 3, P < 0.05) but not at 
lower concentrations. For fAP 1-40, influx into hCMECID3 cells was lower than that for 
fAP 1-42, and was only significantly higher than background at the highest dose 1 J.lM (n = 
3, P < 0.05). In subsequent influx experiments, 1 J.lM fAP 1-40 and 0.1 ~M AP 1-42 were 
used at 24 h incubation. These parameters were selected to ensure that fAP 1-42 cellular 
levels were not maximal in hCMECID3 cells so that any increases due to P-gp or BCRP 
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inhibition could be detected. In the case of fA~ 1-40 only 1 JlM could be used, due to the 
lack of detectable florescence at lower concentrations. 
3.3.4 Role ofP-gp, BCRP and LRP-l in fAP influx into hCMECID3 cells 
An aim of this chapter was to investigate if A~ is a substrate for P-gp or BCRP in 
hCMECID3 cells. The net influx of P-gp and BCRP substrates are enhanced by the 
addition of specific inhibitors as previously demonstrated for rh 123 and daunorubicin in 
hCMECID3 cells [473].Whether this was the case for fA~ peptides was therefore 
investigated. The transcytosis of A~ across EC mono layers has been described to be 
mediated by RAGE and LRP (reviewed in [137]) and as part of this process the A~ peptide 
would be internalised. The effects of LRP inhibition and unlabelled A~ peptides were 
investigated to determine the potential mechanisms of fA~ influx into hCMECID3 cells 
(Figure 3.6). Compared to control levels the influx of 0.1 IlM fA~ 1-42 or 1 IlM fA~ 1-40 
into hCMECID3 cells was unaffected by co-incubation with 300 nM tariquidar, 22 JlM 
vinblastine, 22 IlM FTC, 200 nM RAP, 2 JlM A~ 1-42,2 JlM A~ 1-40,2 IlM sA~ 1-42 or 2 
JlM sA~ 1-40 after 24 h incubation (n = 3, P> 0.05). These results imply that the influx of 
A~ into hCMECID3 cells may not be a receptor-mediated event, and that P-gp and BCRP 
do not playa significant role in A~ influx at concentration> 100 nM. 
3.3.5 Role of P-gp and BCRP in fAP efflux from hCMECID3 cells 
The results described in chapter 2 implicated that the effiux of preloaded P-gp 
substrates from hCMECID3 cells is potentially a more sensitive measurement of P-gp 
activity than net influx as indicated by rh123. Therefore, efflux of pre loaded fA~ from 
hCMECID3 cells was investigated using P-gp and BCRP inhibitors. Initially a 
characterisation of time-dependent efflux was carried out (Figure 3.7). After preloading 
hCMECID3 cells with fA~ peptides, (l IlM, 24 h), the efflux of each peptide was 
determined over time. Efflux (reduction in cell median fluorescence intensity expressed as 
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a % of 4°C treated cells) was time-dependent, with a tll2 of203.2 min ± 14.3 and 216 min 
± 3.1 min for fAP 1-40 and 1-42, respectively (n = 3). For both peptides, the data was 
significantly different at time points over 6 h incubation when compared to preloaded 
hCMECID3 cells incubated at 4°C (n = 3, P < 0.05). 
The efflux ofhCMECID3 cells preloaded with fAP 1-40 or fAP 1-42 in the 
presence oftariquidar (300 nM), vinblastine (22 JlM), FTC (22 J.!M) or a vehicle control 
was then investigated after 6 h incubation. There was no significant difference in median 
fluorescence intensity between any treatments compared to the control for both fAP 1-40 
or fAP 1-42 (n = 8 for fAP 1-42; n = 4 for fAP 1-40; P> 0.05). The results indicate that, at 
high concentration of AP (l J.!M), the contribution ofP-gp and BCRP to AP efflux from 
hCMECID3 cells in negligible. 
3.3.6 Effects of P-gp or BCRP inhibition on the influx of llsI All 1-40 into hCMECID3 
cells 
It is possible that high concentrations of fAP saturated the transport capability of P-
gp in hCMECID3 cells, or that the fluorescein tagged peptides are not P-gp substrates as 
they are more hydrophilic. Therefore, the influx of a lower concentration of 0.1 nM 12S1 AP 
1-40 was investigated, which is closer to physiological levels (reviewed in [313]). Firstly, a 
characterisation of the time-dependent influx of 0.1 nM 1251 AP 1-40 was carried out. 0.1 
nM 1251 AP 1-40 influx into hCMECID3 cells was indeed time-dependent, reaching 
saturation between 3 and 6 h with a tll2 of 35 ± 5.0 min (Figure 3.10) (n = 3). 
Next, the influx of 0.1 nM 1251 AP 1-40 after 30 min incubation with inhibitors for 
P-gp (300 nM tariquidar, 2 J.!M vinblastine), BCRP (FTC 2 J.!M), unlabelled AP or sAP 
(l00 nM) or a DMSO vehicle was investigated (Figure 3.10). Tariquidar significantly 
increased 1251 AP 1-40 influx by 20.9 % ± 0.6 .compared to the control (n = 3, P < 0.05). 
Whilst FTC and vinblastine both increased the influx of 1251 AP 1-40 into hCMECID3 cells 
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(19.6 % ± 1.1, 10.7 % ± 0.7 respectively) but levels did not reach statistical significance (P 
= 0.26 for FTC and 0.07 for vinblastine). AP 1-40 and sAPl-40 did not alter 1251 AP 1-40 
levels compared to the control (n = 3, P < 0.05). These results indicate, that P-gp, and 
possibly BCRP, might act to reduce cellular levels of 1251 A~ 1-40 at 0.1 nM, and that A~ 
influx is not a receptor-specific phenomenon in hCMECID3 cells. 
3.3.7 The role ofP-gp or BCRP on 1151 AP 1-40 emux from hCMECID3 cells 
To further explore the possibility that A~ might be a P-gp or BCRP substrate in 
hCMECID3 cells, the efflux of 1251 A~ 1-40 was investigated (Figure 3.11). After 
preloading hCMECID3 cells with 0.1 nM 1251 A~ 1-40 for 3 h, efflux was time-dependent, 
with a tll2 of 11.6 min ± 0.88 (using preloaded hCMECID3 cells incubated at 4°C as a 
measure of maximal cellular levels). 
hCMECID3 cells were pre loaded with 0.1 nM 1251 A~ 1-40 and incubated for 10 
min with P-gp and BCRP inhibitors. Compared to the control, tariquidar (300 nM) and 
vinblastine (2 ~M) both increased cellular levels of 1251 A~ 1-40 by 62.2 % ± 17.6 and 
53.8 % ± 7.2 , respectively (n = 3, P < 0.05). Whilst FTC (2 J,tM) increased cellular levels 
by 27 % ± 13.6, the levels did not reach statistical significance (n = 3, P > 0.05). The levels 
of cellular 1251 A~ 1-40 in hCMECID3 cells incubated at 4°C for 10 min had increased by 
157.8 % ± 21.1 of controls (n = 3, P < 0.01). These results indicate that P-gp, and to a 
lesser extent BCRP, contribute to 1251 A~ 1-40 efflux from hCMECID3 cells, in addition to 
other mechanisms which may include receptor-mediated transport, vesicle-mediated 
secretion or diffusion from either inside the cells or from the membrane. 
3.3.8 The permeability ofhCMECID3 cells to uSI AP 1-40 
Since P-gp, and to a lesser extent BCRP, have roles in the influx and efflux ofO.l 
nM 1251 A~ 1-40, they may also be a factor in determining the permeability of hCMECID3 
cells to 1251 A~ 1-40. Although the results of chapter 2 have indicated that hCMECID3 cells 
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are not a suitable model for studying the permeability to small molecules (rh123), it has 
been proposed that they are adequate to study the paracellular permeability of tracers with 
a MW of 4 kDa or greater [473]. The permeability ofhCMECID3 cells grown on filters to 
0.1 nM 1251 AP 1-40 in the presence oftariquidar (300 nM), vinblastine (2 ~M) and FTC (2 
JlM) or a vehicle control was thus investigated over 30 min (Figure 3.10 and 11). In order 
to take into account potential alterations in paracellular permeability, the permeability to 
14C inulin, which has a similar molecular weight, was used as a correction factor. 
From the apical-to-basolateral chambers, the permeability of filter inserts to 1251 AP 
1-40 was higher than that ofhCMECID3 cells on filters, by around 250 % (n = 6, P < 
0.05). This was also the case for the basolateral-to-apical transport, where in the absence of 
hCMECID3 cells, 185 % more 1251 AP 1-40 crossed into the apical chamber compared to 
hCMECID3 cells on filters (n = 6, P < 0.05). Higher total 14C inulin also crossed from the 
apical-to-basolateral (152 %) and baolateral-to-apical side (420%) in the absence of cells, 
compared to cells of filters (n = 3, P < 0.05). The hCMECID3 cells therefore formed a 
barrier to the passage of both 1251 AP 1-40 and 14C inulin (Figure 3.10). 
The AP CQAP of hCMECID3 cells when compared to control levels was increased 
by 54.2 % ± 16.3 with tariquidar (300 nM), 40.8 % ± 19.9 with vinblastine (2 ~M) and 
18.9 % ± 4.0 by FTC (2 IlM) (n = 6, P < 0.05). In contrast, the AP CQBL was unaltered by 
tariquidar, vinblastine or FTC (n = 6, P > 0.05). When 1251 AP 1-40 was applied on the 
apical side, cellular levels of 1251 AP 1-40 in hCMECID3 cells was increased by tariquidar 
(20 % ±16), vinblastine (46 % ± 23) and FTC (88 % ± 65), although these increases were 
not statistically significant. When 1251 AP 1-40 was applied to the basolateral side, no such 
increase in influx was observed with any of the inhibitors (Figure 3.11). 
These results suggest that P-gp and BCRP act to prevent the movement of AP from 
the apical-to-basolateral side of the cells, which is consistent with the luminal P-gp 
expression observed in chapter 2. 
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Figure 3.1. Cytotoxicity of AP 1-40 to hCMECID3 cells as assessed by an MTT assay. 
The cytotoxicity of (a) A~ 1-40 or (b) sA~ 1-40 (0 - 5 ~M) to fully confluent hCMECID3 
cells was determined over 48 h in the presence oftariquidar (300 nM), FTC (22 ~M) or a 
vehicle control using an MTT assay. Data represents mean ± SEM, n = 3 with quintuplet 
samples plotted on a semi-logarithmic scale. The SEM of controls values (100) were ± 
12.1 and ± 16.7 for A~ and sA~, respectively. P > 0.05 using Student's t test for raw data 
compared to vehicle control. 
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Figure 3.2. Cytotoxicity of AP 1-42 to hCMECID3 cells as assessed by an MTT assay. 
The cytotoxicity of (a) A~ 1-42 or (b) sA~ 1-42 (0 - 5 flM) to fully confluent hCMECID3 
cells was observed over 48 h in the presence of tariquidar (300 nM), FTC (22 p,M) or a 
vehicle control using an MTT assay. Data represents mean ± SEM, n = 3 with quintuplet 
samples plotted on a semi-logarithmic scale. SEM of controls values (100) were s ± 12.1 
and ± 16.7 for A~ and sA~ respectively. P > 0.05 using Student's t test for raw data 
compared to vehicle control. 
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Figure 3.3. Sub-cellular localisation offA(3 1-42 in hCMECID3 cells as viewed by 
confocal microscopy. hCMECID3 cells were grown to confluence in a 12 well collagen-
coated plate, incubated with 1 ~ fA~ 1-42 for 24 h, detached, fixed in 4 % PAF, stained 
with DRAQ-5, mounted and viewed on a confocal microscope. An XY Z cross-section was 
taken over a selected field (a,c), enabling a three dimensional reconstruction with Volocity 
software (b,d). n = 1 with duplicate samples. 
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(a) (b) 
Figure 3.4. Sub-cellular localisation of fAP 1-40 in hCMECID3 cells as viewed by 
confocal microscopy. hCMECID3 cells were grown to confluence in a 12 well collagen-
coated plate, incubated with 1 JlM fA~ 1-40 for 24 h, detached, fixed in 4 % PAF, stained 
with DRAQ-5 mounted an viewed on a confocal microscope. An XY Z cross-section was 
taken over a selected field (a) , enabling a three dimensional reconstruction with Volocity 
software (b). n = 1 with duplicate samples. 
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Figure 3.5. The effects of time and concentration on the influx of fAP peptides into 
hCMECID3 cells. (a) hCMECID3 cells were grown to confluence on 12 well plates and 
incubated for 1, 6, 24 and 48 h with 1 J..lM fAP 1-40 or 1-42. The cells were then detached 
and analysed via flow cytometry (488 nm '-excitation, 520 nm '-emission). (b) hCMECID3 cells 
were incubated for 24 h with either fAP 1-40 or AP 1-42 at concentrations of 0.001, 0.01, 
0.1 and 1 J..lM before analysis via flow cytometry (488 nm '-excitation, 530 nm '-emission). Data 
represents mean ± SEM, n = 3 with duplicate samples. * P < 0.05, ** P < 0.01 using paired 
t test comparing the fluorescence at each time point to background fluorescence, which in 
(a) is represented by time = 0 min on the graph. 
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Figure 3.6. The effects ofP-gp, BCRP or LRP-l inhibition on the influx offAP 
peptides into hCMECID3 cells. hCMECID3 cells were grown until fully confluent, rested 
for 2 days, and the incubated for 24 h with ether (a) 1 ~M fA~ 1-40 or (b) 0.1 ~M fA~ 1-
42 in the presence tariquidar (300nM), vinblastine (22 ~M), FTC (22 ~M), RAP (200 nM), 
unlabelled A~ 1-40 or sA~ 1-40 or 1-42 (2 ~M) or a DMSO vehicle control. The 
fluorescence was then measured via flow cytometry (488 run !..excitation, 530 run !..emission) and 
expressed as a % of the value for the vehicle control. Data represents mean ± SEM, n = 3 
with duplicate samples. 
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Figure 3.7. The effects of P-gp or BCRP inhibition on the emu of fAP peptides from 
hCMECID3 cells. (a) hCMEC/D3 cells were grown to confluence on 12 well plates and 
preloaded with 1 J..lM fA~ 1-40 or fA~ 1-42 for 24 h. Cells were then detached and 
incubated at 37°C for 1, 3, 6 and 12 h, or left at 4°C. The fluorescence was then measured 
by flow cytometry, and the data expressed as a percentage of fluorescence in cells left at 
4°C. Data represents mean ± SEM, n = 3 with duplicate samples. (b) hCMECID3 cells were 
preloaded with 1 J..lM fA~ 1-40 or fA~ 1-42 for 24 h, and then incubated at 37°C for 6 h 
with tariquidar (300 nM), vinblastine (22 J..lM), FTC (22 J..lM) or DMSO vehicle control. 
The fluorescence was then measured by flow cytometry and the data expressed as a 
percentage of the 4°C treatment. Data represents mean ± SEM, n = 8 fA~ 1-42 and n = 4 
for fA~ 1-40 with duplicate samples. P > 0.05 using paired t test comparing the raw data to 
the control. 
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Figure 3.8. The effects of P-gp or BCRP inhibition on the influx of 1251 AP 1-40 into 
hCMECID3 cells. (a) Fully confluent hCMEC/D3 cells were incubated with 0.1 nM 1251 
A~ 1-40 for 0.5, 1, 3, 6 and 24 h, detached and the cellular levels of 125r A~ 1-40 
(fmoles/mg of total protein) were measured using a y-counter. Data represents mean ± 
SEM, n = 3 experiments with duplicate samples. (b) Fully confluent hCMECID3 cells 
were incubated with 0.1 nM 1251 A~ 1-40 for 30 min in the presence oftariquidar (300 
nM), vinblastine (2 flM), FTC (2 flM), A~ 1-40 (100 nM), sA~ 1-40 (100 nM) or a DMSO 
vehicle control, and the cellular levels of 1251 A~ 1-40 calculated. Data represents mean ± 
SEM, n = 4 experiments with duplicate samples. * P < 0.05, ** P < 0.01 for treatments 
compared to control using paired t test. 
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Figure 3.9. The effects of P-gp or BCRP inhibition on the emu of 1251 AP 1-40 from 
hCMECID3 cells. (a) Fully confluent hCMECID3 cells were preloaded for 3 h with 0.1 
nM 125r A~ 1-40, the cell culture media was changed and the cells were incubated for 7.5, 
15, 30, 60 and 180 min at 37°C. At each time point the cellular levels of 125r A~ 1-40 
(fmoles per mg of total protein) were measured using a y-counter. Data represents mean 
±SEM, n = 3 experiments with duplicate samples. (b) Preloaded hCMECID3 cells were 
incubated with tariquidar (300 nM), vinblastine (2 ~M), FTC (2 ~M) or a DMSO vehicle 
control for 10 min at 37°C, cellular levels of 125r A~ 1-40 (finoles/mg of tot a! protein) were 
measured using a y-counter. Data represents mean ± SEM, n = 4 experiments with 
duplicate samples. * P < 0.05 , ** P < 0.01 for treatments compared to the control using 
paired t test. 
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Figure 3.10. The permeability ofhCMECID3 cells to 11SIAp 1-40 and 14C inulin. 
hCMECID3 cells were grown to confluence on filter inserts and 0.1 nM 125IAP 1-40 and 
0.1 rnM 14C inulin was added to either the (a) apical or (b) basolateral compartments for 30 
min. The total counts in each compartment were measured and the percentage crossing the 
filter calculated. Data represents mean ± SEM, n = 6 with single samples, * P < 0.05, 
compared to filters with no cells using paired t test. 
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Figure 3.11. The effect of P-gp and BCRP inhibition on the clearance quotient of 
hCMECID3 cells to uSI AP 1-40. (a) hCMECID3 cells were grown to confluence on filter 
inserts and rested for 48 h. Fresh culture media was then added to the apical or basolateral 
chamber containing 0.1 nM 125 I A~ 1-40 and 0.1 mM 14C inulin and tariquidar (300 nM), 
vinblastine (2 ~M), FTC (2 ~M) or a vehicle control for 30 min. The 1251 and 14C counts 
were measured and the amyloid clearance quotient calculated. (b) Represents the total 125 I 
125 I A~ 1-40 recorded from the trypsinised cells as a percentage of the total 125 I A~ 1-40 
counts. For both experiments data represents mean ± SEM, n = 6 with single samples, * P< 
0.05, comparing each treatment to the control using a paired t-test. 
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3.4 Discussion 
3.4.1 Mechanism of AP influx and efflux in hCMECID3 cells 
AP peptides have been previously reported to be a substrate for multiple receptors 
at the BBB, which mediate CNS AP transport in the brain-to-blood direction (P-gp, LRP-l) 
or in the blood-to-brain direction (RAGE, megalin). Increased P-gp activity and/or 
expression could therefore be therapeutically beneficial in AD, reducing the brain amyloid 
burden. In this study the roles ofP-gp and BCRP, which shares a similar substrate overlap 
with P-gp, on AP transport by hCMECID3 cells were investigated. The results indicate 
that, at high concentrations of AP, the influx and efflux of AP is mediated by a non-
receptor-mediated process, and both are unaltered by P-gp or BCRP inhibition. At lower 
more physiological concentrations of AP, influx also appeared dependent on a non-
receptor mediated process. However, P-gp, and to a lesser extent BCRP inhibition, results 
in increased infux and decreased efflux of Ap. 
3.4.1.1 Role ofLRP-1 and RAGE onAp influx in hBECs 
The first interesting finding of this study was that LRP-l inhibition and up to a 20 
fold higher concentration of unlabelled AP did not affect the influx offAP into hCMECID3 
cells. Confocal imaging demonstrated that a high proportion of fAP appears intracellularly, 
rather than membrane-associated, and so the measurement of cellular fAP levels most 
likely represented intracellular levels. This finding was confirmed using a low 
concentration of AP, as 1251 AP 1-40 influx into hCMECID3 cells was unaltered by the 
addition of 1000 times excess of unlabelled AP 1-40. Therefore, the influx mechanism of 
Ap into hCMECID3 cells may not be receptor-mediated endocytosis and is possibly 
mediated by diffusion through the membrane, membrane binding or fluid-phase 
endocytosis. 
- 150-
There are two major receptors reported to be involved in the influx of AP into 
BECs and AP clearance at the BBB, LRP-l and RAGE. Conflicting reports exist as to the 
role ofLRP in the transport of AP at the BBB. Shibata et a/ [394] have demonstrated that 
after intracerebral injection of 125IAP 1-40 into mice, rapid clearance across the BBB 
occurs with a tl/2 of < 25 min. The authors also found that 125IAP 1-40 transport was half 
saturated at 15.3 nM with full saturation at 70-100 nM, which was inhibited by antibodies 
against LRP-l and 0-2 macroglobulin (an AP binding partner and LRP-lligand). Ito et a/ 
[560] have confirmed this finding in rats, where the clearance of intracerebral 
microinjections of 125IAP 1-40 was inhibited by 20.3 % by RAP (LRP-l inhibitor), 
although this result does imply that other routes of brain-to-blood transport are present. 
Deane et a/ [395] have demonstrated that AP binds with high affinity to LRP recombinant 
fragments (binding clusters I and IV) and that microinjections of 125IAP 1-40 are cleared 
across the mouse BBB, which was found to be inhibited by RAP and LRP-l neutralising 
antibodies. In addition to transcytosis of AP, LRP can mediate internalisation. Deane et a/ 
[395] demonstrated that mouse capillaries internalise AP 1-40 and AP 1-42 via LRP-l. 
Kang et a/ [396] have found that in mouse fibroblasts transfected with human LRP-l, 
uptake of AP only occurs if 02 macroglobulin is present to form a complex. Ito et a/ [559] 
have found contrasting results as to the ability of LRP ligands to form binding partners 
with AP and mediate transcytosis. This research group has found that AP dimer formation 
and pre-incubation of AP with a2 macroglobulin and ApoE results in a reduced elimination 
of 12SIAp 1-40 injected intracerebrally into the rat brain compared to freshly dissolved Ap. 
However, the uptake of AP was found to be increased after ApoE 2,3 and 4 preincubation 
in a mUltiple myeloma cell line (MEF-l). 
The very nature of LRP-l-mediated AP transcytosis has also been called into 
question. Nazer et a/ [561] have demonstrated that MDCK cells transfected with LRP 
binding domain IV (MDCK-mLRP4) internalise and degrade, but do not transcytose intact 
- 151 -
A~ peptides. The authors found that LRP-l-mediated A~ transport across cells grown on 
filters only occurred for degraded A~ fragments. 
The above data indicates that LRP-l can mediate the transcytosis of A~ across the 
BBB. However, this might not be only route of brain-to-blood transport, and in vitro the 
internalisation of A~ by BECs mediated by LRP might be dependent on monomeric A~ 
species and binding to an LRP-l ligand. The finding in this study that LRP-l is not a major 
pathway involved in A~ influx into hCMECID3 cells might reflect the absence of LRP-l 
ligands binding to A~ in the culture media, or the absence of functional LRP-l expression 
by hCMECID3 cells. Concerning the latter, it is important to note that Nazer et al. [561] 
discovered that 12SI A~ 1-40 uptake and degradation (0.1 nM, 24 h) was inhibited by 500 
nM RAP in hCMECID3 cells, as determined by cell lysate counts. In addition, this 
research group went on to demonstrate that hCMECID3 cells exhibited a time-dependent 
uptake ofHiLyte Fluor 55 A~ 1-40 (100 nM, 6 and 24 h), which was inhibited by 500 nM 
RAP. The contrast between these results and the present study might, in some part, be due 
to the fact that in the study by Nazer et al., hCMECID3 cells, when used for fluorescence 
uptake studies, were at around 10 % confluence if compared to the cells used in this 
current study (fully confluent). Fully confluent hCMECID3 cells might be a better 
refection of fully mature BECs, whilst at 10 % confluence the uptake of A~ by 
proliferating ECs may be dependent on a different pattern of transporter receptor 
expression. Whilst LRP-l expression was demonstrated via western blotting in that study, 
LRP-l levels were much less than those expressed by HUVEC, MDCK-mLRP4 and 
possibly even wild type MDCK cells. Indeed, the proportion of fluorescent hCMECID3 
cells after incubation with HiLyte Fluor 55-conjugated A~ 1-40 was found to be -10 %, 
which was comparable to MDCK cells (- 10 %) but not to MDCK-mLRP4 cells (- 40 %). 
Therefore, hCMECID3 cells might not express high enough levels of LRP-l to allow 
significant internalisation of A~ compared to diffusion. 
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RAGE has been demonstrated to mediate A~ transport in primary isolated hBECs. 
Mackie et al [389] found that the binding of 1251 A~ 1-40 (0.5 nM over 1 h) to primary 
hBECs was time-dependent, polarised to the apical membrane, and inhibited by 63 % by 
co-incubation with an anti-RAGE antibody and CHO cells transfected with human RAGE 
internalise A~. In the current study however, the contribution of RAGE to A~ 
internalisation is unlikely, as excess unlabelled A~ did not block the influx of either fA~ or 
1251 A~ 1-40 with hCMECID3 cells. It is possible that isolated hBECs express increased 
RAGE compared to hCMECID3 cells as is the case for P-gp (chapter 2). The results of this 
study demonstrate that A~ influx into hCMECID3 cells is likely to be mediated by bulk 
flow and that further in vivo investigations should be carried to take into account this 
potential route of A~ entry into BECs. 
3.4.1.2 Role ofP-gp and BCRP onAfJ inflUX and efflux in hBECs 
The second interesting finding of the present study was that P-gp inhibition only 
increases influx and decreases efflux at low concentrations of A~. There are a number of 
possibilities that could explain the lack of a contribution ofP-gp in the influx and efflux of 
fA~. Firstly, the high concentrations offA~ used for influx and efflux might have masked 
the comparatively small contribution of P-gp mediated transport, which was 
indistinguishable by flow cytometry. An additional variable of time might also have 
impacted on the results. hCMECID3 cells were incubated for 24 h with fA~ and 30 min 
with 1251 A~ 1-40 for influx followed by 3 h or 10 min (3 h preloading for 1251 A~ 1-40) for 
efflux respectively. In addition, the fluorescein tag might have altered the physiochemical 
properties of A~, since fluorescein is hydrophilic, and could have altered the ability of fA~ 
to be a substrate for P-gp or BCRP. 
Another possibility factor is that after 24 h incubation with fA~, the peptides are at 
sites inaccessible to P-gp, such as organelle- or vesicle- bound in hCMECID3 cells. 
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Confocal imaging does not rule out this possibility, as fA~ appears mainly located in the 
cytoplasm surrounding the nucleus where the golgi apparatus is located. To be a P-gp 
substrate, localisation to the membrane is considered a prerequisite. Exactly how the fA~ 
then efluxes from the hCMECID3 cells remains unknown. It is possible that another 
transporter or mechanism such as vesicular transport is partially responsible for efflux or 
that diffusion through the membrane is the limiting step for both influx and efflux at high 
concentrations of A~. 
An additional possibility is that for both influx and efflux, fA~ undergoes 
significant degradation, and A~ fragments may not readily be transported by P-gp. BECs 
express enzymes capable of A~ degradation (reviewed in [567]) including neprilysin 
(NEP), [568, 569] insulin degrading enzyme (IDE) [570], endothelin converting enzyme 
(ECE-I and 2) [571] and angiotensin converting enzyme [572]. A possibility therefore, is 
that, rather than efflux, degradation is the main route of A~ elimination from hCMEC\D3 
cells once it has been internalised. Multiple sites exist within the A~ protein sequence for 
enzymatic cleavage by NEP, IDE and ECE, producing various fragments in length ([573, 
574]). For example, Iwata et al.[569] found that 1251 A~ injected into the hippocampus of 
rodents was degraded with a half life of 17.5 min with the major catabolic intermediate, A~ 
10-37, generated by NEP activity. Leissrung et al [575] have demonstrated using a kinase 
assay that IDE hydrolysis can cleave A~ to form various fragments of 1-13, 1-14, 1-19, 1-
29 and 20-40 in length, whilst NEP produced A~ 20-30, 20-28, 20-29 and 14-25. Eckman 
et al [571] found that CHO cells transfected with ECE-l were able to reduce the 
extracellular concentration of A~ 1-40 by up to 90 % with the production of AP fragments 
1-17, 1-19 and 20-40 over a 24 h period. The location of the fluorescein tag on the N 
terminus offA~ raises the possibility that if fragments of I-x in length were produced, they 
would be detected by flow cytometry. In addition, the most lipophilic region of the AP 
peptide is within the C-terminus. It is thus possible that non-fluorescently labelled AP 
fragments are transported out of cells by P-gp. The degradation of AP by hCMECID3 cells 
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has been noted by Nazer et at [561], who found that after incubation of 1 nM 1251 AfH.40 
for 24 h that 44.2 % of the 1251 A~ counts in the whole cell lysate originated from degraded 
A~ in hCMECID3 cells. The group also demonstrated that after the addition of 1 nM 1251 
A~I·40 to the basolateral compartment ofMDCK·LRP cells grown on filters, only 
degraded fragments are released into the apical compartment. This data would indicate that 
a proportion of the degraded peptides still remain intracellular, and that degraded peptides 
can be either transcytosed or effluxed from cell cultures. Since in the present, study 
hCMECID3 cells were preloaded for efflux and incubated for influx for 24 h, the fA~ 
measured via flow cytometry and confocal microscopy most possibly reflected a 
combination of degraded and 'whole' A~, which may more accurately reflect the in vivo 
situation rather than short term exposure. 
In contrast to high concentrations of fA~, the influx and efflux of 125IA~ 1·40 was 
increased by P-gp inhibition, and although not statistically significant, by BCRP inhibition. 
To date, there are no published experiments that have investigated the influx and efflux of 
A~ with p.gp inhibitors in cultured hBECs and none which have reported a possible role 
for BCRP in A~ efflux. The permeability of cell cultures to A~ (see section 3.4.2) and in 
vitro studies however does imply A~ is a P-gp substrate. Lam et af. [406] showed that the 
fluorescence of membrane vesicles from CHO cells transfected with the human MDRI 
gene and labelled with a fluorescence marker, was quenched upon increasing additions of 
A~ peptides with a binding affinity comparable to other P-gp substrates. This research 
group also demonstrated that A~ 1·40 and A~ 1·42 both compete for the uptake of 3H· 
colchicine in MDRI over expressing-CHO cells, with an IC50 of27 J.!M and 22 J.!M for A~ 
1-40 and A~ 1·42, respectively. Intriguingly, the authors do not state the concentration of 
3H-colchicine used, and instead refer to previous papers in the methods section where they 
use 1 J.!M. If that is the case, then these results imply that interaction between p.gp and A~ 
is not very strong in nature, as very high concentrations of A~ were needed to block the 
uptake of 3H-colchicine. More specific vesicle binding of A~ was observed by Kuhne et af . 
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[407], who established that rh123 (10 J!M) was transported by an ATP-dependent 
mechanism into LLC-MDR membrane vesicles, and this was inhibited to 25 % of control 
levels by 10 J!M A~ 1-40 and A~ 1-42. Furthermore, cyclosporin A (10 J!M) and verapamil 
(100 J!M) reduced the uptake ofFITC-conjugated A~I-40 and A~ 1-42 to 65 % of control 
levels in inside-out vesicles. Whilst the ability of amyloid peptides to block rh 123 uptake is 
apparent, the rather modest inhibition of A~ uptake by cyclosporin A implies other 
mechanisms mediating A~ efflux are at work in addition to that mediated by P-gp. The 
results of the above studies were from P-gp over-expressing cell lines and using membrane 
vesicles. Whilst they do indicate that P-gp may function as an A~ transporter, the results in 
the present study indicate that in hBECs this may only be so at physiological 
concentrations of A~. 
3.4.2 The permeability of 1251 All 1-40 to hCMECID3 cells 
Fully confluent hCMECID3 mono layers formed a barrier to the passage of both 
I2SIA~ 1-40 « 1 %) and 14C inulin « 2 %) in both the apical-to-basolateral and 
basolateral-to-apical directions. 14C inulin predominantly crosses BECs via paracellular 
diffusion, and to a much lesser extent, fluid phase endocytosis, whereas the permeability of 
BECs to 125IA~ 1-40 is dependent on several processes: paracellular diffusion, fluid phase 
endocytosis and receptor-mediated transcytosis. Several factors may contribute to the 
differences in permeability between 14C and I2SIA~ 1-40 in untreated hCMECID3 cells. 1) 
A~ may aggregating in the culture media increasing its molecular weight; 2) A~ is highly 
hydrophobic and may stick to the filter and/or plastic; and 3) the molecular shape of 14C 
inulin and 125IA~ 1-40 may be different affecting their ability to diffuse within the culture 
media. For example, 14C inulin may form a more globular structure than 12SIA~ 1-40, a 
property which would result in increased paracellular diffusion compared to A~. The 
results of this current study indicate that BCRP and P-gp both playa role in preventing the 
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apical-to-basolateral, but not the basolateral-to-apical, penneability ofhCMECID3 cells to 
1251 A~ 1-40. Whilst the data was not significant, increased cellular levels of 1251 A~ 1-40 
were also observed following P-gp and BCRP inhibition, indicative of a barrier function of 
each transporter to A~. 
It is unlikely that the transported 1251 A~ 1-40 in the present study represented 
degraded peptide fragments. Mackic et al [389] have demonstrated> 94 % of cellular 1251 
A~ 1-40 remains intact after 60 min incubation with primary hBECs. Whilst Nazer et al 
[561] have found that MDCK-mLRP4 cells only transport degraded fragments, and 44 % 
of hCMECID3 cellular levels of 1251 A~ 1-40 represented the degraded peptide, the 
incubations times used were 24 h, much longer than the 30 min used in this study. 
The role of P-gp in the penneability of the BBB to A~ is an area of controversy. 
Kunhne et aI, [407] found that compared to LLC cells, LLC-MDRI cells have enhanced 
basolateral- to-apical penneability but not apical-to-basolateral penneability to 5 J.l.M 
FITC-A~ 1-40 and A~ 1-42. This enhanced penneability, in cells over-expressing P-gp, 
was inhibited by 10 J.l.M cyc1osporin A after 1 h incubation. In the same study, it was also 
noted that transport ofrh123 (10 J.l.M) was increased only in the basolateral-to-apical 
direction in LLC-MDRI cells compared to LLC cells alone, and this effect was inhibited 
by A~ peptides with an IC 50 of -- 50 J.l.M. Whilst the expression of P-gp LLC-MDRI cells 
was demonstrated to be polarised on the apical membrane with little or no intracellular or 
basolateral staining, it was carried out using confocal microscopy of cells grown on glass 
coverslips not filter inserts, which may have altered the distribution of P-gp expression. In 
contrast, Nazer et al [561] found that the basolateral-to-apical transport of I nM 1251 A~ 1-
40 at 24 and 48 h in MDCK cells over-expressing human MDRI (MDCK-MDR) is not 
increased compared to wild type MDCK cells. It would have been interesting if in that 
study the apical-to-basolateral penneability had been investigated. Mackie et al [389] have 
demonstrated that in isolated hBECs, 1251 A~ 1-40 (0.5 nM 30 and 60 min) exclusively 
binds to the apical membrane and is transported towards the basolateral membrane, not 
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vice- versa, in agreement with the present study. However, these authors demonstrated that 
A~ binding to hBECs was inhibited by non-tagged A~ and was 63 % attributable to 
RAGE. Whilst the results of the current study do not exclude the binding of RAGE to A~ 
in hCMECID3 cells, the influx data indicates that is unlikely to be significant. Differences 
in A~ concentrations, incubations times and cell types makes comparisons between studies 
very difficult. The permeability results found in the present study are consistent with P-gp 
and BCRP protecting the brain from blood-borne A~ species but not transporting A~ from 
the brain. Interestingly, there are no reports on the role ofBCRP and on A~ transport in the 
literature. 
In vivo data has also produced conflicting results with regards to the role of P-gp in 
A~ transport at the BBB. Cirrito et al [408] have found intracerebrally injected A~ 1-40 
and A~ 1-42 accumulates in the brain ofmdrlalb(-I-) mice at higher rates than wild type 
mice (although LRP-l was also down regulated in the mdrla1b(-I-». In the same study, it 
was also found that tariquidar treated Tg 2576 mice have increased basal ISF A~ levels in 
the CNS compared to control after 8 h treatment. Although it should be noted that 
astrocytes may also express P-gp in addition to epithelial cells throughout the body, which 
may have impacted on the results. For example, P-gp inhibition could increase cellular 
retention of AP by astrocytes, reducing brain ISF AP levels. In contrast to these findings, 
Ito et af [560] have demonstrated that the brain elimination of intra cerebrally injected 1251 
A~ 1-40 is unaltered by quinidine and verapamil (both P-gp inhibitors). The differences 
between these two studies could be explained by the finding that in one finding from rat 
tissue, Bendayan et al [213] found that P-gp was primarily located on the abluminal 
membrane. However, there is also evidence for luminal expression in rats [210], and as 
described in section 1.1.1.6.1, the majority of mice and human studies have indicated that 
P-gp is expressed in higher amounts on the luminal membrane at the BBB. The results 
presented in the present study, might in part explain the discrepancy described above. The 
increased ISF fluid A~ levels in Tg 2756 mice after P-gp inhibition described by Cirrito et 
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al [408] may be due to the increased blood-to-brain permeability of the BEC. In the results 
described by Ito et at [558], there was no brain-to-blood P-gp mediated All transport, 
which is consistent with the in vitro data described here. 
Increased AP levels in the brain are believed to be key in the pathogenesis of AD, 
and some research groups argue that decreased BBB clearance is a key component of AD. 
Increased plasma levels of AP are reported in AD patients compared to controls [576]. For 
example Sagare et al [319] have noted a 300-400 % increase in free All levels compared to 
control patients. The results of this study imply that P-gp might protect the CNS from this 
All pool and at higher concentrations of All found in AD patients may become saturated. 
P-gp saturation, RAGE up-regulation and LRP down-regulation in BECs in AD [384], 
might significantly add to the brain AP load. In addition many drugs which are prescribed 
for elderly patients, such as lipid lowering agents and antidepressants, are substrates for P-
gp and in principle might act as competitive substrates for All at the BBB, potentially 
increasing the risk of developing AD. 
3.5 Conclusions 
The results presented here indicate that P-gp, and to a lesser extent BCRP, act to 
decrease influx and increase efflux of low AP concentrations in hRECs. However, at high 
concentration of AP over longer periods of time, neither transporter affects the influx of 
efflux of All. At both concentrations of All, the influx mechanism is a non-receptor 
mediated process. Importantly, P-gp and BCRP both prevented the apical-to-basolateral 
permeability of human brain endothelial cells to AP, which is consistent with blood-brain 
protection in vivo. 
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Chapter 4 
Effect of AP on tight junction and transporter protein expression by 
hCMECID3 cells 
Abstract 
The aim of this study was to investigate the effects of AP on the expression of tight 
junction and transporter proteins by hCMECID3 cells. A 48 h treatment with a non-
cytotoxic dose (5 /lM) of AP 1-40 or AP 1-42 decreased the expression of Glut-l but not P-
gp or the transferrin receptor by hMCECID3 cells as assessed by western blotting. These 
treatments also decreased the expression of the tight junctional protein occludin but not of 
c1audin-5 (CI-5) or ZO-I, as determined by western blotting and flow cytometry. When 
viewed via immunocytochemistry, AP 1-40 reduced occludin expression intracellularly and 
at the level of the tight junctions. At the mRNA level, AP 1-40 decreased occludin levels 
after 24 h, with partial recovery by 48 h. CI-5 mRNA levels were unaltered up to and 
including 48 h treatment with AP, whilst increased ZO-1 mRNA levels were detected after 
48 h but not 24 h. Tight junctional proteins restrict endothelial cell paracellular transport of 
molecules. Thus the permeability ofhCMECID3 cells to the paracellular tracer molecules 
4 kDa and 70 kDa FITC - dextran was investigated. Whilst AP 1-40 or AP 1-42 incubation 
did not alter the permeability to 4 kDa FITC-dextran, both peptides increased the 
permeability to 70 kDa FITC-dextran. These results demonstrate that AP can directly 
induce a leaky BBB in vitro, potentially via the down-regulation of occludin expression. 
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4.1 Introduction 
Vascular dysfunction is emerging as a key pathological hallmark in AD, with 
features that include brain hypoperfusion (reviewed in [410,421]) reduced glucose uptake 
[430,431,436], detrimental BEe morphological alterations [413,414] and increased 
permeability of the BBB [577-581]. Increased BBB permeability could have potentially 
disastrous consequences for the homeostatic neuronal environment, especially with regards 
to alterations in the levels of soluble ions, insulin, glucocorticoids, glutamate and 
pathogens. 
A~ in vitro evokes direct cytotoxic effects in BEes, with increased superoxide 
[582,583] and decreased nitric oxide [412] production proposed as key detrimental factors. 
A~ peptides have also been demonstrated to increase the paracellular permeability of 
porcine artery Ees [442] and BEes of human [443] and porcine origin [444] in culture. In 
vivo, increased BBB permeability has also been noted in AD transgenic animal models [94, 
440,584], and after the intravenous infusion of A~ in rats [441]. Furthermore, blood-borne 
molecules have been detected in the eNS parenchyma of tissue samples from AD patients 
indicative ofa leaky BBB [577-581]. TJ proteins are critical to restrict the paracellular 
leakage of molecules at the BBB. In principle, TJ protein alterations may in part be 
responsible for the increased leakiness found in AD. Indeed, Marco and Skaper [486] 
found that A~ 1-42 decreased occludin levels in cultures of rat BEes after 24 h incubation, 
whilst CI-5 and ZO-1 levels remained unaltered via western blotting. In addition, A~ 1-40 
soluble oligomers have recently been demonstrated to induce ZO-1 translocation from 
junctional areas in primary hBEes [443]. Furthermore, Takechi et at [94] recently 
demonstrated substantially reduced occludin expression in APPIPS 1 mice compared to 
wild type mice and significant plasma protein (lgG) extravasation, indicative of a leaky 
BBB. This evidence implies that alterations in TJ protein expression might playa role in 
the increased BBB permeability observed in AD. 
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Other proteins expressed by BECs are also altered in AD. Decreased Glut-l 
expression has been observed in AD patients in neurons [585] and BECs [146, 438, 586, 
587]. Alterations in Glut-l expression would have the net result of reducing the amount of 
glucose available to neurons and BECs, potentially leading to energy deprivation and 
neuronal and BEC death. Indeed, decreased cerebral glucose utilisation has been observed 
in AD patients [430,431]. In addition, an inverse correlation ofP-gp levels with A~ 
plaques has also been demonstrated in non-demented subjects [409]. Reduced P-gp 
expression would compromise the barrier properties of brain endothelium to a range of 
drugs and signalling molecules. 
The aim of this chapter was investigate the effects of A~ on the expression of 
transporter and TJ proteins by hBECs and the resulting physiological consequences i.e. 
altered permeability. The results of this study are important since they could provide 
information on whether A~ could directly induce alterations in the BBB function, as 
observed in AD patients. 
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4.2 Methods 
4.2.1 Cell culture conditions 
The cell culture conditions used in this study are different to those used in other 
chapters. It was observed by Dr K.Logan (The Open University, personal communication) 
that maximal expression of occludin (as assessed by western blotting) occurred when 
hCMECID3 cells were maintained without a change in culture medium for 2-3 days post 
confluence. Therefore, for all experiments described here, hCMECID3 cells were grown to 
confluence as indicated previously (2.2.3), with culture media changes every 2-3 days, then 
rested for 2-3 days after confluence and treated with A~ in the same media. 
4.2.2 MTT cytotoxicity assay 
hCMECID3 cells grown in collagen-coated 96 well plates were treated with A~ 1-
40, A~ 1-42, sAbl-40, or sA~ 1-42 at concentrations of 0, 0.5, 1,5 and 10 J.lM for 48 h. An 
MTT toxicity assay was then carried out as described in section 2.2.11. 
4.2.3 SDS PAGE and Western blotting 
hCMECID3 cells were grown on collagen-coated 6 well plates and A~ 1-40, A~ 1-
42, sA~ 1-40 or sA~ 1-42 was then added to the culture media to give a final concentration 
of 0.5 or 5 J.lM, and cells were incubated for 24 h or 48 h. At the appropriate time point, 
hCMECID3 cells were washed in HBSS and 250 J.lI of lysis buffer (RIPA buffer containing 
1 mM PMSF, 10 ng/J.llleupeptin, pepstatin and apotinin) was added to each well for 5 min 
at 4°C. Each well was then scraped using a cell scraper (Greiner, Gloucestershire, UK) and 
the resultant lysate was collected and subjected to the same procedure as in 2.2.5. The 
expression ofP-gp (C219, 500 nglml, mouse monoclonal IgG2a), Glut-l (1 J.lglml rabbit 
polyclonal IgG, Abcam, Cambridge, UK) transferrin receptor (1 J.lglml mouse monoclonal 
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IgG), Santa Cruz, CA USA), occ1udin (1 Jlglml of rabbit polyclonal IgG, Zymed, 
California, USA), CI-5 (1 Jlglml mouse monoclonal IgGl Zymed, California, USA) and 
ZO-1 (1 Jlglml rabbit polyclonal IgG, Zymed, California, USA) was then determined using 
appropriate HRP-conjugated secondary antibodies (Anti-mouse/rabbit IgG diluted 1 in 
20,000, Pierce Biotechnology, Cheshire, UK) and visualised by ECL. Membranes were 
then stripped and re-probed for actin (1 Jlg/ml, mouse monoclonal IgG1) as described in 
section 2.2.5. The signal intensities of the bands on the films were analysed using image J 
software and protein expression was normalised with actin. 
4.2.4 Flow cytometry 
hCMECID3 cells grown on collagen-coated 12-well plates were incubated with 5 
11M A~ 1-40, A~ 1-42, sA~ 1-40 or sA~ 1-42 for 48 h. The expression of occludin (2.5 
Ilglml rabbit polyclonal IgG) or CI-5 (2.5 Jlg/ml mouse monoclonal IgG1) was then 
measured using flow cytometry (488 run Aexcitation, 530 run Aemission) as described in section 
2.2.6, with the alteration that the primary and secondary [1 ° Jlg/ml Alexa Fluor-488-rabbit 
polyc1onal IgG (Invitrogen, paisley UK) or FITC-conjugated goat monoclonal IgG] 
antibodies were incubated for 1 hat RT. Statistical analysis was performed on the raw 
data. However, for illustrative purposes, CI-5 or occ1udin expression by hCMECID3 cells 
was expressed as a percentage of cells treated with A~ compared to those treated with the 
sA~ peptide. 
4.2.5 Immunocytochemistry 
hCMECID3 cells were grown on collagen-coated glass cover slips and A~ 1-40 or 
sA~ 1-40 (5 JlM) was added to the culture medium for 48 h. hCMECID3 cells were then 
fixed for 10 min in ice-cold methanol (Sigma-Aldrich, Dorset, UK) and ICC staining was 
carried out described in section 2.2.9, using 2.5 Ilg/ml of an anti-occludin rabbit polyc1onal 
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IgG as the primary antibody, and 10 J,tglml of Alexa Fluor-488-rabbit polyclonal IgG as the 
secondary antibody applied for 1 hat RT. Mounted cells were viewed with a fluorescent 
microscope (Olympus bx61). 
4.2.5 Quantitative RT-PCR 
hCMECID3 cells grown on collagen-coated 12 well plates were incubated with 5 
J,tM AP 1-40, AP 1-42, sAPI-40 or sAP 1-42 for 24 h or 48 h. Total RNA was then 
extracted using TRIzol reagent (Invitrogen, Paisley, UK). hCMECID3 cells were washed 
with HBSS, incubated with 1 ml per well ofTRIzol for 5 min at RT, collected with a cell 
scraper and transferred to a microfuge tube. Chloroform [0.2 mUml (Sigma-Aldrich, 
Dorset, UK)] was then added, and tubes were mixed vigorously for 15 seconds and 
incubated for 3 min at RT. After centrifugation (9000 xg, 15 min, 4°C), the upper aqueous 
phase containing RNA was collected. To precipitate the RNA, isopropyl alcohol (0.5 ml 
per tube) was added to each sample and incubated for 10 min at RT, followed by 
centrifugation (6000 xg, 5 min). The supernatant was then removed and the pellet washed 
with 75 % ethanol. After centrifugation (6000 xg, 5 min, 4°C), the supernatant was 
removed, the pellet air-dried for 5 min at RT and redissolved in 50 J,tl ofDNaselRNAse-
free water. The concentration and purity of RNA was then calculated using UV 
spectrophotometery at 1.,260 and 1.,280. First strand DNA synthesis was then carried out using 
a Reaction Ready First strand cDNA synthesis kit (Superarray, Maryland, USA), as 
directed by the manufacturer's protocol. Briefly, 1 J,tg of RNA was added to 1 J,tlofbuffer 
P and dissolved in RNase-free water to a final volume of 10 Ill. The mixture was then 
placed in a thermal cycler (Bio-Rad, California, USA) at 70°C for 3 min, cooled to 37°C 
and held for 10 min. A cocktail containing reverse transcriptase and RNAse inhibitor was 
then added to the annealing mixture, incubated at 37°C for 60 min, heated to 95°C for 5 
min and held at 4°C. Real time PCR was then carried out using SYBR green and primer 
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sets for CI-5, occludin, ZO-I and actin according to the manufacturer's protocol 
(Superarray, Maryland, USA). Briefly, a mixture was made containing I J..I.I of cDNA 
template, 1 J..I.I of primer mix, 12.5 J..I.I of2x RT2 Real-Time™ SYBR green PCR master mix 
in a final volume of25 J..I.I water. The mixture was then placed in a thermal cycler (DNA 
engine Opticon 2, Bio-Rad, CA, USA), using a 40 cycle program (95°C, 30 sec; 55°C, 30 
sec; and 72°C, 30 sec). Using this method, cycle threshold (CT) values are obtained, which 
corresponds to the cycle number at which the fluorescence curve crosses a predetermined 
threshold (3 x Standard deviation over cycle range). The threshold is designated for the 
data during the logarithmic phase of the graph. 
The data was then calculated using a comparative method. First the difference in 
CT between the target (i.e. occludin, CI-5 or ZO-I) and housekeeping gene (actin) was 
calculated: 
CTtarget - CT actin = 6CT 
Then the difference between each treatment and that of the control was then calculated 
6CT A~-6CTsA~- = 66CT 
The data was then transformed into absolute values; 
C . . I I 2-MCT omparatlve expreSSIon eve s = 
This method is appropriate for primers with similar efficiencies. Dr Logan 
calculated the primer efficiencies of actin, CI-5, occludin, and ZO-I to be 1.81,2.07, 1.70, 
1.58. Due to the difference in primer efficiency between CI-5 and actin the Pfam method 
[588] was employed, which takes these alterations into account: 
Ratio = E target L\CT target 
E ref AeT ref 
Where E represents the primer efficiencies. 
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However, it was found using this method that there was no difference between the 
Pfaffl and comparative method and so all data is shown as calculating using the 
comparative method. 
Actin was considered an appropriate control, since the difference between the CT 
values of the different samples was low (- 0.5 CT value). In addition, the primer efficiency 
of actin was similar compared to ZO-I, CI-S and occludin. 
4.2.6 Permeability of hCMECID3 cells to 4 kDa and 70 kDa FITC-dextran 
hCMECID3 cells were grown on collagen-and fibronectin-coated transwell 
polyester membrane inserts (0.4 11m diameter pore, 12mm diameter) and incubated with 5 
11M A~ 1-40, sA~ 1-40, sA~ 1-42 or 1-42 for 48 h. The permeability ofhCMECID3 cells 
to 2 mg/ml of 4 kDa or 70 kDa FITC-dextran (Sigma-Aldrich, Dorset, UK) added to the 
apical chamber was investigated using the method described in section 2.2.14. Pre-and 
post-A~ incubation, the trans endothelial electrical resistance (TEER) ofhCMECID3 cells 
was measured using an Endohm 12 chamber and an Endohmeter (World precision 
instruments, Florida, USA). 
4.2.7 Statistical analysis 
All data are represented as means +/- SEM and the number of experiments, n, 
indicated each time. Statistical significance was calculated using ANOV A followed by 
Student's t test, comparing each treatment to the control (* P < 0.05, .. P < 0.01). For the 
western blotting, RT-PCR and permeability experiments, a paired t-test was employed. For 
RT-PCR, analysis was carried out using ~CT values as the 2 -MeT method standardised all 
data so that the sA~ value is always 1. 
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4.3 Results 
4.3.1 Cytotoxicity of AP 1-40 and AP 1-42 to hCMECID3 cells 
The aim of this study was to investigate the effects of non-toxic concentrations of 
A~ on hCMECID3 cell protein expression. The cell culture conditions used here are 
different from those in previous chapters and so a separate MTT assay was carried out 
(Figure 4.1). A~ 1-42 and A~ 1-40 incubations did not alter cell viability of hCMECID3 
cells as assessed by the MTT assay at 0.5, } or 5 ~M. However, cell viability was reduced 
at } 0 ~M (n = 3, P < 0.05) after incubation with both AP peptides. AP 1-42 and AP 1-40 
incubation at 10 ~M decreased hCMECID3 cell viability by 26 % ± 7.0 and 30 % ± 7.08 
respectively compared to a vehicle control. These results show that both AP species were 
toxic to hCMECID3 cells at 1 0 ~M after 48 h incubation and therefore 5 ~M was used to 
investigate regulation of protein expression by AP in hCMECID3 cells. 
4.3.2 The effect of AP on the expression of transporter proteins by hCMECID3 cells 
Reduced expression of Glut-l [146,437,586,587] and increased brain levels of 
iron [589] have been observed in brain sections of AD patients in addition to an inverse 
correlation between plaque deposition and P-gp expression in non-demented elderly 
patients [409]. The transferrin receptor is capable of transporting transferrin bound iron at 
the BBB [150, 151]. The effect of AP on the expression ofP-gp, Glut-} and the trasnferrin 
receptor was investigated using western blotting (Figures 4.2-4.4). 
Incubation with a sub-cytotoxic concentrations of AP 1-40 or AP 1-42 did not alter 
the expression levels ofP-gp (Figure 4.2) or transferrin receptor (Figure 4.4) after 24 or 48 
h incubation, when compared to cells incubated with sAP peptides (n = 3, P> 0.05). By 
contrast, A~ 1-42 reduced Glut-l expression levels to 69.5 % ± 1.2 of sAP 1-42 levels after 
24 h and to 51.7 % ± 12.2 after 48 h incubation (Figure 4.3, n = 3, P < 0.05). AP 1-40 also 
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reduced Glut-l levels to 60.5 % ± 5.3 after 48 h incubation (n = 3 experiments, P < 0.05) 
but not after 24 h. These results provide evidence that sub-cytotoxic A~ concentrations do 
not affect P-gp or transferrin receptor protein expression but specifically reduce Glut-l 
expression in hCMECID3 cells. 
4.3.3 The effect of AP on the expression of tight junction proteins by hCMECID3 cells 
There is evidence for a leaky BBB in both AD patients [579] and in transgenic 
mouse [440, 584] models of AD. The aim of this part of the study was to investigate 
whether A~ could decrease the expression ofTJ proteins, which could lead to increased 
hCMECID3 cell permeability (Figure 2.S-2.8). Occludin, CI-S and ZO-l are key 
components of the TJ complex and were the focus of this study. 
ZO-l and CI-S levels were unaltered after 24 hand 48 h incubation with both A~ 
peptides compared to the sA~ peptides (Figure 4.5 and 4.6, n = 3, P> 0.05). Occludin 
levels, though unchanged after 24 h, were reduced after 48 h A~ incubation compared to 
sA~ incubation [n = 3, P> 0.05, (Figures 4.7)]. A~ 1-40 and A~ 1-42 incubation 
decreased occludin expression to 49.0 % ± 8.3 and 58.4 % ± 7.1, respectively, compared to 
cells incubated with sA~ peptides (Figure 4.8). The decreased occludin expression after 48 
h was concentration-dependent, since O.S J.1M of both A~ species did not alter occludin 
levels by hCMECID3 cells (Figure 4.8, n = 3, P> O.OS). The results presented here show 
that incubation ofhCMECID3 cells with either A~ 1-40 or A~ 1-42 results in specific 
occludin down-regulation, but not CI-S or ZO-I, after 48 h incubation. 
4.3.4 The effect of AP on the expression of ocdudin and daudin-5 by hCMECID3 cells 
as assessed by flow cytometry 
For a more quantitative measurement of A~-mediated occludin down-regulation, 
flow cytometry was employed (Figure 4.9). After 48 h incubation with 5 J.1M A~ 1-40, 
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occludin levels were reduced to 73.8 % ± 1.14 compared to cells treated with sAP 1-40 (n 
= 20 experiments, P < 0.01). AP 1-42 incubation induced a similar significant decrease in 
occludin levels to 73.5 % ± 3.3 (n = 3 experiments, P < 0.05). To confirm the specificity of 
AP mediated occludin down-regulation, the expression of CI-5 after 48 h incubation with 
AP 1-40 or sAP 1-40 was investigated. In agreement with the western blotting findings, 
there was no decrease in CI-S levels in cells incubated with AP 1-40 compared to cells 
incubated with sAP 1-40. These results have confirmed the western blotting findings, in 
that AP 1-40 and AP 1-42 both specifically reduce occludin levels after 48 h incubation in 
hCMECID3 cells. 
4.3.5 The effect of AP 1-40 on the expression of occludin by hCMECID3 cells as 
assessed by immunocytochemistry 
Whilst flow cytometry and western blotting data demonstrate occludin down-
regulation mediated by AP, they give no indication as to the sub-cellular location of 
occ1udin. Therefore, the expression of occludin was investigated after 48 h incubation with 
AP 1-40 or sAP 1-40 using ICC (Figure 4.10). Occludin expression after sAP 1-40 
incubation was strongly detected at the cell-cell borders between hCMECID3 cells, 
indicative ofTJ localisation, and intracellularly, albeit at lower levels. In comparison, AP 
1-40 incubation ofhCMECID3 cells caused a decreased staining both at the cell borders 
and intracellularly. For some hCMECID3 cells, a complete loss of occludin was observed 
at the cell junctions. AP induced the loss of occludin at the TJ, which suggests that the 
paracellular permeability ofhCMECID3 cells may be increased. 
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4.3.6 The effed of AP on the expression of tight junction mRNA levels by hCMECID3 
cells 
A decrease in both intracellular and cell junctional occludin was observed 
suggesting that overall levels of occludin may be reduced by Ap. To assess whether AP 
affected the mRNA levels of occludin in addition to the protein levels, quantitative RT-
PCR techniques were used (Figure 4.11). After 24 h incubation, neither AP 1-40 nor AP 1-
42 significantly altered the mRNA levels of CI-5 or ZO-I (n = 4, P > 0.05) by hCMECID3 
cells. By contrast, occludin mRNA levels were decreased significantly in hCMECID3 cells 
(n = 4, samples P < 0.05) after incubation for 24 h with AP 1-40 by - 55 % compared to 
cells treated with sAP 1-40, and whilst the levels were also decreased with AP 1-42, they 
did not reach significance (n = 4, P > 0.05). After 48 h incubation with AP 1-40, mRNA 
levels of CI-5 remained unaltered (n = 3, P> 0.05). Occludin mRNA levels were reduced 
in cells incubated with AP 1-40 after 48 h by - 30 %, compared to those incubated with 
sAPI-40, however this effect was not significant (n = 3, P > 0.05). Interestingly, ZO-1 
mRNA levels were significantly increased by - 30 % after 48 h incubation with AP 1-40 (n 
= 3, P < 0.05). These results show that occludin is suppressed at the mRNA level after 24 h 
incubation with AP 1-40, whilst at the protein level changes are observed at 48 h (Figure 
4.7). 
4.3.7 The effed of AP on the permeability of hCMECID3 cells to 4 and 70 kDa FITC-
dextran 
The permeability of hCMECID3 cells to the paracellular tracers 4 and 70 kDa 
FITC- dextran after AP incubation was investigated to see whether occludin down-
regulation was associated with BBB dysfunction (Figure 4.12). 
After 48 h incubation, neither AP 1-40 nor AP 1-42 altered the permeability of 
hCMECID3 cells to 4 kDa FITC-dextran compared to cells incubated with the sAP 
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peptides (n = 3, P> 0.05). In contrast, AP 1-40 incubation significantly increased 
hCMECID3 cell penneability to 70 kDa FITC-dextran by 53 % ± 10.1 compared to sAP 1-
40 treated cells (n = 6, P < 0.01). After 48 h incubation, A~ 1-42 also increased the 
permeability of hCMECID3 cells to 70 kDa FITC-dextran (an increase of 28 % ± 17), 
however this increase did not reach statistical significance (n = 3, P> 0.05). It is 
interesting to note that the TEER values ofhCMECID3 cells were unaltered by A~ 
incubation (Figure 4.13, n = 6 and 3 for A~ 1-40 and A~ 1-42, respectively, P> 0.05). As 
indicated by the low TEER values pre-incubation, hCMECID3 cells do not fonn an 
extensive barrier to ions when grown on filters. It is therefore no surprise that A~ treatment 
did not alter this already low value. 
These results demonstrate that A~ can increase the paracellular permeability of 
hCMECID3 cells to 70 but not to 4 kDa FITC-dextran. This implies that the occludin 
down-regulation observed at the protein and mRNA levels might have the net result of 
increasing leakiness ofhCMECID3 cells to paracellular tracers. 
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Figure 4.1. Cytotoxicity of AP 1-40 and AP 1-42 to hCMECID3 cells after 48 h 
incubation as assessed by an MTT assay. (a) The cytotoxicity of A~ 1-40 or sA~1-40 
and (b) A~ 1-42 or sA~ 1-42 was investigated in hCMECID3 cells cultured as described in 
section 4.2.1, using an MTT assay, over a 48 h incubation period. Data represents mean ± 
SEM, n = 3 experiments with quintuplet samples. * P < 0.05 comparing each data to 
vehicle control. 
- 173 -
(a) 
WB a - P-gp 
WB a - Actin 
WB a - P-gp 
WB a - Actin 
(b) 
140 
120 
i 100 
... 
0 
~ 80 
c 
:c 
u 
"' 60 -Q. 
r;n 
D.. 
C 40 0 
20 
0 
24h 
sA~ 1-40 A~ 1-40 sA~ 1-42 A~ 1-42 
.(........ 160 kDa 
.(........ 42 kDa 
48h 
sA~ 1-40 A~ 1-40 sA~ 1-42 A~ 1-42 
.(.... .... 160 kDa 
.(.... .... 42 kDa 
24 h 48 h 
AI3 1-40 
C AI3 1-42 
Figure 4.2. The effects of AP 1-40 and AP 1-42 on the expression of P-gp by 
hCMECID3 cells. (a) Fully confluent hCMECID3 cells were incubated with 5 ~M A~ 1-
40, A~ 1-42, sA~I-40 or sAPl-42 for 24 h or 48 h, and the expression ofP-gp (mouse 
monoclonal IgG2a) or actin (mouse monoclonal IgG1) was then assessed by western 
blotting. (b) The optical density corresponding to P-gp (arbitrary units) was divided by the 
optical density corresponding to actin and data was normalised with their respective sAP 
controls. Data represents mean ± SEM, n = 3 experiments with single samples. P> 0.05 
comparing sA~ to A~ raw data values using a paired t test. 
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Figure 4.3. The effects of AP 1-40 and AP 1-42 on the expression of Glut-l by 
hCMECID3 cells. (a) Fully confluent hCMEC/D3 cells were incubated with 5 IlM A~ J-
40, A~ 1-42, sA~I-40 or sAPI-42 for 24 h or 48 h and the expression of Glut-l (rabbit 
polyclonal IgG) or actin (mouse monoclonal IgG) was then assessed by western blotting. 
(b) The optical density corresponding to Glut-l (arbitrary units) was divided by the optical 
density corresponding to actin and data was normalised with their respective sA~ controls. 
Data represents mean ± SEM, n = 3 experiments with single samples. * P < 0.05 
comparing sAP to AP raw data values using a paired t test. 
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Figure 4.4. The effects of AP 1-40 and AP 1-42 on the expression of the transferrin 
receptor by hCMECID3 cells. (a) Fully confluent hCMEC/D3 cells were incubated with 
5 JlM A~ 1-40, A~ 1-42, sAP 1-40 or sAP 1-42 for 24 h or 48 h and the expression of the 
transferrin receptor (TR, mouse monoclonal IgG t ) or actin (mouse monoclonal IgGI) was 
then assessed by western blotting. (b) The optical density corresponding to the TR 
(arbitrary units) was divided by the optical density corresponding to actin and data was 
normalised with their respective sA~ controls. Data represents mean ± SEM, n = 3 
experiments with single samples. P> 0.05 comparing sA~ to A~ raw data values using a 
paired t test. 
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Figure 4.5. The effects of AP 1-40 and AP 1-42 on the expression of ZO-1 by 
hCMECID3 cells. (a) Fully confluent hCMECID3 cells were incubated with 5 JlM A~ 1-
40, A~ 1-42, sA~1-40 or sA~1-42 for 24 h or 48 h and the expression ofZO-1 (rabbit 
polyc1onal IgG) or actin (mouse monoclonal IgG1) was then assessed by western blotting. 
(b) The optical density corresponding to ZO-1 (arbitrary units) was divided by the optical 
density corresponding to actin and data was normalised with their respective sA~ controls. 
Data represents mean ± SEM, n = 3 experiments with single samples. P > 0.05 comparing 
sA~ to A~ raw data values using a paired t test. 
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Figure 4.6. The effects of AP 1-40 and AP 1-42 on the expression of CI-5 by 
hCMECID3 cells. (a) Fully confluent hCMECID3 cells were incubated with 5 ~M A~ 1-
40, A~ 1-42, sA~I-40 or sA~1-42 for 24 h or 48 h and the expression ofC)-5 (mouse 
monoclonal IgG,) or actin (mouse monoclonal IgG,) was then assessed by western 
blotting. (b) The optical density corresponding to CI-5 (arbitrary units) was divided by the 
optical density corresponding to actin and data was normalised with their respective sA~ 
controls. Data represents mean ± SEM, n = 3 experiments with single samples. P >0.05 
comparing sA~ to A~ raw data values using a paired t test. 
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Figure 4.7. The effects of AP 1-40 and AP 142 on the expression of occludin by 
hCMECID3 cells. (a) Fully confluent hCMECID3 cells were incubated with 5 IlM AP 1-
40, AP 1-42, sAP 1-40 or sAP 1-42 for 24 h or 48 h and the expression of occludin (rabbit 
polyclonal IgG) or actin (mouse monoclonal IgG,) was then assessed by western blotting. 
(b) The optical density corresponding to occludin (arbitrary units) was divided by the 
optical density corresponding to actin and data was normalised with their respective sAP 
controls. Data represents mean ± SEM, n = 3 experiments with single samples. * P < 0.05 
comparing sAP to AP raw data values using a paired t test. 
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Figure 4.8. The concentration-dependent effects of AP 1-40 and AP 1-42 on occludin 
expression in hCMECID3 cells after a 48 h incubation period. (a) Fully confluent 
hCMECID3 cells were incubated with 0.5 or 5 J.lM A~ 1-40, A~ 1-42 or 5 J.lM sA~ 1-42 or 
sAP 1-40 for 48 h. The expression of occludin (rabbit polyclonal IgG) or actin (mouse 
monoclonal IgG1) was then assessed by western blotting (b) The optical density 
corresponding to occludin (arbitrary units) was divided by the optical density 
corresponding to actin and data was normalised with their respective sA~ controls. Data 
represents mean ± SEM, n = 4 experiments with single samples. * P < 0.05 comparing sA~ 
to A~ raw data values using a paired t test. 
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Figure 4.9. The effects of AP 1-40 and AP 1-42 on the expression of occludin and CI-5 
by hCMECID3 cells after a 48 h incubation period as assessed by flow cytometry. 
Fully confluent hCMEC/D3 cells were incubated with 5 IlM of either A~ 1-40, A~ 1-42, 
sA~ 1-40 or sA~ 1-42 for 48 h. The cells were then fixed in 4 % PAF, permeabilised with 
0.1 % triton x 100 and the expression of occludin or CI-5 measured by FACS analysis. 
Data represents mean ± SEM. n = 3 experiments with duplicate samples for A~ 1-42 and n 
= 20 for A~ 1-40 occludin expression. n = 3 experiments with duplicate samples for CI-5 
expression. * P < 0.05, ** P <0.01 comparing the raw data for sA~ to AP using a paired t 
test. 
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Figure 4.10.The expression of occludin by hCMECID3 cells after 48 h AP 1-40 
incubation as assessed by immunocytochemistry. Fully confluent hCMECID3 cells were 
incubated with 5 ~M (a) sA~ 1-40 or (b) A~ 1-40 for 48 h. The cells were then fixed in 
methanol, permeabilised with 0.1 % triton x 100 and the expression of occludin (rabbit 
polyc1onal IgG) measured by ICC. Results are from one experiment representative of2. 
The scale bar represents 50 ~M. 
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Figure 4.11. The effects of AP peptides on the mRNA levels of occludin, ZO-l and CI-
S after 24 and 48 h incubation in hCMECID3 cells. <a) Fully confluent hCMECID3 cells 
were incubated with 5 ~M A~ 1-42, A~ 1-40, sA~ 1-40 or sA~ 1-42 for 48 h and the 
mRNA levels ofCI-5, occIudin and ZO-1 was calculated using RT-PCR Data represents 
mean ± SEM. n = 4 experiments with duplicate samples. * P <0.05 comparing 6CT values 
using a paired t test. (b) mRNA levels of the TJ proteins were assessed after 48 h 
incubation with AP 1-40. Data represents mean ± SEM. n = 3 experiments with duplicate 
samples * P < 0.05 comparing 6CT values. 
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Figure 4.12. Permeability coefficient of hCMECID3 cells to 4 and 70 kDa FITC-
dextran after 48 h AJU-40 or AP 1-42 incubation. hCMECID3 cells grown to confluence 
on transwell filter inserts were treated with 5 J..lM AP 1-40, AP 1-42, sAP 1-42 or sAP 1-40 
for 48 h. The permeability of the cells to the paracellular tracers (a) 4 kDa or (b) 70 kDa 
FITC-Dextran was then investigated. Data represents mean ± SEM. n = 3 with duplicate 
samples for with the exception of AP 1-40 and sAP 1-40 in (b) where n = 6 with duplicate 
samples. * P < 0.05 , ** P <0.01 using a paired t test. 
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TEER (O.cm2) 
Pre incubation Post incubation 
sAPI-40 27.8± 1.6 28 ± 2.7 
AP 1-40 28.5± 2.6 29.7 ± 3.8 
sAPI-42 27.8 ± 2.9 28.5 ± 3.7 
AP 1-42 28.8 ± 3.5 30 ± 3.9 
Figure 4.13. The trans-endothelial electrical resistance of hCMECID3 cells after 48 h 
incubation with Ap. hCMECID3 cells were grown to confluence on collagen- and 
fibronectin- coated 12 well transwell inserts and incubated for 48 h with 5 J.1M AP 1-40, AP 
1-42, sAP 1-42 or sAP 1-40. The trans-endothelial cell electrical resistance ofhCMECID3 
cells was recorded before and after AP incubation. n = 3 with duplicate samples. P> 0.05 
using a paired t test. 
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4.4 Discussion 
4.4.1 Cytotoxicity of AP to hCMECID3 cells 
In the current study, both A~ 1-40 and A~ 1-42 peptides were only toxic at 
concentrations of 10 flM (when compared to their scrambled counterparts) to hCMECID3 
cells after 48 h incubation. Results from other groups have found a large variation in 
concentrations needed to evoke toxic effects ranging from 100 nM to 20 flM using 
different EC types (Table 4.1). The toxicity of A~ to ECs is believed to involve caspase 
activation [582], superoxide oxide production [582] and decreased nitric oxide production 
[412]. The confluent state ofECs might constitute a factor which can affect the 
cytotoxicity of A~. Using bovine aortic ECs, Balcells et al [590] found that A~ 1-42 
secreted from CHO cells co-transfected with APP and mutated PS genes was not toxic to 
confluent ECs, but displayed toxic properties to sub-confluent ECs. In this study, fully 
confluent hCMECID3 cells were used and both A~ 1-40 and 1-42 only displayed modest 
toxicity after 48 h incubation. This result is in partial agreement with Eisenhower et al 
[464], who found that A~ 1-40 was only toxic to primary hBECs at 20 flM, to but not at 2 
flM. In contrast however, this group found that A~ 1-42 displayed toxic effects at much 
lower concentrations, between 2 and 20 flM. It is worth mentioning that concentrations as 
high as 20 flM A~ 1-42 have been added to primary rat BECs and shown no appreciable 
toxicity [486]. In addition to EC confluence, A~ aggregation might in part explain the 
differences in concentrations needed to elicit toxic responses. Eisenhower et al [464] have 
demonstrated that aggregated A~ 1-40 is more toxic to primary BECs than unaggregated 
A~ 1-40. Recently, soluble oligomers have been hypothesised as the more toxic species of 
A~. Shankar et al [591] demonstrated that A~ dimers isolated directly from AD patients 
are capable of impairment of synaptic plasticity and memory in rodents. Furthermore, 
Klein et al [357] have demonstrated that A~ 1-42 oligomers are up to 40 times more toxic 
to neuronal cell cultures than unaggrgeated A~ 1-42, with oligomer concentrations as low 
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as 10 nM eliciting a cytotoxic response. The overall consensus from this study, and other 
publications, is that A~ can cause direct toxicity to BECs in vitro, albeit at high 
concentrations if unaggregated. Brain capillaries in AD display a number of morphological 
changes including basement membrane thickening, pericyte degeneration, endothelial 
shape changes, endothelial degeneration and luminal buckling [413]. This has led some 
researchers to argue that these events occur prior to the onset of AD symptoms as a result 
of cerebral blood flow reduction [421]. However, the observation that A~ causes EC death 
in vitro, implies a further possible mechanism for BBB dysfunction in AD. Accumulation 
of A~ as cerebrovascular deposits, could act to disturb the function of the BBB and provide 
a further neuropathogenic mechanism for AD. 
4.4.2 Effects of AP on the expression of transporter proteins by hCMECID3 cells 
The protein levels ofP-gp were unaltered by A~. Currently, there are no reports on 
the effect of A~ on the expression of P-gp by BECs in vitro and only one report from tissue 
samples [409]. Vogelgesgang et al [409] reported an inverse correlation between A~ 
plaque deposition and P-gp expression in the medial temporal lobe of non-demented 
subjects. The results from the present study, however, do not demonstrate a direct link 
between A~ and P-gp protein expression. Unpublished data from Margery Barrand 
(University of Cambridge, personal communication) has demonstrated P-gp down-
regulation in capillaries from AD patient tissue samples. This apparent discrepancy might 
suggest that A~ is not directly linked to P-gp down-regulation in AD, rather that other 
indirect mechanisms might contribute to this effect. For example, A~ might act on other 
cell types such as astrocytes, pericytes, or microglia, which could secrete factors that 
mediate P-gp down-regulation. Astrocytic end feet swelling [373], microglia activation 
[374] and either pericytic atrophy [375] or an increase in pericyte capillary coverage [376], 
as a potential second line of defence, have been observed in tissue sections from AD 
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patients. In the CSF, plasma and brains of AD patient's, the cytokines IL-l oJ!}, IL-6 and 
TNF-a are found elevated and A~ in vitro can induce astrocytes and microglia to produce 
these cytokines [374, 377]. TNF-a has been demonstrated to decrease the activity ofP-gp 
in an immortalised rat BEC cell line (GPNT)[246], whilst IL-6 can down-regulate P-gp 
expression in cultured rat hepatocytes [592] and in vivo in mice after intraperitoneal 
injection [593] (reviewed [594]). IL-l~ is also found to decrease P-gp expression in rat 
hepatocytes in vitro [592]. P-gp down-regulation in AD might therefore be mediated by an 
indirect mechanism induced by A!} or as a result of inflammation. 
Iron accumulation has been observed in different brain regions in AD including the 
hippocampus and cerebral cortices [589]. The interaction ofiron with AP causes ROS 
production and AP aggregation and it has been hypothesised that redox active iron is a key 
mediator in AP toxicity [595, 596]. The transferrin receptor is a key transporter molecule 
for iron at the BBB, acting to transport iron into ECs from the blood [150, 151]. In this 
chapter, A~ did not alter the protein levels of the transferrin receptor. This result implies 
that increased levels of iron in the brain, would not be due to A~-induced transferrin 
receptor up- regulation and hence iron transport. This is in agreement with Kalaria et al 
[597], who noted that 1251 transferrin binding was decreased in hippocampal regions. 
However, in this current study there were no differences in cerebral microvessel binding in 
AD patients compared to controls. Morris et al [598] have also found decreased transferrin 
receptor levels in brain regions most prone to senile plaques, notably the hippocampus, 
though not at the microvessellevel. The increased iron found in AD patients might 
originate from brain resident cells such as microglia, which can release iron from ferritin in 
vitro [599], or by binding of iron to A~ deposits rather than from an absolute increase in 
iron levels in brain ISF. Increased iron concentrations in the brain might also be the result 
of BBB changes in AD patients. The up-regulation of an alternate iron receptor, such as 
melanotransferrin [600] could mediate blood-to-brain iron transport. Also, since there are 
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increased levels of iron in the plasma compared to CSF levels, a leaky BBB as found in 
AD patients, could allow diffusion of iron into the brain [150, 151,601]. 
In the present study, A~ 1-40 and A~ 1-42 were both shown to decrease the 
expression of Glut-1 by hCMECID3 cells after 48 h incubation. This finding is in 
agreement with investigations in AD patients, where decreased glucose utilisation has been 
observed [431]. Reduced glucose metabolism in the hippocampus [432], neocortex [434] 
and posterior cingulate gyrus [435] has been noted in patients with AD. The decreased 
glucose metabolism might be due in part to a decreased uptake of glucose into the brain 
across the BBB. Glut-1 is highly expressed by BECs and is responsible for the transport of 
glucose across the BBB [138]. Using both immunolabelling and covalent binding of 
cytochalasin B, decreased Glut-1 levels have been observed in brain tissue from AD 
patients at the level of the BBB [146,586,587]. Mooradian et af [438] have further 
demonstrated in AD patients that Glut-1 is altered at the protein level, but not at the mRNA 
level. There is also evidence that A~ can cause Glut-1 down-regulation in vivo. Using 
APPIPS1 mice, Hooijmans et af [437] found that A~ load in the hippocampus precedes 
Glut-1 reduction, and that Glut-l density per capillary was decreased In vitro, A~ 25-35 
has also been demonstrated to decrease the uptake of glucose in porcine pulmonary ECs, 
however Glut-1 levels were not assessed [442]. Taken together, the results of the present 
study and the data described above indicate that A~ can cause a down-regulation in the 
Glut-1 receptor, which could contribute to reduced neuronal activity contributing to the 
pathogenesis of AD. 
4.4.3 Effect on All tight junction protein expression by hCMECIDJ cells 
The results from this present study have demonstrated that A~ incubation induces 
occludin down-regulation at the protein and mRNA level and increased hCMECID3 cell 
paracellular permeability. These results suggest that the two findings are interlinked, i.e. 
occludin is a key component of endothelial cell permeability. The importance of occludin 
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in conferring restrictive TJs has been demonstrtaed in vitro [84, 85, 134] and in vivo [91, 
92,276]. Transfection of truncated occludin or siRNA knockdown in MDCK cells or 
Xenopus embryo cells results in increased paracellular permeability [84, 85, 134]. 
Occludin down-regulation and increased permeability has been observed in animal models 
of oxidative stress [276], IL-l-induced neutrophil BBB breakdown [91] and inflammatory 
pain [92]. Occludin down-regulation, as observed in the current study, is in partial 
agreement with Marco and Skaper [486], who observed that AP 1-42 at 20 llM induced 
occludin down-regulation in rat BECs at 24 h, but not at 48 or 72 h incubation. In addition, 
these authors did not detect any alterations in overall CI-5 or ZO-1 levels, in agreement 
with our study, although they reported that CI-5 translocated to the cytoplasm and they did 
not investigate endothelial cell permeability. Soluble AP 1-40 oligomers, but not 
unaggregated AP 1-40 species, have also been demonstrated to increase the paracellular 
permeability ofhBEC cultures after 24 h incubation, which was associated with ZO-l 
translocation to the cytoplasm and nucleus from the cell membrane [443]. In that study. the 
expression of occludin was not investigated. and the totallevels of ZO-1 were not 
quantified. Therefore, whilst in this current study total levels of ZO-1 were not decreased, 
as assessed by western blotting, it cannot be ruled out that ZO-l could have translocated 
away from the membrane after AP 1-40 incubation. 
Decreased occludin expression and increased BBB permeability has been noted by 
Takechi et at in APPIPS 1 mice [94]. Stewart et at [376] have described that in AD patients 
there is a reduction in the number ofTJs per vessel length. Therefore the evidence suggests 
that TJ disorganisation and occludin down-regulation might contribute significantly to the 
pathology in AD. 
4.4.4 BBB permeability in AD 
The results of this study have shown that incubation with AP 1-40 increases the 
permeability ofhCMECID3 cells to the paracellular tracer FITC-dextran of70 kDa but not 
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that of 4 kDa. The lack of an effect of AP 1-40 incubation on the permeability of 
hCMECID3 cells to 4 kDa FITC-dextran may be related to the relatively high permeability 
of the hCMECID3 cells to smaller molecules prior to AP treatment. Indeed, the P e of 
hCMECID3 cells to 4 kDa FITC-dextran was -- 5 fold higher than that to 70 kDa FITC-
dextran. 
Some studies have shown increased CSF/plasma protein ratios of albumin and IgG, 
suggesting that a leaky BBB is a common occurrence in AD patients [577-581]; however 
other studies have not confirmed this finding [602-604]. The most compelling evidence for 
an increased BBB permeability in AD was provided by Zipser ef al [439], who found that 
prothrombin leakage from the blood into the CNS was significant in advanced stage AD. 
Matsumoto ef al. [579] recently demonstrated, using CSF measurements and MRI, that 
increased BBB permeability to albumin was associated with medial temporal atrophy in 
AD patients. Other evidence, using AD animal models, also suggests that an increased 
BBB permeability can be induced by Ap. Using Tg 2576 mice, Ujii et al [584] observed 
increased BBB permeability after 4 months of age, prior to plaque deposition and disease 
onset, which can be reversed via AP peptide immunisation [440]. Su ef al [441] have also 
demonstrated that intravascular jugular vein injections of AP 1-40 can induce a leaky BBB 
and microglia activation in rats. AP 25-35 and AP 1-40 have also been demonstrated to 
increase the permeability of EC cultures in vitro including porcine BECs [442], human 
BECs [443] and porcine pulmonary ECs [444]. 
The increased BBB permeability induced by AP in vitro, as noted by others and in 
this study, is in agreement with data found in AD patients and in vivo models. This raises 
the question as to what extent a leaky BBB would induce alterations in CNS function. 
Increased BBB permeability has been proposed as a key pathogenic mechanism in other 
diseases such as stroke [605], multiple sclerosis [606] and the progression of epilepsy 
[607]. TJs at the BBB serve to limit the permeability of hydrophilic substances from the 
blood into the CNS, although transporters allow transfer of molecules. A breakdown of the 
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BBB in principle could lead to enhanced brain content of insulin, glucocorticoids [608], 
glutamate [155], plasma proteins and ions [609]. Insulin entry into the brain could compete 
with insulin degrading enzyme for the degradation of A~, increasing A~ brain load. 
Extravasation of serum proteins in the brain has been linked to epilepsy and, interestingly, 
BBB breakdown is correlated with seizure frequency in mannitol-treated rats [607]. 
Similarly, the efflux of glucocorticoids by P-gp would be disrupted by a leaky BBB, which 
in turn could cause neuronal catabolism [610]. A leaky BBB would also decrease the 
efflux capability of all ABC transporters at the BBB, allowing unwanted potentially toxic 
xenobiotics entry to the CNS. Increased glutamate in the brain as a result of a leaky BBB 
could results in excitotoxic events. As mentioned previously, increased iron concentrations 
are found associated with AD plaques, in addition to other heavy metal ions. Transferrin-
bound iron exists at much higher concentrations in the plasma than in brain tissue. A 
potential route of entry could therefore be via a leaky BBB. 
The abnormal presence of serum-derived proteins in AD patients, via a leaky BBB, 
might act to cause inflammation and neuronal degeneration. Albumin levels are much 
higher in blood than the brain, and albumin has been demonstrated to activate microglia 
[611], and induce cholinergic cell death in vitro [612]. Albumin is also bound to A~ in the 
plasma [613] and plasma proteins are frequently found as a component of A~ plaques [614, 
615]. A leaky BBB in AD patients could lead to the diffusion of serum proteins into the 
brain, which in tum could cause direct and indirect, via A~ aggregation, neuronal 
degeneration. It would be expected that increased permeability ofthe BBB to serum 
proteins would lead to oedema as is the case in stroke. However, there are no reports 
suggesting the presence of oedema in AD patient's brains. This suggests that the BBB 
leakiness in AD patients may be subtler in nature. 
Recently, Stone [616] has hypothesised that capillary haemorrhages might be an 
underlying cause of AD. Stone suggested that microhaemorrhages cause ischemia, which 
results in oxidative damage and increased neuophil A~ production, and the release of 
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haemoglobin into the neuropil, which binds to Ap to produce oligomers. Whilst the results 
of this study do not demonstrate a causative role for BBB leakiness in AD, they do provide 
a further mechanism of BBB dysfunction in this disease. Increased AP production could 
induce a leaky BBB, resulting in haemoglobin extravasation into the eNS. Haemoglobin 
could bind to AP and promote oligomer formation. In line with this view, haemoglobuIin 
has been demonstrated to promote the formation of AP oligomers in vitro and is associated 
with senile plaques in AD patients [617]. 
A further consequence ofBBB permeability could be the access of the brain of 
pathogens. Interestingly, increased levels of herpes simplex virus have been noted in the 
elderly and in AD patients [618], and pathogens have been proposed by some researchers 
to be a causative factor in AD [619, 620]. Increased BBB permeability caused by AP could 
increase the susceptibility of the brain to infection. 
Whilst evidence that the BBB is compromised in AD patients is compelling, and 
numerous studies in vitro and in animal models have suggested possible mechanisms by 
which a leaky BBB might contribute to the pathogenesis of AD, unfortunately, to date, 
there is no evidence for direct BBB dysfunction underlying neuronal degeneration in AD 
patients. 
4.5 Conclusions 
The results of the present study demonstrate that AP can down-regulate Glut-l 
expression in BEes, which may consequently reduce the amount of glucose available to 
neurones and promote neuronal degeneration. At the TJ level, non-toxic concentrations of 
AP induce a decrease in occludin expression by BEes, which was associated with an 
increased paracellular permeability. These results suggest that Ap-induced BBB 
dysfunction, might contribute significantly to the pathogenesis of AD patients. 
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Cell ~____ __ . Concentration of All required for toxicity Pathway involved Assessed by 
Bovine post capillary 
heart venular ECs 
Primary hwnan BECs 
RatBECs 
5 J.LM A~ 1-40/1 -42 evoke 71% and 62 % of control A~ induced ROS and caspase -3 
~~~ ~~~ 
A~ 1-40 toxic at 20 J.LM, whilst A~ 1-42 toxic at 2 
and 20 J.LM 
1 - 100 nM A~ 1-40 and A~ 1-42 enhance necrosis 
and apoptosis after 3 h but not 48 h 
MIT 
MIT 
TUNEL, 
lactate 
dehydrogenase 
Reference 
[582] 
[464] 
[621] 
Bovine aortic ECs A~ 25-35 and A~ 1-40 ~ I J.LM induces apoptosis. Decreased NO production and K + ion 
channel disruption 
MIT [622] 
RatBECs 
Rodent coronary ECs 
Bovine aortic ECs 
Bovine aortic ECs 
MurineBECs 
A~ at concentrations of 100 nM and higher were 
toxic 
5-100 nM proliferation of EC, 500 nM and above 
toxic of AP 1-40. 
A~ 1-40 50 J.LM caused endothelial cell death. 
AP 1-40 1 J.LM induce apoptosis. 
API-40 caused 40 % toxicity after 48 h. 25-35 also 
evoked a strong endothelial cell death. 
Possibly NO 
ERK/1/2 inhibition possibly mediated Cell counts 
via decrease in FGF-2 production 
Hoesrst 
Toxicity deceased after SOD addition. Light 
Also NO dysfunction. microscopy 
Reversed by caspase and an anti- MIT 
oxidant both decreased cell death 
Bovine aortic ECs AP secreted from CHO over secreting A~ cells. Not -
toxic unless ECs were sub confluent 
Cell counts 
Table 4.1. Selected references on the toxicity of All to ECs 
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[623] 
[624] 
[625] 
[583] 
[626] 
[590] 
ChapterS 
Molecular mechanisms mediating A~ 1-40- induced occludin down-
regulation and increased hCMECID3 cell permeability 
Abstract 
The aim of this study was to investigate the pathway(s) involved in AP 1-40-
mediated occludin down-regulation in hCMECID3 cells. Pharmacological inhibitors of 
signalling pathways which AP is known to activate (GSK-3p, NF-KB, JNK, p38MAPK, 
ERK) and others implicated in the regulation of occludin levels (Src, ROCK, PI3K, PKC) 
were used. Inhibitors of JNK (SP600125, TAT-TI-JIP1S3_163) and p38MAPK (SB203580) 
selectively prevented AP 1-40- mediated occ1udin down-regulation as assessed by flow 
cytometry. All three MAPK family members (p38MAPK, JNK-46 kDa and ERK2) were 
activated at 24 hand 48 h by AP 1-40. After 48 h incubation with AP 1-40, SB203580 
inhibited p3 8MAPK and JNK activation by AP 1-40; however, SP600 125 and TAT -TI-
JIP153-163 only blocked JNK activation. JNK and p38MAPK inhibitors prevented the AP 1-
40-mediated increase in hCMECID3 cell permeability to 70 kDa FITC-dextran. The 
aggregation of AP 1-40 as a possible mechanism mediating this effect was also 
investigated. When assessed by western blotting, using an anti-Ap antibody, it was 
observed that levels of the 4 kDa AP 1-40 monomer decreased over 48 h in the supernatant 
and celllysates, whilst a large 150 kDa protein was detected from 24 h. This 150 kDa band 
did not correspond to endogenous APP and might represent the activating AP species, 
since it appeared at the same time as MAPK activation. These results demonstrate that the 
JNK pathway is critical in the signalling of AP 1-40 mediating occ1udin down-regulation 
and increased paracellular permeability in hCMECID3 cells. JNK inhibition could 
represent a therapeutic target for AD to prevent BBB dysfunction found in AD patients. 
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5.1 Introduction 
A~ has been shown to induce several signalling pathways in many cell types, with 
investigations focused mainly on neuronal and EC death, or glial cell activation (reviewed 
in [627D. The toxicity of A~ to neurones involves complex molecular mechanisms, 
potentially involving multiple pathways, both extra and intracellular, such as ROS and 
cytokine release [627]. Three main intracellular signalling pathways are commonly 
described as being activated by A~ in neurones or in different cell types, namely GSK-3~, 
JNK and NF-kB. 
GSK-3~ forms part of the PI3K-Akt mediated cell survival pathway and is 
proposed to play multiple roles in AD [628,629], including tau hyperphosphorylation, A~ 
production and neuronal apoptosis. Recently, it has been demonstrated that GSK-3~ 
inhibition [345] and PI3K activation [347], which in turn leads to GSK-3~ inactivation, 
prevents A~- induced neuronal cell death in rat hippocampal neurones. Akt and GSK-3~ 
are also implicated in A~ toxicity to ECs. HUVEC cells transfected with APP, have been 
demonstrated to produce A~ 1-42, which is associated with reduced AKT and increased 
GSK-3~ activation, inducing apoptosis [630]. 
The JNK pathway also represents a potential therapeutic target in AD (reviewed in 
[631 D. In brain tissue from AD patients, JNK activation has been found associated with 
both intracellular A~ in neurones from the cerebral cortex [632], and A~ plaques and NFT 
in the hippocampus [633]. In vitro, JNK activation can be induced following incubation of 
cultured neurones with A~ [353, 634-636]. Wei et al. [353] have demonstrated, using the 
neuroblastoma cell line SH-SY5Y, that A~ 25-35 and A~ 1-42 rapidly induce JNK 
activation and cell death, which is prevented by JNK inactivation, albeit indirectly via 
insulin-like growth factor. Bozyczko-coyne et at [634] and Troy et al [636] have also 
demonstrated that direct JNK inhibition can prevent A~- induced cell death in rat cortical 
neurones and PC12 cells, respectively. 
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There is conflicting evidence regarding the role ofNF-kB in AD. NF-kB has been 
reported to be activated in neurones and astrocytes surrounding early amyloid plaques in 
the cortex and hippocampus of AD patients brains [637]. NF-kB activation has also been 
described in the neurones of the hippocampus and enterohinal cortex [638,639] and also, 
in large cholinergic neurones in AD patients [640]. A~ can also induce the activation of 
NF-kB in primary rat cerebellar granule cells [637] and human neuroblastoma cells [641]. 
In vitro, NF-kB inhibitors have been demonstrated to prevent A~ toxicity in rat primary 
neurones [351]. In contrast, Kaldschmidt et al [344] showed that NF-kB inhibition can 
potentiate the toxicity of A~ 1-40 in rat primary neurones, and demonstrated a reduction in 
NF-kB staining in neurones surrounding plaques in AD brain tissue, compared to age-
matched controls. The authors have explained this discrepancy by suggesting that a certain 
threshold levels ofNF-kB is protective, whilst too high or low levels are neurotoxic [642]. 
The overall aim of this chapter was to investigate the signalling pathway(s) 
involved in occludin down-regulation and increased permeability mediated by A~. A~ 1-40 
was used in preference to A~ 1-42 in this study, since this particular species is most 
abundant in AD patients plasma and whole brain homogenates [313]. In addition, Oijen ef 
al [321] also found that high plasma concentrations of A~ 1-40 are associated with an 
increased risk of developing dementia, and A~ 1-40 is the species found at the highest 
levels in cerebrovascular deposits [643]. Therefore, in this study, inhibitors for JNK, GSK-
3~ and NF-kB, the main signalling pathways mediating A~ actions, were initially used in 
an attempt to reverse the A~ 1-40- mediated occludin down-regulation in hCMECID3 
cells. Other pharmacological inhibitors were also employed for PI3K, ROCK, Src and 
PKC pathways which have been previously shown to regulate occludin expression and/or 
induce post-translational changes at the protein level. 
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5.2 Methods 
5.2.1 Signalling pathway inhibitors 
For this study, various inhibitors of signalling pathways, or soluble receptor 
antagonists for cytokines were employed (Table 5.1). For each inhibitor, concentrations 
were used that have been previously shown to inhibit the pathway under investigation in 
vitro, either reported in the literature, or as previously demonstrated in the laboratories at 
The Open University (Dr Ignacio Romero, personal communication). Two exceptions were 
the soluble cytokine receptors, and the JNK 2/3 inhibitor N-(3-Cyano-4,5,6,7-tetrahydro-l-
benzothien-2-yl)-I-naphthamide. For the cytokine receptors, at least a lOx higher 
concentration than the IC50 described by the data sheet was used. For N-(3-Cyano-4,5,6,7-
tetrahydro-I-benzothien-2-yl)-I-naphthamide, as yet, there are no reported in vitro studies 
that have used this inhibitor. Initial experiments conducted as part of this study found N-
(3-Cyano-4,5,6, 7-tetrahydro-I-benzothien-2-yl)-I-naphthamide to be toxic to hCMECID3 
cells. Therefore, an MTT assay (0.25, 0.5, 1, 5, 10, 20 J.lM) was carried out to determine 
non-toxic concentrations for use in subsequent experiments (Figure 5.1). 
5.2.2 Flow cytometry 
Fully confluent hCMECID3 cells (grown as in 4.2.4) were pre-incubated for 30 min 
in the presence or absence of the pharmacological inhibitors/antagonists listed in Table 5.1. 
5 J.i.M A~ 1-40 or sA~ 1-40 was then added to the supernatant for 48 h, and the expression 
of occludin measured by flow cytometry as described in section 4.2.4. 
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Modulator Pathway Concentration Source Reference 
inhibited 
SP600125 JNK 1,2 and 3 10, 50 ~M Calbiochem NJ, [644] 
USA. 
TAT-TI-JIP 153-1 63 JNK 1,2 and 3 1,5, 10 ~M Calbiochem NJ, [645] 
USA. 
N-(3-Cyano-4,5,6,7- JNK 2 and 3 0.5 ~M Calbiochem NJ, [646] 
tetrahydro-l- USA. 
benzothien-2-yl)-I-
naphthamide. 
SB203580 p38MAPK 20~M Calbiochem NJ, [647] 
USA 
PD98059 MEK 50~M Calbiochem NJ, [648] 
USA 
pp2 Src family 10 ~M Calbiochem NJ, [649] 
USA 
Y-27632 ROCK inhibitor 700nM Calbiochem NJ, [650] 
USA 
Bisindolylmaleimide PKC 10 ~M Calbiochem NJ, [651] 
-1 (Bis-I) USA 
LY294002 PI3-kinase 300 ~M Calbiochem NJ, [652] 
USA 
Lithium chloride GSK-3~ 5mM Sigma-Aldrich, [345] 
(LiCI) Dorset, UK 
sn50 NF-k~ 200~M Calbiochem NJ, [653] 
USA 
sn50-m Control sn-50 200 ~M Calbiochem NJ, 
USA 
sIL-lra IL-l 10 nglml Prospec, IC 50- 0.5 
Rehovot, Israel nglml 
sTNF-Rl TNF-(l 10 nglml Prospec, IC 50- 0.4-
Rehovot, Israel 1 nglml 
s1L-6 R IL-6 10 nglml Prospec, 
Rehovot, Israel 
Table 5.1. Signalling pathway modulators and soluble cytokine receptors used to 
investigate AP 1-40 - mediated ocdudin down-regulation in hCMECID3 cells. 
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5.2.3 Permeability of hCMECID3 cells to 70 kDa FITC-dextran 
hCMECID3 cells were grown to confluence in collagen- and fibronectin· coated 
transwell polyester membrane inserts (0.4 ~m pore diameter, 12mrn diameter). SP600125 
(50 ~M), TAT-TI·JIPIS3_163 (10 ~M), SB203580 (10 ~M) or a vehicle control was then 
added to the apical chamber for 30 min. sA~ 1-40 or A~ 1-40 was then added to the culture 
medium in the apical chamber for 48 h. The permeability ofhCMECID3 cells to 70 kDa 
FITC-dextran was determined as described in section 4.2.6 in addition to the trans 
endothelial electrical resistance (TEER). 
5.2.4 SDS-PAGE and Western blotting 
hCMECID3 cells were grown to full confluence in collagen·coated 6-well plates 
and incubated with sA~ 1-40 or A~ 1·40 for 0, 1, 5, 15, 30 and 60 min or 1, 3, 6, 24 and 48 
h. A further experiment was carried out whereby hCMECID3 cells were pre· incubated 
with SP600125 (50 ~M), TAT-TI-JIPIS3_163 (10 ~M), SB203580 (10 ~M), N-(3-Cyano-
4,5,6,7-tetrahydro.l-benzothien.2.yl).1-naphthamide (0.5 ~M), or a vehicle control and 
then incubated with A~ 1-40 or sA~ 1-40 for 48 h. Celllysates were then obtained as 
described in section 4.2.3. The expression of active JNK, p38MAPK and ERK was then 
assessed by western blotting using specific antibodies for the phosphorylated form of each 
signalling molecule (Table 5.2). To normalise the results, the western blots were stripped 
as described in section 2.2.5 and re-probed with antibodies specific for total JNK, 
p38MAPK or ERK2 (Table 5.2). As a positive control, hCMECID3 cells were placed 
under UV for 30 min, lysed and processed as above 
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Anti- Species Concentration Source 
Phospho- Thr183/Tyr185 rabbit 1 in 1000 dilution Cell signalling, 
JNK polyclonal Massachusetts, USA 
Phospho- Thr 180/Tyr 182 rabbit 1 in 1000 dilution Cell signalling, 
p38MAPK polyclonal Massachusetts, USA 
Phospho- Thr185/Tyr187 mouse IgG) 1 in 1000 dilution Biosource, 
ERK1I2 monoclonal California, USA 
JNK rabbit 1 in 1000 dilution Cell signalling, 
polyclonal Massachusetts, USA 
p38MAPK rabbit 1 in 1000 dilution Cell signalling, 
polyclonal Massachusetts, USA 
ERK2 mouse IgG2a 1 in 1000 dilution Upstate California 
monoclonal USA 
Table 5.2. List of antibodies used for western blotting. 
5.2.5 Ap peptide in whole celllysates and culture supernatants as assessed by SDS-
PAGE and western blotting 
hCMECID3 cells were grown to full confluence in collagen-coated 6-well plates, 
and incubated with A~ 1-40 for 1,3,6,24 and 48 h. To determine A~ aggregation in the 
absence of cultured cells, A~ 1-40 was added to collagen- coated tissue culture plates, with 
no hCMECID3 cells, for the same time points. 20 ).11 of each culture medium sample was 
added to 5 JlI of 4 X Laemmli's buffer, whereas cells or collagen-coated wells were 
scraped and treated as described in section 4.2.3. A~ levels were then assessed in both the 
celllysates and medium samples using SDS-PAGE on 15 % and 8 % gels and western 
blotting techniques (Antibody 6E 10 directed against A~ 1-16, 1 in 100 dilution mouse 
monoclonal IgG) , Abeam, Cambridge, UK). The membranes were stripped and reprobed, 
as described in section 2.2.5, for APP (22Cll directed against APP 66-81, diluted I in 100, 
mouse monoclonal IgG), Chemicon, Mannheim, Germany). 
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5.2.5 Statistical analysis. 
All data are represented as means +/- SEM and the number of experiments, n, 
indicated each time. Statistical significance was calculated using ANOVA followed by 
Student's t test, comparing each treatment to the control (* P < 0.05, .. P < 0.01). For the 
permeability experiments, a paired t-test was employed. 
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5.3 Results 
5.3.1 Signalling pathways involved in AP 1-40- mediated occludin down-regulation by 
hCMECID3 cells 
The aim of this experiment was to investigate the contribution of various signalling 
pathways in A~- mediated occludin down-regulation. Initially pathways known to be 
activated by A~ (NF-KB, GSK-3~, JNK) [627], and others that have been previously shown 
to regulate TJ expression (Rock, Src, PKC) were investigated [131] (Figure 5.2). 
A~ 1-40 caused a decrease in occludin expression by 29 % ± 6.3 (compared to sA~ 
1-40) in hCMECID3 cells. Pre-incubation with inhibitors ofSrc (Pp2), ROCK (Y-27632), 
PKC (Bis-l), NF-KB (sn50), GSK-3~ (LiCI) or PI3K (LY294002) did not prevent A~ 1-40-
induced occludin down-regulation (Figure 5.2a). However, this effect was completely 
blocked by pre-incubation with 50 JlM SP600125, a JNK inhibitor. 
JNK is a member of the mitogen activated protein kinase (MAPK) family of which 
there are three members, p38MAPK, JNK and ERK. Therefore, to investigate the 
specificity of the JNK pathway involvement in A~-induced occludin down-regulation, 
hCMECID3 cells were pre-incubated with two further inhibitors of JNK (TAT-TI-JIPm _t63 
and N-(3-Cyano-4,5,6, 7 -tetrahydro-l-benzothien-2-yl)-I-naphthamide), a p38MAPK 
inhibitor (SB203580) or an indirect inhibitor ofERK (PD98059) at different 
concentrations (Figure 5.2b). JNK exists as three isoforms (JNKl, 2 and 3). JNKl and 3 
are described as important for Ap-mediated toxicity to neurones [654]. N-(3-Cyano-
4,5,6,7-tetrahydro-l-benzothien-2-yl)-I-naphthamide [646] is reported to be specific for 
JNK2/3 and so was used in an attempt to elucidate the isoform responsible for AP 
signalling in hCMECID3 cells. SP600125 at a lower concentration of 10 JlM inhibited the 
A~ 1-40- mediated occludin down-regulation (n = 3, P < 0.05) as found with the 50 JlM 
dose (Figure 5.2a and b). 10 JlM TAT-TI-JIPtS3.t63 rescued occludin down-regulation in 
hCMECID3 cells (n = 3, P < 0.05), although 5 JlM and 1 JlM doses were not effective. N-
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(3-Cyano-4,5,6, 7 -tetrahydro-I-benzothien-2-yl)-I-naphthamide was toxic to hCMECID3 
cells at concentrations of 1 JlM and upwards (Figure 5.1). When used at 0.5 JlM, however, 
there was no inhibition of occludin down-regulation, and similarly the MEK inhibitor 
PD98059 also had no effect (n = 3, P > 0.05). Interestingly, 20 JlM SB2035580 completely 
blocked the down-regulation of occludin (n = 3, P < 0.05). These results demonstrate that 
p3 8MAPK and JNK inhibition both attenuate Ap-mediated occludin down-regulation in 
hCMECID3 cells. 
5.3.2 Time-dependent activation of JNK, ERK and p38MAPK as assessed by western 
blotting 
The next issue to be addressed was whether JNK and p38MAPK were activated in 
hCMECID3 cells by AP 1-40 treatment (Figures 5.3- Figure 5.5). The activation ofERK 
was also investigated to determine the specificity of MAPK activation. Neither JNK nor 
p38MAPK were activated at early time points of 1,5, 15,30 and 60 min (Figure 5.3). By 
contrast, activation of all three kinases was observed after 24 hand 48 h incubation with 
AP 1-40 (Figures 5.4 and 5.5). 
JNK activation was detected as early as 6 h post incubation with AP 1-40 and 
increased with time up to 48 h, but no JNK activation was observed following sAP 1-40 
incubation. JNK resolves as two bands of 52 kDa and 46 kDa. AP 1-40 activated 46 kDa 
JNK but not 52 kDa, whilst the positive control (UV light, 30 min) stimulated both. ERK 
was also activated by AP 1-40 at 24 h and 48 h. Two forms ofERK exist, ERKI (44 kDa) 
and ERK 2 (42 kDa) and AP 1-40 appeared to exclusively activate ERK 2. p38MAPK 
activation was determined following 24 h and 48 h incubation with AP 1-40, however the 
band resolved was very weak and difficult to fully identify. 
The activation of JNK, p38MAPK and ERK after 48 h incubation with AP 1-40 
was then investigated, in the presence or absence of their specific inhibitors (Figure 5.6 and 
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5.7): 10 JlM TAT-TI-JIP1S3_163, 20 JlM SB203580, 50 JlM SP600125 and 10 JlM PD98059. 
Both JNK inhibitors (TAT-TI-JIP153_163 and SP600125) reduced the activation of JNK 
caused by A~ 1-40, but did not inhibit the activation ofp38MAPK or ERK2. Similarly, 
PD98059 decreased the activation ofERK but not that of JNK or p38MAPK. By contrast, 
SB203580 inhibited both JNK and p38MAPK activation but not ERK2. These results show 
that SB203580 also prevented JNK activation and so might not be specific for the 
p38MAPK pathway, or that p38MAPK signalling mediates the activation of JNK through 
an as yet undefined mechanism. 
N-(3-Cyano-4,5,6, 7 -tetrahydro-I-benzothien-2-yl)-I-naphthamide) increased the 
activity ofERK, p38MAPK and JNK, indicating that hCMECID3 cells were under stress 
(Figure 5.8). It is therefore unsurprising that this compound did not prevent A~-mediated 
occludin down-regulation, since it activated rather than inhibited JNK. 
5.3.3 The effect of soluble cytokine receptors on AP 1-40-mediated occludin down-
regulation by hCMECID3 cells 
The activation ofp38MAPK is associated with the production of inflammatory 
mediators, which in principle could act to decrease the expression of occludin by 
hCMECID3 cells in a JNK-dependent manner. IL-l~, TNF-a and IL-6 are all elevated in 
AD patients [377] and IL-l~ [265-270] or TNF-a [655, 656] can alter the expression ofTJ 
proteins. In this study, sTNF-RI, sIL-Ira, combined sTNF-RlIsIL-lra or a sIL-6 RaIl 
failed to prevent occludin down-regulation (Figure 5.8). These results suggest that either 
another unknown secreted factor is released by A~-stimulated BECs, or a direct activation 
of JNK or p38MAPK is crucial in the observed down-regulation of occludin levels by 
hCMECID3 cells. However, the lack of activation ofp38MAPK as assessed by western 
blotting at early time points appears to rule out the possibility of the secretion of an 
unknown mediator by hCMECID3 cells, unless it is released via a p38MAPK-independent 
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mechanism. Indeed, p38MAPK, JNK and ERK activation were all observed at the same 
time of24 h upwards, indicative of co-activation. The fact that TAT-TI-JIP\S3_163, 
SP600125 inhibit JNK and not p38MAPK, and SB203580 inhibits both, implies that JNK 
is the critical pathway in occludin down- regulation mediated by Ap. 
5.3.4 The effed of JNK and p38MAPK inhibition on AP 1-40-mediated intreased 
hCMECID3 tell paracellular permeability 
Since TAT-TI-JIP153_163, SB203580 and SP600125 all attenuated occludin down-
regulation mediated by AP 1-40, their effect on the Ap-mediated increase in hCMECID3 
cell penneability was investigated (Figure 5.10 and II). The TEER ofhCMECID3 cells 
was unaltered by AP 1-40 incubation and also by the incubation of 10 JlM TAT·TI-JIP153_ 
163,20 JlM SB203580 or 50 JlM SP600125 (Figure 5.10, n = 3, P> 0.05). These results 
imply that none of the treatments sufficiently alter the penneability ofhCMECID3 cells to 
small ions, probably due to the relatively poor basal TEER of the hCMECID3 cells. 
AP 1-40 increased the penneability coefficient of hCMECID3 cells to 70 kDa 
FITC-dextran compared to the sAP peptide by 69.7 ± 8.5% (Figure 5.11, n = 3, P < 0.05). 
This effect was inhibited by pre-incubation with TAT·TI-JIP1S3-163, or SP600125 prior to 
AP 1·40 incubation (n = 3, P> 0.05). There was also no increased paracellular 
penneability after pre-incubation with SB203580 and subsequent AP 1·40 incubation (n = 
3, P> 0.05). Although, it should be noted, that pre-incubation ofhCMECID3 cells with 
SB203580 slightly increased the penneability coefficient when incubated with both sl·40 
and Ap 1-40 by 33.8 ± 22.5 % and 26.7 ± 12.6 %, respectively, when expressed as a 
percentage of vehicle pre-incubated sAP 1·40 control, however the data was not significant 
(n = 3, P > 0.05). These results show that JNK and p38MAPK inhibition can prevent the 
Ap 1·40 mediated increase in hCMECID3 cell penneability to 70 kDa - FITC dextran, 
most likely via occludin down-regulation. 
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5.3.5 AfJ peptide in whole ceUlysates and culture supernatants as assessed by SDS· 
PAGE and western blotting 
A~ has a high tendency to self aggregate and there is some debate as to the most 
toxic form of A~ (reviewed [359]). To investigate which AP species might be responsible 
for occludin down-regulation in hCMECID3 cells, AP levels in celllysates and culture 
medium were assessed via western blotting. Using a 15 % acrylamide gel, a time-
dependent reduction of a 4 kDa protein in both the supernatant and cell lysate was 
observed when A~ 1-40 was incubated with fully confluent hCMECID3 cells, but not in 
the absence of cells (Figure 5.12). Interestingly, at 6, 24 and 48 h, increasing amounts of a 
large protein of -150 kDa was detected in both celllysates and the culture medium. To 
further investigate the identity of this protein, samples were electrophoresed on an 8 % 
acrylamide gel (Figures 5.12 and 5.13), which was blotted for AP, then stripped and re-
probed for APP. As observed on the 15 % acrylamide gel, alSO kDa protein was observed 
in hCMECID3 celllysates and culture medium (Figure 5.12 and 5.13). In addition, in the 
supernatant ofhCMECID3 cells incubated with AP 1-40, a decreased expression ofa 50 
kDa protein was observed using an APP antibody. The results suggest that either AP of 4 
kDa is degraded by hCMECID3 cells or that AP aggregates with other AP molecules or 
with another protein(s), without the production of intermediate species. 
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Figure 5.1. The toxicity of N-(3-Cyano-4,5,6,7-tetrahydro-l-benzothien-2-yl)-I-
naphthamide to hCMECID3 cells. Fully confluent hCMECID3 cells were incubated with 
different concentrations ofN-(3-Cyano-4,5,6,7-tetrahydro-l-benzothien-2-yl)-I-
naphthamide for 48 h and the cell viability measured using an MTT assay. Data represents 
mean ± S.D. n = I experiment with quintuplet samples. 
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Figure 5.2. The role of signalling pathway inhibition on occludin expression by 
hCMECID3 cells following AP 1-40 incubation for 48 h. (a) Fully confluent hCMECID3 
cells were pre-incubated for 30 min with inhibitors for the PI-3K, NF-KB, GSK-3~, Src, 
ROCK, PKC and JNK pathways and subsequently incubated for 48 h with either AP 1-40 
or sA~ 1-40, and the expression of occludin assessed via flow cytometry, (b) Fully 
confluent hCMECID3 cells were pre-incubated with inhibitors for the MAPK family 
before sA~ 1-40 or AP 1-40 incubation. Data represents mean ± SEM. n = 3 experiments 
with duplicate samples, * p < 0,05 using a Student's t test comparing each treatment to the 
control. 
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(a) JNK 
AP 1-40 sAP 1-40 
Time (min) 5 15 30 60 5 15 30 60 
.- 52kDa 
a - phospho-JNK 
.- 46kDa 
a -Total JNK .- 52 kDa 
.- 46kDa 
(b) p38MAPK 
AP 1-40 sAP 1-40 
Time (min) 5 15 30 60 5 15 30 60 
a - phospho-p38MAPK .- 42 kDa 
a -Total p38MAPK 
.- 42kDa 
Figure 5.3. The effect of AP 1-40 treatment on the activation of JNK and p38M.APK 
by hCMECID3 cells over 60 min. (a) Fully confluent hCMECID3 cells were incubated 
with AP 1-40 or sAP 1-40 for 1, 5, 15,30 and 60 min. The cells were then lysed and the 
protein levels of active/phosphorylated JNK (rabbit polyclonal IgG) and total JNK (rabbit 
polyc\onal IgG) was assessed via western blotting techniques. (b) Active and total 
p38MAPK (both rabbit polyclonal IgG) after AP 1-40 incubation. Results are from one 
experiment representative of 3 with single samples. 
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(a) JNK 
API-40 sAP 1-40 
Time (b) 3 6 24 48 3 6 24 48 uv 
+- 52kDa 
a - phospho-INK +- 46kDa 
+- 52kDa 
a -Total JNK 
+- 46kDa 
(b) ERK 
AP 1-40 sAP 1-40 
Time (b) 3 6 24 48 3 6 24 48 UV 
(1 - phospho-ERK2 +- 42 kDa 
(l -Total ERK2 +- 42kDa 
(e) p38MAPK 
AP 1-40 sAP 1-40 
Time (b) 3 6 24 48 3 6 24 48 UV 
(l - phospho-p38MAPK +- 42kDa 
a - Total-p38MAPK +- 42 kDa 
Figure 5.4. The effect of AP 1-40 treatment on the activation of JNK, ERK, 
p38MAPK by hCMECID3 cells over 48 h. (a) Fully confluent hCMECID3 cells were 
incubated with A~ 1-40 for 1, 3, 6, 24 and 48 h. The cells were then lysed and the protein 
levels of active and total JNK (rabbit polyclonal IgG) was assessed via western blotting. 
(b) Active (mouse monoclonal IgG1) and total ERK2 (mouse monoclonal IgG2a) after A~ 
incubation. (c) Active (rabbit polyclonal IgG) and total p38MAPK (rabbit polyclonal IgG) 
after A~ incubation. Results are from one experiment representative of two. 
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Figure 5.5. The activation of JNK, ERK and p38MAPK over 48 h after treatment 
with Ap 1-40 as assessed by optical density analysis of west em blots, The OD of the 
active JNK (46 kDa) ERK2 and p38MAPK bands fTom Figure 5.4 were divided by total 
JNK, ERK and p38MAPK respectively (arbitrary units) and normalised to sA~ control. 
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(a) INK 
A~ 11 J2 13 p38 E sA~ 
52 kDa 
a - phospho-INK 
46 kDa 
52 kDa 
a -Total JNK 
I:..O:.C---.:....... ......... ______________ ---' +- 46 kDa 
(b) p38MAPK 
sA~ A~ 11 J2 E p38 13 
a - phospho-p38MAPK 
+-42 kDa 
a - Total-p38MAPK +-42 kDa 
(c) ERK 
A~ 11 J2 J3 E p38 sA~ 
a - phospho-ERK2 +- 42 kDa 
a -Total ERK2 
Key: 
11 = SP600125, 
J2 = TAT-TI-JIP\530163. 
13 = N-(3-Cyano-4,5,6,7-tetrahydro-l-benzothien-2-yl)-1-naphthamide. 
E = PD98059. 
p38 = SB203580. 
Figure 5.6. The role of signalling pathway inhibition on the activation of JNK, ERK 
and p38MAPK by hCMECID3 cells following AP 1-40 incubation for 48 h. (a) Fully 
confluent hCMEC/D3 cells were pre-incubated with SP600125 (50 IlM), TAT-TI-JIP\530163 
(10 IlM),PD98059 (50 IlM), SB203580 (20 IlM) orN-(3-Cyano-4,5,6,7-tetrahydro-l-
benzothien-2-yl)-1-naphthamide (0.5 IlM) for 30 min and then incubated with A~ 1-40 or 
sA~ 1-40 for 48 h. The expression of active and total INK was then assessed via western 
blotting techniques. (b) The expression of active and total p38MAPK and (c) ERK was 
also measured. Results are from one experiment representative of two. 
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Figure 5.7. The role of signalling pathway inhibition on the relative activation of JNK, 
ERK and p38MAPK by hCMECID3 cells following AP incubation for 48 h as 
assessed by optical density analysis of west em blots. Fully confluent hCMECID3 were 
pre-incubated with SP600125, TAT-TI-JIP 153_163 , PD98059, SB203580 or for 30 min and 
then incubated with API-40 or sAP 1-40 for 48 h. The OD of the active JNK (46 kDa) 
ERK2 and p38MAPK bands from Figure 5.6 were divided by total JNK, ERK and 
p38MAPK respectively. 
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Figure 5.S. The activation of JNK, p3SMAPK and ERKl after AP 1-40 incubation 
with N-(3-Cyano-4,5,6,7-tetrahydro-l-benzothien-2-yl)-I-naphthamide as assessed via 
optical density analysis by hCMECID3 ceOs. Fully confluent hCMEC/D3 were pre-
incubated with N-(3-Cyano-4,5,6, 7-tetrahydro-l-benzothien-2-yl)-1-naphthamide or for 30 
min and then incubated with A~I-40 or sA~ 1-40 for 48 h. The OD of the active JNK (46 
kDa) ERK2 and p38MAPK bands from Figure 5.6 were divided by total INK, ERK and 
p38MAPK respectively. The data was then normalised to A~ 1-40. 
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Figure 5.9. The effect of soluble cytokine receptors on AP 1-40-mediated occludin 
down-regulation by hCMECID3 cells. Fully confluent hCMECID3 cells were incubated 
with AP 1-40 or sAP 1-40 in the presence or absence of sTNF-R, slL-1 ra, s1L-6 receptor or 
combined sTNF-R and sIL-l ra. Data represents mean ± SEM. n = 3 experiments with 
duplicate samples. P> 0.05 using a Student's t test comparing each treatment to their sAP 
counterparts. 
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TEERO.cm2 
Pre incubation Post incubation 
Control A~ 1-40 29 ± 1.5 29 ± 2.0 
sA~ 1-40 29 ± 1.3 28 ± 1.6 
SP600125 A~ 1-40 30 ± 2.5 28 ± 1.3 
sA~ 1-40 30 ± 2.4 29 ± 2.8 
TAT -JI-JIP 153-163 A~ 1-40 30 ± 1.8 28 ± 1.59 
sA~ 1-40 30 ± 1.7 29 ± 2.2 
SB203580 A~ 1-40 29 ± 1.5 28 ± 1.09 
sA~ 1-40 29 ± 1.1 28 ± 0.9 
Figure 5.10. The trans-endothelial electrical resistance (TEER) of hCMECID3 cells 
after 48 hAP 1-40 incubation with JNK and p38MAPK inhibiton. hCMECID3 cells 
were grown to confluence on collagen- and fibronectin- coated transwell filter inserts, pre-
incubated with TAT-TI-lIP 153_163 (10 ~M), SB203580 (20 ~M), SP600125 (50 ~M) and 
incubated with 5 ~M A~ 1-40 or sA~ 1-40 for 48. The trans-endothelial cell electrical 
resistance of hCMEC/D3 cells was recorded before and after A~ incubation. n = 3 with 
duplicate samples. P> 0.05 using a paired t test compared cells incubated with sA~ 1-40 to 
those treated with A~ 1-40. 
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Figure 5.11. The effect of JNK and p38MAPK inhibition on AP 1-40- mediated 
increased hCMECID3 cell permeability to 70 kDa FITC-dextran. hCMECID3 cells 
were grown to confluence on collagen and fibronectin coated- tranwell filter inserts, pre-
incubated with TAT-TI-JIP 153_163 (10 llM), SB203580 (20 llM), SP600125 (50 llM) and 
incubated with 5 llM AP 1-40 or sAP 1-40 for 48 h. The penneability of the cells to 70-kDa 
FITC dextran was then investigated. Data represents mean ± SEM. n = 3 experiments with 
duplicate samples. ** P < 0.01 using a paired t test comparing each treatment to the sAP 1-
40 control. 
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(a) Supernatant. 
Collagen-coated plastic hCMECID3 cells 
3 6 24 48 3 6 24 48 
(b) Cell lysate. 
Collagen-coated plastic hCMECID3 cells 
3 6 24 48 3 6 24 48 
225 kDa 
150kDa 
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Figure 5.12. AP 1-40 in cells and supernatants after 48 h incubation with hCMECID3 
cells or collagen coated plastic. (a) A~ 1-40 was added to either a collagen-coated tissue 
culture plate or hCMEC/D3 cells for 1,6,24 or 48 h. The supernatant was collected and 
the protein levels of A~ (6EIO, mouse monoclonal IgG1) was investigated using western 
bloting techniques and a 15 % acrylamide gel. (b) The protein levels of A~ were measured 
in cell lysate at each time point on 15 % acrylamide gels. The experiment was carried out 
once. 
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Figure 5.13. AP 1-40 in cells after 48 h incubation with hCMECID3 or collagen coated 
plastic. (a) A~ 1-40 was added to either a collagen- coated tissue culture plate or 
hCMECID3 cells for 1, 6,24 or 48 h. The cell lysate was collected and the protein levels of 
A~ (6ElO, mouse monoclonal IgG I) and (b) APP (22Cll, mouse monoclonal IgG1) was 
investigated using western blotting techniques and a 8 % acrylamide gel. Result from one 
experiment, representative of three. No treatment (NT) corresponds to wells to which no 
A~ was added to the supernatant. 
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(a) APl-40 
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NT I 3 6 24 48 NT I 3 6 24 48 
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....... ... .. 70KDa 
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Figure 5.14. AP 1-40 in supernatants after 48 h incubation with hCMECID3 or 
collagen coated plastic. (a) AP 1-40 was added to either a collagen coated tissue culture 
plate or hCMECID3 cells for 1, 6, 24 or 48 h. The supernatant was collected and the 
protein levels of AP (6El 0, mouse monoclonal IgG I ) and (b) APP (22Cll, mouse 
monoclonal IgG t ) was investigated using western blotting techniques and a 8 % 
acrylamide gel. Result from one experiment, representative of three. No treatment (NT) 
corresponds to wells to which no AB was added to the supernatant. 
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5.4 Discussion 
5.4.1 Role of intracellular signalling pathways involved in All 1-40- mediated occludin 
down-regulation 
A main aim of this study was to investigate the signalling pathway(s) involved in 
Ap-mediated occludin down-regulation in hCMECID3 cells. The intracellular regulation of 
occludin is potentially very complex (reviewed in [131]) and therefore only pathways 
activated by AP or those most likely to be involved in the regulation of occludin expression 
were investigated. 
Src, a non-receptor tyrosine kinase, is suggested to playa role in TJ assembly 
[657]. Sabath et al [657] identified Src as a key component of the TJ complex in MDCK 
cells. Furthermore, the group found that activation of the G protein G a 12, induced 8rc 
phosphorylation of ZO-l and dissociation of occludin and Cl-l from the TJ complex. If AP 
was acting via Src in hCMECID3 cells, disruption in ZO-1 and possibly CI-5 expression 
would be expected, however this was not observed at the protein or mRNA level. There are 
no reports of Src activation by AP in the literature and so it is unsurprising that its 
inhibition had no effect on Ap-mediated occludin down-regulation. 
Rho-associated kinases (ROCK) are serine/threonine kinases which can alter TJ 
protein expression (discussed in [131]). Persidsky et al [132], have demonstrated that the 
migration of HIV -1 infected monocytes across primary hBECs in vitro, occurs via 
rholROCK activation. In that study the activation of RholROCK in hBECs induced the 
phosphorylation and disruption of occludin and CI-5. In this study ROCK inhibition did 
not alter Ap-induced occludin down-regulation and there was no alteration in CI-5 levels. 
PKC is a family of SerlThr specific kinases of which 12 isoforms exist. The 
activation of PKC, rather than inhibition, is a suggested therapeutic target for AD, 
(reviewed in [658]) as a preventative measure for neuronal cell death. The effect ofPKC 
on occludin is complex and isoform-specific. For example, Andreeva et al [659] have 
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found that PKCa activation can cause TJ disassembly whilst PKCo can mediate TJ 
assembly in MDCK cells. Bisindolylmaleimide -1 used here, is a non-specific PKC 
inhibitor and did not alter the A~-mediated occludin decrease in hCMECID3 cells. 
PKC, ROCK and Src appear to act via modifications ofTJ protein phosphorlyation, 
or to alter the association of each TJ protein with each other. In general these processes are 
post-translational in nature and can occur quite rapidly. For example, ROCK- dependent 
migration of HI V monocytes occurs within hours [132], whilst TJ disruption as the result 
of low Ca + levels, used in many models to investigate junction assembly, occurs within 20 
h [659]. In the current study, a reduction in occludin at the protein level occurred only after 
48 h, and occludin was also down-regulated at the mRNA level. This implies that A~ may 
be acting at the level of transcriptional activity and/or ofmRNA stability. For this reason, 
transcription factors or signalling pathways leading to modification in transcriptional 
activity (NF-KB, JNK, GSK-3~) were investigated. 
NF-KB is an inducible transcription factor found in many cell types including ECs 
[660], neurones and glia [642]. NF-kB is activated by multiple signalling molecules 
including TNF-a, IL-l, LPS and A~ (summarised in [642]). High levels ofNF-kB 
activation induced by A~ can lead to neuronal cell death in vitro [351,641], whilst low 
activation might afford neuroprotection [344, 642]. Indeed, Kalschmidt et al [344, 642] 
have found that TNF-a at low concentrations (2 ng/ml) protects primary rat cerebellar 
granule cells against A~ 1-40- mediated toxicity via NF-kB activation. In the present study 
however NF -kB inhibition did not reverse occludin down-regulation. 
The PI3K, AKT, GSK-3Wa pathway is commonly described as an AD therapeutic 
target [628, 629]. Class I PI3K converts phosphatidyinositol4,5 diphosphate (PI 4,5) to 3, 
4,5 triphosphate on the inner leaflet of the plasma membrane. PI 3,4,5 tri-phosphate causes 
AKTIPKB translocation to the membrane. Subsequent AKT activation, by phosphorylation 
at Ser473 and Thr308, suppresses the activity ofGSK-3~, via phosphorylation at serine 9. 
GSK-3~ activation has been noted in response to ROS [661,662] and A~ [345,347] in 
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neuronal cell cultures. Schafer et al [661] have found that treatment of murine 
hippocampal cells with LiCI (GSK-3p inhibitor, 1 0 mM), increases their resistance to 
glutamate and hydrogen peroxide- induced oxidative stress. Ap-induced activation of 
GSK-3p has been observed in both neuronal [345,347] and EC cultures [630]. In neuronal 
cultures, AP neurotoxicity is associated with GSK-3p activation. Koh et al [345] found that 
LiCI at 5 and 10 mM increased the survival of rat hippocampal neuronal cell cultures 
treated with 20 J.lM AP 1-42. In a follow up study, Lee et al [347] have found that PI3K 
activation can also reverse the AP- mediated toxicity. Specifically, for ECs, Suhara et al 
[630] have demonstrated that virally- encoded AP 1-42 was pro-apoptotic, via the 
inhibition of AKT phosphorylation and GSK activation, in HUVEC cells. The role ofPI3K 
in TJ regulation is not fully known. PI3K activation in response to TGF-p can result in the 
translocation ofZO-1 from the TJ [663]. It the present study, the finding that LiCI did not 
reverse Ap-mediated occludin down-regulation does not rule out that cytoxic effects at 
higher concentrations of AP may occur via the GSK-3p pathway. It is unsurprising 
however, that the PI3K inhibitor used in this study had no effect on occludin down-
regulation, as there are no reports on AP directly activating PI3K. A future study into the 
signalling pathways mediating AP cytotoxicity in hCMECID3 cells would be interesting. It 
is noteworthy that other pathways converging on GSK-3p, such as the GSK-3p inhibitory 
protein Wnt [664], are also proposed targets in AD. 
MAPK are Ser/Thr kinases that respond to a variety of stimuli (e.g. stress), and act 
to regulate a plethora of activities including gene expression, mitosis and apoptosis. There 
are three main groups called ERK, p38MAPK and JNK. MAPK signalling has a 
demonstrable role ofTJ expression (reviewed in [131]). The activation ofp38MAPK and 
ERK 112 can cause an increase or a decrease in T J protein expression, depending on the 
stimulus and cell type [131]. The MAPK family are implicated in AD pathogenesis [665], 
since ERK [666, 667], JNK [633] and p38MAPK[668] are all found to be up-regulated in 
neurones from AD patients. Furthennore, Ap-mediated neuronal cell death in vitro has 
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been reported as being JNK-dependent [353, 634]. In this study, inhibitors of JNK 
(SP600125 TAT-TI-JIP1S3-163) and p38MAPK (SB203580) prevented AP -mediated 
occludin down-regulation and Ap-mediated increased hCMECID3 cell permeability. 
Alternative explanations for these results are that both p38MAPK and JNK 
pathways are important for the occludin down-regulation, or that the inhibitors used in this 
study are not specific for one pathway. Both SP600125 and TAT-TI-JIPm-163 inhibited 
JNK but not p38MAPK or ERK2, however SB203580 inhibited both JNK and p38MAPK. 
The key pathway in AP 1-40-mediated occludin down-regulation appears therefore to be 
JNK, whereas the role ofp38MAPK remains to be determined. 
The specificity ofSP600125 [669] and SB203580 [670] has recently been 
investigated in vitro. Using an in vitro kinase assay, SP600125 at 10 llM, was found to 
inhibit in addition to JNK 112, thirteen other protein kinases (including SGK, S6Kl, 
AMPK, CDK2, CK13 and DYRKIA) [669]. Numerous studies have used SP600125 for the 
inhibition of JNK (discussed in [654, 671, 672]). However to confirm the finding of AP 1-
40 mediated occludin down-regulation via JNK activation; TAT-TI-JIPm _163 was used. 
Scaffold proteins known as JNK-interacting proteins (JIP) are thought to form an important 
part of the JNK pathway, by permitting JNK activation. A short conserved sequence of 
JIpt has been demonstrated to bind to and inhibit JNK, by preventing JIPI-JNK 
inteactions [645,654,671-674]. TAT-TI-JIPm-163 is a small cell permeable peptide [675], 
containing an inhibitor sequence for JNK. TI-JIPm-163 in vitro was shown to not inhibit 
ERK or p38MAPK [673]. TAT-TI-JIP1S3_163.1ike SP600125, completely reversed occludin 
down-regulation. 
In contrast to the JNK inhibitors used, SB203580 may not be specific for 
p38MAPK. Using an in vitro kinase assay, Bain et al [670] have demonstrated that 
SB203580 at I llM inhibits not only p38MAPK, but also GSK-3p, CKl, RIP2 and GAK. 
Furthermore SB203580 also decreased the activation of two of the three JNK isoforms; 
JNK2 (40 % inhibition) and JNK3 (72 % inhibition). In this study, SB203580 inhibited 
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JNK activation, occ1udin down-regulation and the increase in paracellular penneability as a 
result of AP treatment. SB203580 may therefore prevent the actions of AP to hCMECID3 
cells by the inhibition of JNK rather than p38MAPK. Bain et af [670] also found that pp2, 
a src inhibitor, could decrease the activity ofp38MAPK alP isofonns by 57 % and 62 % 
respectively. In the present study pp2 did not reverse the Ap-mediated occ1udin down-
regulation, and therefore the p38MAPK pathway is not likely to be involved. 
5.4.2 Role of extracellular soluble facton in AP 1-40- mediated occludin down-
regulation by hCMECID3 cells 
Although the data described above points to JNK rather than p38MAPK activation 
as being involved in the AP 1-40-mediated occ1udin down-regulation in hCMECID3 cells, 
it has been shown that p38MAPK activation is associated with the production of 
inflammatory cytokines. Microglia activation by AP is associated with the production of 
inflammatory cytokines [374]. In vitro, various cytokines including IL-l, TNF and IL-6 are 
produced after AP incubation in a p38MAPK- dependent manner by microglia [676, 677], 
and in isolated glia from AD patients [678]. Crucially, a novel p38MAPK inhibitor was 
found to suppress hippocampus levels ofTNF-a and IL-IP following 
intracerebroventricular infusion of AP 1-42 in mice [378]. In that study, synaptic 
dysfunction and behavioural deficits were attenuated after treatment. AP peptides have also 
been demonstrated to induce IFN-y and IL-IP production in HUVEC cells [679]. Increased 
cytokine levels are found in AD patients, particularly IL-1P, TNF-a and IL-6 [377, 680]. 
IL-IP [265-268] and TNF-a [655,656] can induce increased penneability in cell lines that 
fonn TJs. Importantly, IL-l P has been shown to decrease occ1udin at the mRNA level in a 
human retinal pigment epithelial [265] and HUVEC [660] cell lines, whilst TNF-a has 
been shown to decrease occ1udin at the protein level in HUVEC cells [681]. It is therefore 
possible that AP activates p38MAPK in hCMECID3 cells, to produce a cytokine, which 
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could act to down-regulate occludin. In this study however, sIL-I-ra and sTNF-Rl, when 
used singly or in combination, had no effect on AP- mediated occludin down-regulation. 
IL-6 is relatively unique, in that the soluble form of the receptor (sIL-6) can bind to IL-6 
and function as a signalling receptor via gp130 activation [682-684]. ECs express gp130 
[682], and therefore, ifIL-6 was produced by hCMECID3 cells, one would predict that 
sIL-6 would enhance occludin down-regulation. The possibility remains that when 
hCMECID3 cells are treated with AP, a soluble factor is released such as IFN-y [685-688], 
though this has yet to be accounted for. It is of note however, that the activation of 
p38MAPK was not found at time points earlier than 6 h and the activation ofp38MAPK, 
JNK and ERK all occurred around the same time. It therefore seems unlikely that a 
p38MAPK-dependent secreted factor is acting on hCMECID3 cells, or p38MAPK 
activation would occur prior to JNK and ERK activation. These results imply that JNK is 
likely to be the key pathway in Ap-mediated occludin down-regulation in hCMECID3 
cells. 
5.4.3 JNK as a therapeutic target in AD 
JNK is a promising therapeutic target for AD, potentially decreasing AP production 
[689], offering protection for neurones and, as found in this study, preventing occludin 
down-regulation in BEC. There are three genes that encode JNK in mammalian systems-
jnkl,jnk2,jnk3; and each gene is alternatively spliced to create 46 and 55 kDa forms of the 
proteins [654,672,690]. The significance of each variant is not fully known, however JNK 
I and 2 are widely expressed whilst JNK3 is largely restricted to the brain (reviewed in 
[654]). Morishima ef al [635] have demonstrated that AP 25-35 toxicity is significantly 
reduced in cortical neurones derived from JNK3 knock-out mice compared to control 
neurones, however they also state that JNKI-deficient neurones are also resistant to 
apoptosis. Fogarty ef al [691] concur with the involvement of JNKI in neuronal cell death, 
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as they found that rat cortical neurones were resistant to Ap-induced apoptosis if INK J, but 
not INK2, was depleted using antisense technology. SP600125 [692] and TAT-TI-JIPm_163 
[645,675] are non-specific JNK inhibitors, whilst N-(3-Cyano-4,5,6,7-tetrahydro-l-
benzothien-2-yl)-I-naphthamide has been demonstrated to inhibit JNK2 and 3, but not 
INKI [646]. In this study, N-(3-Cyano-4,5,6,7-tetrahydro-I-benzothien-2-yl)-1-
naphthamide was found to be toxic to hCMECID3 cells at doses in excess of 0.5 JlM. At a 
non-toxic concentration, N-(3-Cyano-4,5,6, 7-tetrahydro-l-benzothien-2-yl)-I-naphthamide 
did not reverse the Ap-mediated occludin down-regulation. Indeed, western blotting 
analysis revealed that this compound activated rather than inhibited JNK. It therefore 
appears that N-(3-Cyano-4,5,6, 7-tetrahydro-l-benzothien-2-yl)-1-naphthamide, at the 
concentrations used here, initiates a cascade(s) that activates JNK, potentially leading to 
hCMECID3 cell death. There are no current reports ofN-(3-Cyano-4,5,6,7-tetrahydro-l-
benzothien-2-yl)-I-naphthamide used in cell culture settings, and it is possible that this 
compound may act on an as yet unidentified pathway to stimulate INK. This part of the 
investigation has shown that JNK inhibition can reverse Ap-mediated occludin down-
regulation; however the JNK isoform involved was not identified. These results further 
support the view that JNK inhibition might be an attractive therapeutic target in AD, acting 
to prevent both neuronal cell death and BBB dysfunction. 
5.4.3 Role of peptide aggregation in All 1-40-mediated occludin down-regulation by 
bCMECID3 cells 
The exact form of AP that is toxic to neurones is under debate, although soluble 
oligomers are emerging as a highly toxic species [357, 359]. A~ exists as 4 kDa monomer, 
but has a high tendency to self aggregate to form larger soluble species as wells as larger 
insoluble fibrils and plaques. In the current study, it was found that the levels of 
monomeric AP 1-40 (4 kDa) were reduced over time in both the supernatant and cell 
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lysate. This could reflect either the degradation of AP by hCMECID3 cells, or the 
aggregation of Ap. A second finding was the appearance ofa large 150 kDa component at 
24 and 48 h, which did not correspond to APP. The appearance of this species coincided 
with the activation of JNK, ERK and p38MAPK. A literature search revealed that the 
largest soluble aggregate previously resolved via western blot is 100 kDa in size and 
corresponds to soluble oligomers [693]. Kuo et al [694] were able to resolve a range of 
non-fibrillar forms of AP from AD patients into four molecular weight catagories based on 
filter exclusion: > 100 kDa, 30-100 kDa, 10 -30 kDa and < 10 kDa. Wu et a/ [617] have 
identified a 120 kDa AP aggregate, which forms after co-incubation with haemoglobin. 
The 150 kDa AP species identified here might therefore correspond to either a large 
soluble oligomer, or an insoluble aggregate. A future study should be carried out to 
centrifuge the supernatant (100,000 g. 30 min) to determine if the protein fulfils the criteria 
of an oligomer. The appearance of the large AP form could be explained by self 
aggregation, binding to a hCMECID3 cell- derived molecule, or by the detection of a 
protein not corresponding to AP by the antibody (6EI0). A PubMed blast search (National 
Center for Biotechnology Information http://blast.ncbi.nhn.nih.gov/Blast.cgi) for the 
sequence detected by 6EIO (amino acids 1-16 of AP) did not detect any high molecular 
weight proteins with the exception of APP. This finding potentially rules out the theory of 
unspecific recognition by 6EIO, unless the protein is as yet unidentified. As yet there are 
no reports of AP binding to proteins to produce a 150 kDa species. The potential 
aggregation found in this study is interesting in that there are no intermediate species of 
AP, only 4 or 150 kDa. The samples used in this study were under reducing and boiled 
conditions, which would have disrupted any weak non-covalent interactions. It is therefore 
possible that aggregation intermediates were disaggregated, whilst the larger aggregate was 
resistant. Argueing against this explanation is the fact that under reducing conditions AP 
dimers and trimers are successfully resolved on western blotting gels [617]. Whilst there 
- 229-
are no reports of covalent binding of AP to an EC secreted factor of 150 kDa in size, this 
hypothesis cannot be disregarded. 
Interestingly, in APP blots, a 50 kDa protein was observed to be decreased over 
time with AP treatment, and this protein was not detected by 6E 10. APP typically resolves 
as three bands between 100 and 130 kDa in size and so it is unlikely that the protein 
corresponds to full - length APP. To date there are no reports of a 50 kDa product of APP. 
APP belongs to a gene family that includes APP, APLPI and APLP2. The possibility that 
the APP antibody was detecting APLP1I2 was considered. However, the molecular weight 
of APLPI or 2 does not correspond to 50 kDa [695-697]. Furthermore a Blast search using 
the sequence of APP which the antibody recognises did not detect any proteins of 50 kDa 
which would be recognised by the antibody. The most likely explanation is that this 
unidentified protein is a fragment of APP. 
5.5 Conclusions 
The Ap-mediated increase in permeability was reversed by JNK inhibition, most 
likely due to the prevention of occludin down-regulation. The JNK pathway might 
represent a potential therapeutic target of BBB dysfunction in AD. 
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Chapter 6 
General discussion 
6.1 The role of P-gp in AfJ transport across the BBB 
In the current study, the interactions ofP-gp and BCRP with A~ were investigated 
using hCMECID3 cells. The results described in chapters 2 and 3 demonstrate that P-gp, 
and to a lesser extent BCRP, can act as A~ efflux transporters at picomolar but not 
micromolar concentrations of A~. Figure 6.1 summarises the routes of A~ transport at the 
BBB, based upon this and other studies (reviewed in [137]). In this study, it has been 
demonstrated using hCMECID3 cells, that both P-gp and BCRP restrict the passage of A~ 
in the apical-to-basolateral direction, but do not act to facilitate the basolateral-to-apical 
passage of A~. These novel results are consistent with P-gp and BCRP acting to protect the 
brain from blood-borne A~, but not to clear A~ peptides localised in the CNS parenchyma 
into the blood. Unfortunately, comparisons between plasma A~ concentrations in AD 
patients and non-demented controls are difficult due to the binding of A~ to plasma 
proteins [320, 613], oligomerisation of A~ [698] and high intra- and inter- person 
variability [699]. None-the-Iess, there are numerous reports of increased A~ 1-40 and A~ 
1-42 in the plasma of AD patients compared to controls [321,699-703]. Quoted 
concentrations of free A~ are in the nM to pM range, for example Mehta et al [703] found 
that plasma levels of A~ 1-40 were higher in AD patients (0.063 nM) than in controls 
(0.052). Kuo et al [320] have recently demonstrated that, once released from plasma 
proteins, A~ 1-40 levels in serum are higher in AD patients (2.53 nM) compared to elderly 
non-demented subjects (1.83 nM). P-gp and BCRP may serve as a protective mechanism 
for the brain if any of the A~ bound to plasma proteins is released free [319, 701]. Sagare 
et al [319] recently demonstrated that sLRP, a major plasma Ap-binding protein, is -32.5 
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% lower in AD patients than controls, and this effect is associated with an elevated level of 
free unbound A~ 1-40 (22 pM compared to 5 pM in controls). The concentrations of free 
AP in the plasma of AD patients are within the range used in this study, suggesting that P-
gp and BCRP could indeed act to protect the brain from circulating unbound Ap. The 
increased plasma A~ levels found in AD could represent either increased production by the 
brain, or a peripherally produced pool of A~. In support of the latter hypothesis, Galloway 
et al [704, 705] have found that small intestine epithelial cells can secrete A~. Interestingly 
a high saturated fat and cholesterol diet, a high risk factor for AD, can induce A~ 
production by epithelial cells [94]. Increased plasma A~ levels, might saturate P-gp and 
BCRP, allowing blood-to-brain transport via diffusion or RAGE. There is not much 
evidence for the increased production of A~ by brain resident cells in AD. However, 
transgenic mice produced from single or double mutations found in FAD have increased 
levels of A~ in the brain parenchyma [331, 332], and neuronal cultures can be induced to 
increase their production of A~ by oxidative stress [689]. A~ produced within the brain 
could diffuse or be transported across the BBB, and P-gp could act to limit its re-entry into 
the CNS. 
Decreased A~ clearance from the brain parenchyma is emerging as a potential 
mechanism in AD pathogenesis [137]. LRP-I binding at the abluminal membrane ofBECs 
causes brain-to-blood A~ transport, and decreased LRP-I expression has been noted in AD 
patients [384]. To date, P-gp was also hypothesised to mediate brain-to-blood A~ transport 
since decreased BEC P-gp expression is associated with plaque deposition [409] and in 
vitro evidence demonstrates P-gp-A~ binding [406]. In addition, Cirrito et al [408] 
demonstrated in vivo, that tariquidar treatment increases AP ISF levels in APP mice. By 
contrast, the results presented here are constant with no significant P-gp or BCRP transport 
of AP in the brain-blood direction, possibly since most P-gp is located on the luminal 
membrane. The finding ofCirrito et al [408], might reflect inhibition of blood-to-brain AP 
transport, as indicated by this study, or an inhibition ofP-gp expressed by other cells which 
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act to uptake AP e.g. astrocytes, epithelial cells. In AD, P-gp may therefore be important 
for the prevention of blood-to-brain AP transport, unlike LRP-l which acts as a brain-to-
blood AP transporter. It is also possible that P-gp down-regulation is a feature of BBB 
dysfunction observed in AD (Dr Barrand, Cambridge University, personal 
communication). If this is the case, brain AP load would probably increase by diffusion of 
the blood-borne peptide across BECs. However, a direct effect of AP on hCMECID3 cell 
expression ofP-gp was not observed in this study, suggesting that an alternate indirect 
mechanism e.g. cytokines may induce the down-regulation ofP-gp by brain capillaries. 
The results of this study have opened up further questions, including whether AP 
transported across BECs is a degradation product or intact Ap. BECs express enzymes 
capable of AP degradation (e.g. NEP, ICE, ECE) and it has been noted by Nazer et al 
[561], using MDCK cells grown on filters, that LRP can transport degraded peptides. It 
would be interesting therefore to distinguish between intact and degraded peptides in 
transport experiments. This could be achieved by re-suspending the supernatants in 
trichloroacaetic acid and centrifuging to precipitate the intact peptide before counting the 
radiation in both separated fractions [561]. In addition to AP degradation, aggregation of 
AP might also be a factor affecting the ability of P-gp or BCRP to bind Ap. It would be 
interesting to pre-aggregate AP and determine the efflux and permeability characteristics of 
AP across this in vitro BBB model. This could be carried out with non-tagged AP and 
ELISA techniques or tagged Ap. 
A further question raised by the results is the concentration range within which the 
efflux and transport of AP by BCRP or P-gp may operate. In order to test this, increasing 
concentrations of 1251 AP 1-40 or native AP peptides could be used for efflux and 
permeability experiments with BCRP and P-gp inhibitors. Alternatively, hCMECID3 cells 
could be made to express increasing levels ofP-gp following cell transfection with vectors 
containing the MDRI gene, in order to investigate whether higher concentrations of AP 
could be effluxed or transported. In terms of the permeability ofhCMECID3 cells, the 
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effect on transport of increasing A~ concentrations on the basolateral and apical sides 
should be investigated further. This would be achieved by altering the concentration of A~ 
to achieve either equal concentrations on each side, or higher concentrations in the 
basolateral chamber. This is potentially significant in AD, as if increased brain production 
of A~ is the cause of AD, any potential protective effect of P-gp or BCRP pumping A~ out 
of BECs into the plasma could be insignificant when compared to bulk flow out from the 
brain. There are no reports ofBCRP-A~ interactions in the literature and to further 
demonstrate BCRP -A~ interactions, dual immunolabelling should be carried out. This 
could be performed in vitro, by incubating A~ with hCMECID3 cells and co-
immunolabelling to investigate sub-cellular localisation, and also in vivo using brain tissue 
from AD mouse models. 
Finally, a general limitation of a two dimensional cell culture model of BECs is that 
is does not take into account the role of the cerebral blood flow. A novel technique has 
been developed [474] which uses hCMECID3 cells grown in the lumen of hollow 
microporous fibers that are exposed to a physiological pulsatile flow. This model would be 
useful to investigate A~ mediated P-gp and BCRP transport as the conditions mimic more 
appropriately the in vivo situation. Furthermore, to extrapolate the findings to the in vivo, 
rodents could be pretreated with a P-gp inhibitor or vehicle control, and then in situ 
perfusion carried out with A~ alone or with a P-gp inhibitor, and the cerebral ISF levels 
measured. 
6.2 AP mediated down-regulation of Glut-l at the BBB 
An interesting finding of this study is that A~ can induce robust Glut-l down-
regulation in hCMECID3 cells. This result is in agreement with data from AD CNS tissue 
samples, in which decreased Glut-l expression is a common feature [146, 586, 587]. 
Decreased Glut-l expression could have the effect of decreasing the amount of glucose 
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available to neurones, causing an energy crisis. Indeed, decreased glucose metabolism is a 
common feature of AD patients [430,431]. The finding that A~ is sufficient to decrease 
Glut-l expression in vitro should be taken further experimentally. Firstly, it should be 
determined whether Glut-l down-regulation by hCMECID3 cells results in a functional 
decrease in glucose transport. This could be carried out by measuring the intracellular 
accumulation of 14CPH-2-deoxyglucose in Ap-treated cells. Secondly, inhibitors for 
pathways activated by AP could be employed in an attempt to reverse Glut-l down-
regulation. Thirdly, the mechanisms of A~-mediated Glut-l down-regulation could be 
investigated further using hCMECID3 cells transfected with vectors containing the Glut-l 
promoter, to determine if AP suppresses transcriptional activity of the Glut-l promoter. 
6.3 Role of JNK in Ap-mediated increased BBB permeability 
In this study, the effect of AP on the expression of BEC proteins and permeability 
was investigated. The results from this study have demonstrated that AP in vitro can 
increase the permeability of BECs to paracellular markers. This data is in agreement with 
the findings that in AD patients increased BBB permeability [579] is observed as indicated 
by the abnormal presence of plasma proteins on the brain parenchyma. Increased BBB 
permeability could induce local neuronal degeneration through disruption of homeostasis. 
The present study provides evidence that increased AP levels might be the causative factor 
for increased BBB permeability. As described previously, elevated plasma levels of AP are 
reported in AD patients [319] and elevated brain levels of AP are hypothesised to be 
critical in the pathogenesis of AD [302]. Furthermore, in a vast majority of AD patients, 
cerebral amyloid angiopathy occurs in which AP is deposited on the vasculature walls 
[643]. Therefore, high local concentrations of AP could in principle lead to a leaky BBB. 
In fact, the results from chapters 4 and 5 show that AP added to the luminal side of the 
hCMECID3 cell cultures was sufficient to induce increased hCMECID3 cell permeability. 
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Results from this study also imply that specific occludin down-regulation at the TJs is 
responsible for the increased permeability of hCMECID3 cells. This is in agreement with 
Marco and Skaper [486], who found a partial decrease in occludin levels in rat BECs after 
A~ incubation and Tachehci et al [94], who demonstrated, using an in vivo model 
(APPIPS I mice), down-regulation of occludin and increased BBB permeability. Overall, 
the results described here expand on the mechanisms leading to a leaky BBB in AD and 
identify A~ as having a central role in this effect, acting to decrease occludin expression by 
BECs. 
A novel finding of the present study is that JNK inhibition can prevent the A~­
induced increased permeability and occludin down-regulation in BECs. This finding 
demonstrates that JNK inhibitors might be a potential therapeutic target for the treatment 
of AD, preventing a leaky BBB. Further experimentation should be carried out both in 
vitro and in vivo in order to fully characterise the interplay between A~, JNK and occ1udin 
down-regulation. 
Although the results imply that JNK rather than p38MAPK is the main pathway 
involved in A~-mediated occludin down-regulation, the results from this study have not 
exclusively ruled out p38MAPK involvement. To confirm involvement of different 
components of the MAPK family, BECs could be stimulated by A~ in the presence or 
absence of MAPK inhibitors and quantitatively assessed for MAPK activity using various 
available ELISA kits. In addition, AD patient tissue from different BRAAK stages and 
areas of the brain could be stained for plasma proteins as a guide ofBSB leakiness and 
examined for correlation with decreased occludin levels and phosphorylated MAPK family 
members, as well as other TJ proteins. This would determine whether JNK and/or 
p38MAPK activation is associated with decreased occludin expression at the BBB in AD 
patients. Furthermore, transgenic mouse models could be used. Tg2576 [584] and 
TASTPM [706] mice show increased BBB permeability. TJ protein expression and JNK 
activation should also be investigated at the levels of the BBB in these mice. 
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Another area for further investigation is the mechanism of Ap-induced JNK 
activation. The activity of upstream JNK activators (e.g MAPKK, MAP KKK) could be 
assessed via western blotting using phosphorylated-state specific antibodies in hCMECID3 
cells after AP incubation. MKK4 and MKK7 are the two MAPKKs that activate JNK, 
which themselves are activated by a range ofMAPKKKs. For example, TNF-l and IL-I, 
known stimulators of the JNK pathway, stimulate the MAP KKK TAKI [707]. Once and if 
identified, the gene of each identified signalling component could be silenced in 
hCMECID3 cells using siRNA, and the effects on AP mediated occludin down-regulation 
assessed. Furthermore, AD patient tissue and transgenic models could be stained for each 
identified signalling component. AP may also activate reactive oxygen species (ROS), 
which in tum could lead to JNK activation. This mechanism of JNK activation could be 
investigated in vitro, by measuring whether AP increases ROS levels in hCMECID3 cells. 
In addition, the downstream consequences of JNK activation by AP could be 
investigated. Potentially, JNK could act to suppress occludin at the transcriptional level, on 
mRNA stability, directly at the protein level or even a combination of all three (Figure 
6.2). To investigate Ap-induced changes at the transcriptional level, the promoter of 
occludin could be cloned into reporter vectors and then transfected into hCMECID3 cells. 
The effect of AP on occludin promoter activity could then be investigated in the presence 
or absence of JNK inhibitors to determine if this is a significant mechanism of occludin 
down-regulation. Subsequent experiments (e.g. EMSA) could then be carried out to 
determine which transcription factor(s) are involved in this effect. To investigate JNK 
effects on occludin mRNA stability, qRT-PCR could be carried out. This could be 
achieved by investigating whether AP enhances the degradation of occludin mRNA in the 
presence of transcriptional inhibitors, i.e. actinomycin D, and also the effects of JNK 
inhibitors on this process. To investigate any possible direct effects of JNK at the protein 
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level, occludin could be isolated via immunoprecipitation and the phosphorylated state of 
different splice forms investigated in the presence and absence of JNK inhibitors assessed 
via western blotting. Once indentified in vitro, the results could be investigated in vivo 
from both AD patient tissue and AD transgenic mouse models. Using both AD patient 
tissue and AD transgenic mouse models, binding of any transcription factors to the 
occludin promoter in hCMECID3 cells could be investigated by chromatin 
immunoprecipitation, and compared to age matched controls. 
It would also be interesting to identify the JNK isoform activated by Ap. siRNA 
knockdown of each JNK isoform in hCMECID3 cells could be carried out, and the effect 
of AP on occludin down-regulation determined. Alternatively, kinase assays on AP 
hCMECID3 celllysates could be analysed for the levels of each active JNK isoform. 
The combined results of these experiments would elucidate the molecular 
pathway(s) leading to the down-regulation of occludin by AP, and perhaps suggest novel 
therapeutic ways of manipulating these pathway(s). A major future direction for this work, 
would be the assessment of JNK inhibitors as an AD therapeutic agent. Tg27S6 and 
T ASTPM mice could be treated with JNK inhibitors and the effect on BBB leakiness and 
occludin expression observed. A water maze assessment could also be carried out to 
investigate whether a reversal in BBB effects improves cognition in the mouse models. 
Since JNK inhibition can also protect neurones, a detailed neuronal investigation should 
also be carried out in regions susceptible to AD e.g. the hippocampus. The diagnosis of AD 
is based on symptoms and significant neurodegeneration and BBB dysfunction might have 
already occured. Therefore, as therapeutic agents, JNK inhibitors would most likely be 
administered after the onset of any damage. Further in vitro and in vivo evaluation of the 
ability of JNK inhibition to stall disease progression, or better yet, reverse vascular and 
neuronal dysfunction after symptoms have already occurred could be carried out in the 
mouse models of AD. 
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In principle, JNK might represent an attractive dual target, preventing both 
neurotoxicity and increased BBB leakiness. Indeed, JNK inhibition can prevent AP-
induced neuronal death in vitro [353, 634, 636], and activated JNK is found in neurones 
from AD patient's tissue [632,633]. It is thus possible, that with earlier diagnosis of AD in 
patients, administration of JNK inhibitors may become a novel therapy to protect against 
any further damaging effects of AP at the level of both neurons and the cerebral 
vasculature. 
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Figure 6.1. The transport of Af3 at the BBB mediated via LRP, p.gp and RAGE. The 
blood-to-brain transport of A~ (black dot) is mediated by RAGE and LRP-2/megalin, 
whilst the brain-to-blood transport is mediated by LRP-l. The results of this study, 
indicated by a grey box, have demonstrated that P-gp and BCRP form a blood-brain A~ 
transport barrier. 
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Figure 6.2. Potential mechanisms of Ap-mediated increased permeability in 
hCMECID3 cells. A~ induces down-regulation of occludin via JNK activation in 
hCMECID3 cells. JNK activation could theoretically act to alter occJudin levels via 
transcription activity suppression, mRNA degradation or a direct effect on occludin at the 
protein level. - = A~ monomer a = oligomer species 
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